Ophthalmic composition

ABSTRACT

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No.17/681,560, filed Feb. 25, 2022, which is a continuation of Ser. No.16/677,538, filed Nov. 7, 2019, now U.S. Pat. No. 11,382,909, issuedJul. 12, 2022, which is a continuation of U.S. application Ser. No.15/568,381, filed Oct. 20, 2017, now U.S. Pat. No. 10,842,787, issuedNov. 24, 2020, which is a § 371 U.S. National Stage Application ofInternational Application No. PCT/US2016/029222, filed Apr. 25, 2016,which is a continuation in part of International Application No.PCT/US2015/037249, filed Jun. 23, 2015, which is a continuation in partof U.S. application Ser. No. 14/726,139, filed May 29, 2015, now U.S.Pat. No. 9,421,199, issued Aug. 23, 2016, which claims the benefit ofU.S. Provisional Application No. 62/151,926, filed Apr. 23, 2015;PCT/US2015/037249 claims benefit of U.S. Provisional Application No.62/151,926, filed Apr. 23, 2015; PCT/US2016/029222 claims benefit ofU.S. Provisional Application No. 62/151,926, filed Apr. 23, 2015,PCT/US2016/029222 is a continuation in part of U.S. application Ser. No.14/726,139, filed May 29, 2015, now U.S. Pat. No. 9,421,199, issued Aug.23, 2016, all of which are fully incorporated herein by reference.

BACKGROUND OF THE DISCLOSURE

Pharmaceutical formulations have an expiration date which is based onthe degradation of the active ingredient.

SUMMARY OF THE DISCLOSURE

Provided herein are ophthalmic compositions. In some embodiments,disclosed herein is an ophthalmic composition, comprising from about0.001 wt % to about 0.05 wt % of a muscarinic antagonist and deuteratedwater, at a pD of from about 4.2 to about 7.9.

In some embodiments, provided herein is an ophthalmic composition,comprising from about 0.001 wt % to about 0.05 wt % of a muscarinicantagonist and deuterated water, at a pD of from about 4.2 to about 7.9,wherein the muscarinic antagonist does not extend singlet oxygenlifetime.

In some embodiments, the muscarinic antagonist comprises atropine,atropine sulfate, noratropine, atropine-N-oxide, tropine, tropic acid,hyoscine, scopolomine, tropicamide, cyclopentolate, pirenzapine,homatropine, or a combination thereof. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, scopolomine,homatropine, or a combination thereof. In some embodiments, themuscarinic antagonist is atropine. In some embodiments, the muscarinicantagonist is atropine sulfate.

In some embodiments, the muscarinic antagonist quenches photogeneratedsinglet oxygen species in the composition. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist comprisesatropine, atropine sulfate, scopolomine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist is atropine. Insome embodiments, the muscarinic antagonist is atropine sulfate.

In some embodiments, the ophthalmic composition has a pD of one of: lessthan about 7.9, less than about 7.3, less than about 7.2, less thanabout 7.1, less than about 7, less than about 6.8, less than about 6.5,less than about 6.4, less than about 6.3, less than about 6.2, less thanabout 6.1, less than about 6, less than about 5.9, less than about 5.8,less than about 5.2, or less than about 4.8 after extended period oftime under storage condition.

In some embodiments, the ophthalmic composition has a pD of one of: lessthan about 7.9, less than about 7.8, less than about 7.7, less thanabout 7.6, less than about 7.5, less than about 7.4, less than about7.3, less than about 7.2, less than about 7.1, less than about 7, lessthan about 6.9, less than about 6.8, less than about 6.7, less thanabout 6.6, less than about 6.5, less than about 6.4, less than about6.3, less than about 6.2, less than about 6.1, less than about 6.

In some embodiments, the ophthalmic composition comprises one of: atleast about 80%, at least about 85%, at least about 90%, at least about93%, at least about 95%, at least about 97%, at least about 98%, or atleast about 99% of the muscarinic antagonist based on initialconcentration after extended period of time under storage condition. Asdescribed in this disclosure, the percentage of the ophthalmic agent inthe composition after storage is based on the amount of ophthalmic agentthat is initially present in the composition (i.e. prior to the storagecondition).

In some embodiments, the ophthalmic composition further has a potency ofone of; at least 80%, at least 85%, at least 90%, at least 93%, at least95%, at least 97%, at least 98%, or at least 99% after extended periodof time under storage condition. As described in this disclosure, thepotency of the ophthalmic agent in the composition after storage isbased on the potency of ophthalmic agent that is initially present inthe composition (i.e. prior to the storage condition).

In some embodiments, the extended period of time is one of; about 1week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about3 months, about 4 months, about 5 months, about 6 months, about 8months, about 10 months, about 12 months, about 18 months, about 24months, about 36 months, about 4 years, or about 5 years.

In some embodiments, the storage condition has a storage temperature offrom about 2° C. to about 10° C. or from about 16° C. to about 26° C. Insome embodiments, the storage condition has a storage temperature ofabout 25° C. In some embodiments, the storage condition has a storagetemperature of about 40° C. In some embodiments, the storage conditionhas a storage temperature of about 60° C.

In some embodiments, the storage condition has a relative humidity ofabout 60%. In some embodiments, the storage condition has a relativehumidity of about 75%.

In some embodiments, the muscarinic antagonist is present in thecomposition at a concentration of one of: from about 0.001 wt % to about0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about 0.001 wt% to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, fromabout 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.

In some embodiments, the composition comprises less than 20% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 15% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition.

In some embodiments, the composition comprises less than 10% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 5% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 2.5% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 2.0% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 1.5% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 1.0% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 0.5% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 0.4% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 0.3% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 0.2% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 0.1% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the major degradant istropic acid. As described in this disclosure, the percentage of theprimary degradant in the composition after storage is based on theamount of ophthalmic agent that is initially present in the composition(i.e. prior to the storage condition).

In some embodiments, the composition is in a form of an aqueoussolution.

In some embodiments, the composition further comprises an osmolarityadjusting agent. In some embodiments, the osmolarity adjusting agent issodium chloride.

In some embodiments, the ophthalmic composition further comprises apreservative. In some embodiments, the preservative is selected frombenzalkonium chloride, cetrimonium, sodium perborate, stabilizedoxychloro complex, SofZia, polyquaternium-1, chlorobutanol, edetatedisodium, polyhexamethylene biguanide, or combinations thereof.

In some embodiments, the ophthalmic composition further comprises abuffer agent. In some embodiments, the buffer agent is selected fromborates, borate-polyol complexes, succinate, phosphate buffering agents,citrate buffering agents, acetate buffering agents, carbonate bufferingagents, organic buffering agents, amino acid buffering agents, orcombinations thereof.

In some embodiments, the ophthalmic composition further comprises atonicity adjusting agent. In some embodiments, the tonicity adjustingagent is selected from sodium chloride, sodium nitrate, sodium sulfate,sodium bisulfate, potassium chloride, calcium chloride, magnesiumchloride, zinc chloride, potassium acetate, sodium acetate, sodiumbicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate,disodium hydrogen phosphate, sodium dihydrogen phosphate, potassiumdihydrogen phosphate, dextrose, mannitol, sorbitol, dextrose, sucrose,urea, propylene glycol, glycerin, trehalose or a combination thereof.

In some embodiments, the composition is stored in a plastic container.In some embodiments, the material of the plastic container compriseslow-density polyethylene (LDPE). In some cases, the material of theplastic container comprises polypropylene.

In some embodiments, the ophthalmic composition is essentially free ofprocaine and benactyzine, or pharmaceutically acceptable salts thereof.

In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 50%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 40%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 30%.In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 20%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 10%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 5%.In some embodiments, the dose-to-dose ophthalmic agent concentrationvariation is based on 10 consecutive doses. In some embodiments, thedose-to-dose ophthalmic agent concentration variation is based on 8consecutive doses. In some embodiments, the dose-to-dose ophthalmicagent concentration variation is based on 5 consecutive doses. In someembodiments, the dose-to-dose ophthalmic agent concentration variationis based on 3 consecutive doses. In some embodiments, the dose-to-doseophthalmic agent concentration variation is based on 2 consecutivedoses.

In some embodiments, the composition further comprises a pD adjustingagent. In some embodiments, the pD adjusting agent comprises DCl, NaOD,CD₃COOD, or C₆D₈O₇.

In some embodiments, the composition further comprises apharmaceutically acceptable carrier. In some embodiments, theophthalmically acceptable carrier further comprises at least oneviscosity-enhancing agent. In some embodiments, the viscosity-enhancingagent is selected from cellulose-based polymers,polyoxyethylene-polyoxypropylene triblock copolymers, dextran-basedpolymers, polyvinyl alcohol, dextrin, polyvinylpyrrolidone, polyalkyleneglycols, chitosan, collagen, gelatin, hyaluronic acid, or combinationsthereof.

In some embodiments, the ophthalmic composition comprises one of lessthan 60% of H₂O, less than 55% of H₂O, less than 50% of H₂O, less than45% of H₂O, less than 40% of H₂O, less than 35% of H₂O, less than 30% ofH₂O, less than 25% of H₂O, less than 20% of H₂O, less than 15% of H₂O,or less than 10% of H₂O.

In some embodiments, the ophthalmic composition comprises one of: lessthan 5% of H₂O, less than 4% of H₂O, less than 3% of H₂O, less than 2%of H₂O, less than 1% of H₂O, less than 0.55% of H₂O, less than 0.1% ofH₂O, or 0% of H₂O.

In some embodiments, the ophthalmic composition is stored below roomtemperature prior to first use. In some embodiments, the ophthalmiccomposition is stored at between about 2° C. to about 10° C. prior tofirst use. In some embodiments, the ophthalmic composition is stored atbetween about 4° C. to about 8° C. prior to first use.

In some embodiments, the ophthalmic composition is stored at roomtemperature after first use. In some embodiments, the ophthalmiccomposition is stored at between about 16° C. to about 26° C. afterfirst use.

In some embodiments, the ophthalmic composition is not formulated as aninjectable formulation.

In some embodiments, the ophthalmic composition does not comprisewater-hydrolyzable derivatives of α-amino or α-hydroxy-carboxylic acids.

In some embodiments, the ophthalmic composition is essentially free ofprocaine and benactyzine, or pharmaceutically acceptable salts thereof.

In some embodiments, the ophthalmic composition is formulated as anophthalmic solution for the treatment of an ophthalmic disorder. In someembodiments, the ophthalmic disorder or condition is pre-myopia, myopia,or progression of myopia. In some embodiments, the ophthalmiccomposition is formulated as an ophthalmic solution for the treatment ofpre-myopia, myopia, or progression of myopia.

In some embodiments, the ophthalmic composition is a solution.

In some embodiments, disclosed herein is a method of treating anophthalmic disorder comprising administering to an eye of an individualin need thereof an effective amount of an ophthalmic compositiondescribed herein. In some embodiments, described herein is a method oftreating an ophthalmic disorder, comprising administering to an eye ofan individual in need thereof an effective amount of an ophthalmiccomposition comprising from about 0.001 wt % to about 0.05 wt % of amuscarinic antagonist and deuterated water, at a pD of from about 4.2 toabout 7.9. In some embodiments, the ophthalmic composition isadministered at predetermined time intervals over an extended period oftime. In some embodiments, the ophthalmic composition is administeredonce every day. In some embodiments, the ophthalmic composition isadministered every other day. In some embodiments, the ophthalmiccomposition is administered over 1 week, 2 weeks, 1 month, 2 months, 3months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7years, 8 years, 9 years, 10 years, 11 years, or 12-15 years. In someembodiments, the ophthalmic composition is stored below room temperatureprior to first use. In some embodiments, the ophthalmic composition isstored at between about 2° C. to about 10° C. prior to first use. Insome embodiments, the ophthalmic composition is stored at between about4° to about 8° C. prior to first use. In some embodiments, theophthalmic composition is stored at room temperature after first use. Insome embodiments, the ophthalmic composition is stored at between about16° C. to about 26° C. after first use.

In some embodiments, disclosed herein is a method of arresting myopiadevelopment that comprises administering to an eye of an individual inneed thereof an effective amount of an ophthalmic composition describedherein. Also described herein is a method of preventing myopiadevelopment that comprises administering to an eye of an individual inneed thereof an effective amount of an ophthalmic composition describedherein. In some embodiments, described herein is a method of arrestingor preventing myopia development, comprising administering to an eye ofan individual in need thereof an effective amount of an ophthalmiccomposition comprising from about 0.001 wt % to about 0.05 wt % of amuscarinic antagonist and deuterated water, at a pD of from about 4.2 toabout 7.9. In some embodiments, the ophthalmic composition isadministered at predetermined time intervals over an extended period oftime. In some embodiments, the ophthalmic composition is administeredonce every day. In some embodiments, the ophthalmic composition isadministered every other day. In some embodiments, the ophthalmiccomposition is administered over 1 week, 2 weeks, 1 month, 2 months, 3months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7years, 8 years, 9 years, 10 years, 11 years, or 12-15 years. In someembodiments, the ophthalmic composition is stored below room temperatureprior to first use. In some embodiments, the ophthalmic composition isstored at between about 2° C. to about 10° C. prior to first use. Insome embodiments, the ophthalmic composition is stored at between about4° C. to about 8° C. prior to first use. In some embodiments, theophthalmic composition is stored at room temperature after first use. Insome embodiments, the ophthalmic composition is stored at between about160° C. to about 26° C. after first use.

In some embodiments, disclosed herein is an ophthalmic solution thatcomprises from about 0.001 wt % to about 0.05 wt % of a muscarinicantagonist and deuterated water, at a pD of from about 4.2 to about 7.9.In some embodiments, the ophthalmic solution has a pD of one of: lessthan about 7.3, less than about 7.2, less than about 7.1, less thanabout 7, less than about 6.8, less than about 6.5, less than about 6.4,less than about 6.3, less than about 6.2, less than about 6.1, less thanabout 6, less than about 5.9, less than about 5.8, less than about 5.2,or less than about 4.8 after extended period of time under storagecondition. In some embodiments, the muscarinic antagonist comprisesatropine, atropine sulfate, noratropine, atropine-N-oxide, tropine,tropic acid, hyoscine, scopolomine, tropicamide, cyclopentolate,pirenzapine, homatropine, or a combination thereof. In some embodiments,the ophthalmic solution comprises one of: less than 5% of H₂O, less than4% of H₂O, less than 3% of H₂O, less than 2% of H₂O, less than 1% ofH₂O, less than 0.5% of H₂O, less than 0.1% of H₂O, or 0% of H₂O. In someembodiments, the ophthalmic composition comprises one of: at least about80%, at least about 85%, at least about 90%, at least about 93%, atleast about 95%, at least about 97%, at least about 98%, or at leastabout 99% of the muscarinic antagonist based on initial concentrationafter extended period of time under storage condition. In someembodiments, the ophthalmic composition further has a potency of one of:at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, atleast 97%, at least 98%, or at least 99% after extended period of timeunder storage condition. In some embodiments, the extended period oftime is one of: about 1 week, about 2 weeks, about 3 weeks, about 1month, about 2 months, about 3 months, about 4 months, about 5 months,about 6 months, about 8 months, about 10 months, about 12 months, about18 months, about 24 months, about 36 months, about 4 years, or about 5years. In some embodiments, the muscarinic antagonist is present in thecomposition at a concentration of one of: from about 0.001 wt % to about0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about 0.001 wt% to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, fromabout 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about0.008 wt %, or from about 0.001 wt % to about 0.005 wt %. In someembodiments, the storage condition has a storage temperature of fromabout 2° C. to about 10° C. or from about 16° C. to about 26° C. In someembodiments, the ophthalmic composition has a dose-to-dose muscarinicantagonist concentration variation of one of: less than 50%, less than40%, less than 30%, less than 20%, less than 10%, or less than 5%. Insome embodiments, the dose-to-dose muscarinic antagonist concentrationvariation is based on one of: 10 consecutive doses, 8 consecutive doses,5 consecutive doses, 3 consecutive doses, or 2 consecutive doses.

In some embodiments, disclosed herein is an ophthalmic composition,comprising from about 0.001 wt % to about 0.05 wt % of a muscarinicantagonist and water, at a pH of from about 3.8 to about 7.5.

In some embodiments, the muscarinic antagonist comprises atropine,atropine sulfate, noratropine, atropine-N-oxide, tropine, tropic acid,hyoscine, scopolomine, tropicamide, cyclopentolate, pirenzapine,homatropine, or a combination thereof. In some embodiments, themuscarinic antagonist is atropine or atropine sulfate.

In some embodiments, the ophthalmic composition comprises one of: atleast about 80%, at least about 85%, at least about 90%, at least about93%, at least about 95%, at least about 97%, at least about 98%, or atleast about 99% of the muscarinic antagonist based on initialconcentration after extended period of time under storage condition.

In some embodiments, the ophthalmic composition has a pH of one of: lessthan about 7.3, less than about 7.2, less than about 7.1, less thanabout 7, less than about 6.8, less than about 6.5, less than about 6.4,less than about 6.3, less than about 6.2, less than about 6.1, less thanabout 6, less than about 5.9, less than about 5.8, less than about 5.2,less than about 4.8, or less than about 4.2 after extended period oftime under storage condition.

In some embodiments, the ophthalmic composition further has a potency ofone of: at least 80%, at least 85%, at least 90%, at least 93%, at least95%, at least 97%, at least 98%, or at least 99% after extended periodof time under storage condition.

In some embodiments, the extended period of time is one of: about 1week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about3 months, about 4 months, about 5 months, about 6 months, about 8months, about 10 months, about 12 months, about 18 months, about 24months, about 36 months, about 4 years, or about 5 years.

In some embodiments, the storage condition has a storage temperature ofone of: about 25° C., about 40° C., or about 60° C. In some embodiments,the storage condition has a storage temperature of from about 2° C. toabout 10° C. or from about 16° C. to about 26° C.

In some embodiments, the storage condition has a relative humidity ofabout 60% or about 75%.

In some embodiments, the muscarinic antagonist is present in thecomposition at a concentration of one of: from about 0.001 wt % to about0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about 0.001 wt% to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, fromabout 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.

In some embodiments, the ophthalmic composition further comprises anosmolarity adjusting agent. In some embodiments, the osmolarityadjusting agent is sodium chloride.

In some embodiments, the ophthalmic composition further comprises apreservative. In some embodiments, the preservative is selected frombenzalkonium chloride, cetrimonium, sodium perborate, stabilizedoxychloro complex, SofZia, polyquaternium-1, chlorobutanol, edetatedisodium, polyhexamethylene biguanide, or combinations thereof.

In some embodiments, the ophthalmic composition further comprises abuffer agent. In some embodiments, the buffer agent is selected fromborates, borate-polyol complexes, succinate, phosphate buffering agents,citrate buffering agents, acetate buffering agents, carbonate bufferingagents, organic buffering agents, amino acid buffering agents, orcombinations thereof.

In some embodiments, the ophthalmic composition further comprises atonicity adjusting agent. In some embodiments, the tonicity adjustingagent is selected from sodium chloride, sodium nitrate, sodium sulfate,sodium bisulfate, potassium chloride, calcium chloride, magnesiumchloride, zinc chloride, potassium acetate, sodium acetate, sodiumbicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate,disodium hydrogen phosphate, sodium dihydrogen phosphate, potassiumdihydrogen phosphate, dextrose, mannitol, sorbitol, dextrose, sucrose,urea, propylene glycol, glycerin, trehalose or a combination thereof.

In some embodiments, the ophthalmic composition is stored in a plasticcontainer. In some embodiments, the material of the plastic containercomprises low-density polyethylene (LDPE).

In some embodiments, the ophthalmic composition has a dose-to-dosemuscarinic antagonist concentration variation of one of: less than 50%,less than 40%, less than 30%, less than 20%, less than 10%, or less than5%.

In some embodiments, the dose-to-dose muscarinic antagonistconcentration variation is based on one of: 10 consecutive doses, 8consecutive doses, 5 consecutive doses, 3 consecutive doses, or 2consecutive doses.

In some embodiments, the ophthalmic composition has a pH of one of: fromabout 3.8 to about 7.5, from about 4.2 to about 7.5, from about 4.8 toabout 7.3, from about 5.2 to about 7.2, from about 5.8 to about 7.1,from about 6.0 to about 7.0, or from about 6.2 to about 6.8.

In some embodiments, the ophthalmic composition further comprises a pHadjusting agent. In some embodiments, the pH adjusting agent comprisesHCl, NaOH, CH₃COOH, or C₆H₈O₇.

In some embodiments, the ophthalmic composition comprises one of: lessthan 60% of D₂O, less than 55% of D₂O, less than 50% of D₂O, less than45% of D₂O, less than 40% of D₂O, less than 35% of D₂O, less than 30% ofD₂O, less than 25% of D₂O, less than 20% of D₂O, less than 15% of D₂O,or less than 10% of D₂O.

In some embodiments, the ophthalmic composition comprises one of: lessthan 5% of D₂O, less than 4% of D₂O, less than 3% of D₂O, less than 2%of D₂O, less than 1% of D₂O, less than 0.5% of D₂O, less than 0.1% ofD₂O, or 0% of D₂O. In some embodiments, ophthalmic composition isessentially free of D₂O.

In some embodiments, the composition further comprises apharmaceutically acceptable carrier.

In some embodiments, the ophthalmic composition is formulated as anophthalmic solution for the treatment of an ophthalmic disorder. In someembodiments, the ophthalmic disorder or condition is pre-myopia, myopia,or progression of myopia.

In some embodiments, the ophthalmic composition is not formulated as aninjectable formulation.

Other features and technical effects of the methods and compositionsdescribed herein will become apparent from the following detaileddescription. It should be understood, however, that the detaileddescription and the specific examples, while indicating specificembodiments, are given by way of illustration only.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the disclosure are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present disclosure will be obtained by reference tothe following detailed description that sets forth illustrativeembodiments, in which the principles of the disclosure are utilized, andthe accompanying drawings of which:

FIG. 1A-FIG. 1C show the shelf life prediction of 0.01% atropine sulfatesolution with a primary degradant RRT 0.87-0.89, and a n.m.t. of 0.5%area, based on data obtained from samples stored at 25° C. and 40° C.The pH range of the atropine sulfate solution is from 5.9-6.2.

FIG. 2A-FIG. 2C show the shelf life prediction of 0.01% atropine sulfatesolution with a primary degradant RRT 0.87-0.89, and a n.m.t. of 0.5%area, based on data obtained from samples stored at 25° C. and 60° C.The pH range of the atropine sulfate solution is from 5.9-6.2.

FIG. 3 illustrates mass balance at 4 weeks and at 60° C. condition foratropine sulfate formulations disclosed in Example 9.

FIG. 4 illustrates atropine sulfate (0.010%) formulation stability inacetic acid. The atropine sulfate formulation is formulated with aceticacid and either with H₂O (top panel, Formulation 3) or D₂O (bottompanel, Formulation 7). Formulation 3 has a pH of 4.8 and Formulation 7has a pD of 5.2. Both formulations are stored at 60° C. for 4 weeksprior to analysis.

FIG. 5 illustrates atropine sulfate (0.01%) formulation stability incitric acid. The atropine sulfate formulation is formulated with citricacid and either with H₂O (top panel, Formulation 5) or D₂O (bottompanel, Formulation 8). Formulation 5 has a pH of 5.8 and Formulation 8has a pD of 6.2. Both formulations are stored at 60° C. for 4 weeksprior to analysis.

FIG. 6 illustrates comparison of total RS and tropic acid for atropinesulfate (0.025%) formulation (Formulation 4) at pH 4.8 in H₂O.

FIG. 7 illustrates comparison of total RS and tropic acid for atropinesulfate (0.01%) formulation (Formulation 7) at pD 5.2 in D₂O.

FIG. 8 illustrates comparison of total RS and tropic acid for atropinesulfate (0.01%) formulation (Formulation 5) at pH 5.8 in H₂O.

FIG. 9 illustrates comparison of total RS and tropic acid for atropinesulfate (0.025%) formulation (Formulation 6) at pH 5.8 in H₂O.

FIG. 10 illustrates estimated shelf lives for D₂O and H₂O formulationsdisclosed in Examples 11 and 12.

FIG. 11A-FIG. 11C illustrate stability of atropine sulfate formulation 8in H₂O and D₂O under three storage conditions.

DETAILED DESCRIPTION OF THE DISCLOSURE

The present disclosure recognizes that there is a need for a stabilizedophthalmic composition with extended shelf life upon storage. Thepresent disclosure also recognizes that there is a need for stabilizingan ophthalmic composition through arresting or reducing hydrolysis of atleast some of its active agents. The present disclosure furtherrecognizes that there is a need for an ophthalmic composition thatprovides convenient and effective delivery of a muscarinic antagonistsuch as atropine in the eye of a patient.

The present disclosure recognizes that muscarinic antagonist (e.g.atropine or its pharmaceutically acceptable salts) prevents or arreststhe development of myopia in humans, for example as evidenced byreduction of the rate of increase of myopia in young people. The presentdisclosure also recognizes the effects of muscarinic antagonist (e.g.atropine or its pharmaceutically acceptable salts) on reduction of axialelongation and myopia in visually impaired chick eyes, and on oculargrowth and muscarinic cholinergic receptors in young rhesus monkeys.

In addition, the present disclosure recognizes that systemic absorptionof muscarinic antagonist (e.g. atropine) sometimes leads to undesirableside effect, and that localized delivery of muscarinic antagonist (e.g.atropine or its pharmaceutically acceptable salts) reduces or preventsthe aforementioned systemic exposure.

Further, the present disclosure recognizes that some liquid muscarinicantagonist (e.g. atropine) compositions are formulated at a relativelylower pH range (e.g. less than 4.5) for stability of muscarinicantagonist (e.g. atropine or its pharmaceutically acceptable salts). Forsome individuals, the lower pH range in some instances causes discomfortor other side effects such as pain or burning sensation in the eye,which is prevented or alleviated by formulating muscarinic antagonist(e.g. atropine) compositions at higher pH ranges. For some individuals,the lower pH in some instances elicits a tear response which reduces theabsorption of the drug in the eye and therefore the effectiveness.

Still further, the present disclosure recognizes that some muscarinicantagonist (e.g. atropine) liquid compositions formulated at lowerconcentrations (e.g. 0.001% to 0.05%) present stability challenges thatare less so in higher concentrations (e.g. 0.1-1%). Without wishing tobe bound by any particular theory, it is contemplated that the somemuscarinic antagonist (e.g. atropine) contributes to the stability of anophthalmic composition, such as an aqueous solution. For example, theconcentration of the muscarinic antagonist (e.g. atropine) in someembodiments affects the pH or pD of the ophthalmic composition, such aswith the muscarinic antagonist acting as a buffering agent. Furthermore,the concentration of the muscarinic antagonist (e.g. atropine) in someembodiments affects the interaction between the muscarinic antagonistand other ingredients of the ophthalmic composition, which in turnaffects the stability of the ophthalmic composition.

Finally, the present disclosure recognizes that deuterated waterstabilizes ophthalmic compositions. In some cases, the deuterated wateris a weak acid as compared to H₂O, as such deuterated water comprises alower concentration of the reactive species (e.g., —OD) which in someinstances leads to base catalyzed hydrolysis of an active agent in theophthalmic composition. As such, in some instances compositionscomprising deuterated water leads to reduced base catalyzed hydrolysiswhen compared to compositions comprising H₂O. In some instances,deuterated water further lowers the buffering capacity of an ophthalmiccomposition, leading to less tear reflex in the eye.

Myopia, axial elongation of the eye, affects a large proportion of thepopulation. The onset of myopia is generally during the grade schoolyears and progresses until growth of the eye is completed. The presentdisclosure recognizes the importance of compositions and treatments forpreventing or arresting the development of myopia, especiallycompositions and treatments that allow convenient administration, reducepotential side effects, has suitable stability, and/or providerelatively consistent therapeutic effects.

Ophthalmic Muscarinic Antagonist Composition

Provided herein is an ophthalmic composition containing lowconcentrations of an ophthalmic agent. In some embodiments, theophthalmic composition includes from about 0.001 wt % to about 0.05 wt %of an ophthalmic agent for treatment of an ophthalmic disorder orcondition; and an ophthalmically acceptable carrier, wherein theophthalmic agent is distributed with substantial uniformity throughoutthe ophthalmically acceptable carrier. In some instances, the ophthalmicagent is a muscarinic antagonist.

Provided herein is an ophthalmic composition containing lowconcentrations of a muscarinic antagonist. In some embodiments, theophthalmic composition includes from about 0.001 wt % to about 0.05 wt %of a muscarinic antagonist for treatment of an ophthalmic disorder orcondition; and an ophthalmically acceptable carrier, wherein themuscarinic antagonist is distributed with substantial uniformitythroughout the ophthalmically acceptable carrier.

In some instances, the muscarinic antagonist includes atropine, atropinesulfate, noratropine, atropine-N-oxide, tropine, tropic acid, atropinemethonitrate, diphenhydramine, dimenhydrinate, dicyclomine, flavoxate,oxybutynin, tiotropium, hyoscine, scopolomine (L-hyoscine), hydroxyzine,ipratropium, tropicamide, cyclopentolate, pirenzapine, homatropine,solifenacin, darifenacin, benzatropine, mebeverine, procyclidine,aclidinium bromide, trihexyphenidyl/benzhexol, tolterodine, or acombination thereof. In some instances, the muscarinic antagonistincludes atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, hyoscine, scopolomine, tropicamide,cyclopentolate, pirenzapine, homatropine, or a combination thereof. Insome embodiments, the muscarinic antagonist is atropine, or apharmaceutically acceptable salt or prodrug thereof. In someembodiments, the muscarinic antagonist is atropine sulfate.

In some embodiments, the ophthalmic composition comprise a muscarinicantagonist selected from atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, atropine methonitrate,diphenhydramine, dimenhydrinate, dicyclomine, flavoxate, oxybutynin,tiotropium, hyoscine, scopolomine (L-hyoscine), hydroxyzine,ipratropium, tropicamide, cyclopentolate, pirenzapine, homatropine,solifenacin, darifenacin, benzatropine, mebeverine, procyclidine,aclidinium bromide, trihexyphenidyl/benzhexol, tolterodine, or acombination thereof. In some instances, the muscarinic antagonistincludes atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, hyoscine, scopolomine, tropicamide,cyclopentolate, pirenzapine, or homatropine.

In some embodiments, the ophthalmic composition comprise two or moremuscarinic antagonists in which the two or more muscarinic antagonistscomprises atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, atropine methonitrate, diphenhydramine,dimenhydrinate, dicyclomine, flavoxate, oxybutynin, tiotropium,hyoscine, scopolomine (L-hyoscine), hydroxyzine, ipratropium,tropicamide, cyclopentolate, pirenzapine, homatropine, solifenacin,darifenacin, benzatropine, mebeverine, procyclidine, aclidinium bromide,trihexyphenidyl/benzhexol, tolterodine, or a combination thereof. Insome instances, the muscarinic antagonist includes atropine, atropinesulfate, noratropine, atropine-N-oxide, tropine, tropic acid, hyoscine,scopolomine, tropicamide, cyclopentolate, pirenzapine, homatropine, orany combination thereof.

In some embodiments, the ophthalmic composition comprises one or moremuscarinic antagonist in combination with one or more sympatheticagonists. In some embodiments, the sympathetic agonist is selected fromphenylephrine or hydroxyamphetamine. In some embodiments, the ophthalmiccomposition comprises one or more of muscarinic antagonist: atropine,atropine sulfate, noratropine, atropine-N-oxide, tropine, tropic acid,atropine methonitrate, diphenhydramine, dimenhydrinate, dicyclomine,flavoxate, oxybutynin, tiotropium, hyoscine, scopolomine (L-hyoscine),hydroxyzine, ipratropium, tropicamide, cyclopentolate, pirenzapine,homatropine, solifenacin, darifenacin, benzatropine, mebeverine,procyclidine, aclidinium bromide, trihexyphenidyl/benzhexol, ortolterodine; in combination with one or more of sympathetic agonists:phenylephrine or hydroxyamphetamine.

Provided herein is an ophthalmic composition containing lowconcentrations of atropine or its pharmaceutically acceptable salts. Insome embodiments, the ophthalmic composition includes from about 0.001wt % to about 0.05 wt % of atropine or its pharmaceutically acceptablesalts for treatment of an ophthalmic disorder or condition; and anophthalmically acceptable carrier, wherein the ophthalmic agent isdistributed with substantial uniformity throughout the ophthalmicallyacceptable carrier.

Provided herein is an ophthalmic composition containing lowconcentrations of atropine sulfate. In some embodiments, the ophthalmiccomposition includes from about 0.001 wt % to about 0.05 wt % ofatropine sulfate for treatment of an ophthalmic disorder or condition;and an ophthalmically acceptable carrier, wherein the ophthalmic agentis distributed with substantial uniformity throughout the ophthalmicallyacceptable carrier.

In some embodiments, the ophthalmic disorder or condition is pre-myopia,myopia or progression of myopia.

The present disclosure further recognizes that the clinical use ofatropine as a therapy has been limited due to its ocular side effectsincluding glare from pupillary dilation and blurred vision due to lossof accommodation. Without wishing to be bound by any particular theory,it is contemplated that the limited use of atropine against myopiadevelopment, include its ocular side effects, is attributable to theconcentration of atropine used in known ophthalmic formulations (e.g. 1wt % or higher).

The present disclosure further recognizes the challenges present informulation of compositions that contain low concentrations, especiallyvery low concentrations (e.g. from about 0.001 wt % to about 0.5 wt %),of ophthalmic agents, such as muscarinic antagonist (e.g. atropine orits pharmaceutically acceptable salts). In particular, pharmaceuticalcompositions with ophthalmic agent at such low concentrations aredifficult to maintain dose-to-dose uniformity in term of ophthalmicagent content and/or distribution.

In some aspects, described herein are formulations or solutions ofmuscarinic antagonist (e.g., atropine) formulated in deuterated water.In some aspects, formulations or solutions of muscarinic antagonist(e.g., atropine) formulated in deuterated water are stable at differenttemperatures, at different relative humidity, with an acidic pD, andwith a potency of at least 80% relative to the ophthalmic agent. Inadditional aspects, formulations or solutions of muscarinic antagonist(e.g., atropine) formulated in deuterated water has a lowered bufferingcapacity. In such instances, the lowered buffering capacity of theophthalmic formulations or solutions when administered into the eyeallows the ophthalmic formulation or solution to reach physiological pHat a faster rate than compared to an equivalent ophthalmic formulationor solution formulated in H₂O.

In some aspects, described herein are formulations of muscarinicantagonist (e.g. atropine) at low concentrations that does not have adose-to-dose variation. In some aspects, described herein areformulations of muscarinic antagonist (e.g. atropine) at lowconcentrations that are stable at different temperatures, at differentrelative humidity, with an acidic pD, and with a potency of at least 80%relative to the ophthalmic agent.

In other aspects, described herein include formulating the ophthalmiccomposition as an ophthalmic gel or an ophthalmic ointment. For example,some ophthalmic gel or an ophthalmic ointment described herein allowsdesirable dose-to-dose uniformity, reduced or limited systemic exposure,or combinations thereof.

Ophthalmic Solution Muscarinic Antagonist Composition

Disclosed herein, in certain embodiments, is an ophthalmic compositionformulated as an aqueous solution. In some embodiments, the ophthalmiccomposition comprises from about 0.001 wt % to about 0.05 wt % of amuscarinic antagonist and deuterated water. As used herein, deuteratedwater refers to D₂O, DHO, heavy water, and/or deuterium oxide.

In some embodiments, the composition comprises at least about 70% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 75% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 80% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 81% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 82% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 83% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 84% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 85% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 86% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 87% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 88% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 89% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 90% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 91% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 92% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 93% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 94% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 95% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 96% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 97% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition. Insome embodiments, the composition comprises at least about 98% of theophthalmic agent (e.g. muscarinic antagonist) for an extended period oftime under storage condition. In some embodiments, the compositioncomprises at least about 99% of the ophthalmic agent (e.g. muscarinicantagonist) for an extended period of time under storage condition.

In some embodiments, the composition has a potency of at least about 80%after extended period of time under storage condition. In someembodiments, the composition has a potency of at least about 81% afterextended period of time under storage condition. In some embodiments,the composition has a potency of at least about 82% after extendedperiod of time under storage condition. In some embodiments, thecomposition has a potency of at least about 83% after extended period oftime under storage condition. In some embodiments, the composition has apotency of at least about 84% after extended period of time understorage condition. In some embodiments, the composition has a potency ofat least about 85% after extended period of time under storagecondition. In some embodiments, the composition has a potency of atleast about 86% after extended period of time under storage condition.In some embodiments, the composition has a potency of at least about 87%after extended period of time under storage condition. In someembodiments, the composition has a potency of at least about 88% afterextended period of time under storage condition. In some embodiments,the composition has a potency of at least about 89% after extendedperiod of time under storage condition. In some embodiments, thecomposition has a potency of at least 90% after extended period of timeunder storage condition. In some embodiments, the composition has apotency of at least 91% after extended period of time under storagecondition. In some embodiments, the composition has a potency of atleast 92% after extended period of time under storage condition. In someembodiments, the composition has a potency of at least 93% afterextended period of time under storage condition. In some embodiments,the composition has a potency of at least 94% after extended period oftime under storage condition. In some embodiments, the composition has apotency of at least 95% after extended period of time under storagecondition. In some embodiments, the composition has a potency of atleast 96% after extended period of time under storage condition. In someembodiments, the composition has a potency of at least 97% afterextended period of time under storage condition. In some embodiments,the composition has a potency of at least 98% after extended period oftime under storage condition. In some embodiments, the composition has apotency of at least 99% after extended period of time under storagecondition.

In some embodiments, the extended period of time is at least 1 week. Insome embodiments, the extended period of time is at least 2 weeks. Insome embodiments, the extended period of time is at least 3 weeks. Insome embodiments, the extended period of time is at least 1 month. Insome embodiments, the extended period of time is at least 2 months. Insome embodiments, the extended period of time is at least 3 months. Insome embodiments, the extended period of time is at least 4 months. Insome embodiments, the extended period of time is at least 5 months. Insome embodiments, the extended period of time is at least 6 months. Insome embodiments, the extended period of time is at least 7 months. Insome embodiments, the extended period of time is at least 8 months. Insome embodiments, the extended period of time is at least 9 months. Insome embodiments, the extended period of time is at least 10 months. Insome embodiments, the extended period of time is at least 11 months. Insome embodiments, the extended period of time is at least 12 months(i.e. 1 year). In some embodiments, the extended period of time is atleast 18 months (i.e. 1.5 years). In some embodiments, the extendedperiod of time is at least 24 months (i.e. 2 years). In someembodiments, the extended period of time is at least 36 months (i.e. 3years). In some embodiments, the extended period of time is at least 3years. In some embodiments, the extended period of time is at least 5years, or more.

In some embodiments, the temperature of the storage condition is betweenabout 20° C. and about 70° C. In some embodiments, the temperature ofthe storage condition is between about 25° C. and about 65° C., about30° C. and about 60° C. about 35° C. and about 55° C., or about 40° C.and about 50° C. In some embodiments, the temperature of the storagecondition is about 25° C. In some embodiments, the temperature of thestorage condition is about 40° C. In some embodiments, the temperatureof the storage condition is about 60° C.

In some embodiments, the relative humidity of the storage condition isbetween about 50% and about 80%, or between about 60% and about 75%. Insome embodiments, the relative humidity of the storage condition isabout 60%. In some embodiments, the relative humidity of the storagecondition is about 75%.

In some embodiments, the composition comprises less than 60% of H₂O. Insome embodiments, the composition comprises less than 55% of H₂O. Insome embodiments, the composition comprises less than 50% of H₂O. Insome embodiments, the composition comprises less than 45% of H₂O. Insome embodiments, the composition comprises less than 40% of H₂O. Insome embodiments, the composition comprises less than 35% of H₂O. Insome embodiments, the composition comprises less than 30% of H₂O. Insome embodiments, the composition comprises less than 25% of H₂O. Insome embodiments, the composition comprises less than 20% of H₂O. Insome embodiments, the composition comprises less than 15% of H₂O. Insome embodiments, the composition comprises less than 10% of H₂O.

In some embodiments, the composition comprises from less than 5% of H₂Oto 0% of H₂O. In some embodiments, the composition comprises less than5% of H₂O. In some embodiments, the composition comprises less than 4.5%of H₂O. In some embodiments, the composition comprises less than 4% ofH₂O. In some embodiments, the composition comprises less than 3.5% ofH₂O. In some embodiments, the composition comprises less than 3% of H₂O.In some embodiments, the composition comprises less than 2.5% of H₂O. Insome embodiments, the composition comprises less than 2% of H₂O. In someembodiments, the composition comprises less than 1.5% of H₂O. In someembodiments, the composition comprises less than 1% of H₂O. In someembodiments, the composition comprises less than 0.5% of H₂O. In someembodiments, the composition comprises less than 0.4% of H₂O. In someembodiments, the composition comprises less than 0.3% of H₂O. In someembodiments, the composition comprises less than 0.2% of H₂O. In someembodiments, the composition comprises less than 0.1% of H₂O. In someembodiments, the composition comprises 0% of H₂O.

In some embodiments, the composition has a pD of between about 4 andabout 8, about 4.5 and about 7.8, about 5 and about 7.5, or about 5.5and about 7. In some embodiments, the composition has a pD of less thanabout 7.5. In some embodiments, the composition has a pD of less thanabout 7.4. In some embodiments, the composition has a pD of less thanabout 7.3. In some embodiments, the composition has a pD of less thanabout 7.2. In some embodiments, the composition has a pD of less thanabout 7.1. In some embodiments, the composition has a pD of less thanabout 7. In some embodiments, the composition has a pD of less thanabout 6.9. In some embodiments, the composition has a pD of less thanabout 6.8. In some embodiments, the composition has a pD of less thanabout 6.7. In some embodiments, the composition has a pD of less thanabout 6.6. In some embodiments, the composition has a pD of less thanabout 6.5. In some embodiments, the composition has a pD of less thanabout 6.4. In some embodiments, the composition has a pD of less thanabout 6.3. In some embodiments, the composition has a pD of less thanabout 6.2. In some embodiments, the composition has a pD of less thanabout 6.1. In some embodiments, the composition has a pD of less thanabout 6. In some embodiments, the composition has a pD of less thanabout 5.9. In some embodiments, the composition has a pD of less thanabout 5.8. In some embodiments, the composition has a pD of less thanabout 5.7. In some embodiments, the composition has a pD of less thanabout 5.6. In some embodiments, the composition has a pD of less thanabout 5.5. In some embodiments, the composition has a pD of less thanabout 5.4. In some embodiments, the composition has a pD of less thanabout 5.3. In some embodiments, the composition has a pD of less thanabout 5.2. In some embodiments, the composition has a pD of less thanabout 5.1. In some embodiments, the composition has a pD of less thanabout 5. In some embodiments, the composition has a pD of less thanabout 4.9. In some embodiments, the composition has a pD of less thanabout 4.8. In some embodiments, the composition has a pD of less thanabout 4.7. In some embodiments, the composition has a pD of less thanabout 4.6. In some embodiments, the composition has a pD of less thanabout 4.5. In some embodiments, the composition has a pD of less thanabout 4.4. In some embodiments, the composition has a pD of less thanabout 4.3. In some embodiments, the composition has a pD of less thanabout 4.2. In some embodiments, the composition has a pD of less thanabout 4.1. In some embodiments, the composition has a pD of less thanabout 4.

In some embodiments, the composition comprising deuterated water has alowered buffering capacity than an equivalent composition comprisingH₂O. As described elsewhere herein, in some embodiments, the loweredbuffering capacity allows the composition comprising deuterated water tonormalize to physiological pH at a faster rate than a compositioncomprising H₂O. In some embodiments, the lowered buffering capacityallows the composition to induce less tear reflex than an equivalentcomposition comprising H₂O.

In some instances, the composition comprising deuterated waterstabilizes muscarinic antagonist (e.g., atropine). In some embodiments,this is due to a lower concentration of the reactive species (e.g., —OD)in the D₂O aqueous system compared to the concentration of the reactivespecies (e.g., —OH) in an equivalent H₂O aqueous system. In some cases,base catalyzed hydrolysis leads to the presence of tropine degradantfrom atropine. In some cases, with a lower concentration of the reactivespecies that causes tropine degradant formation, atropine solution ismore stable in a D₂O aqueous system than compared to an equivalent H₂Oaqueous system. In some embodiments, the ophthalmic compositionformulated with deuterated water allows for a more stable ophthalmiccomposition relative to the ophthalmic composition formulated with H₂O.

In some embodiments, the composition comprises less than 20% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 15% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition.

In some embodiments, the composition comprises less than 10% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 5% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 2.0% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 1.5% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 1.0% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 0.5% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 0.4% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition comprises less than 0.3% of major degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition comprisesless than 0.2% of major degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition comprises less than 0.1% of majordegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the major degradant is tropic acid.

In some embodiments, the primary degradant is an early eluting relatedsubstance at RRT of 0.87-0.89 according to the UPLC method describedherein (Table 10). In some instances, the early eluting relatedsubstance is referred to as RRT 0.87-0.89. In some embodiments, theprimary degradant is RRT 0.87-0.89.

In some embodiments, the composition does not stabilize singlet oxygenupon irradiation with UV. In some cases, one or more of muscarinicantagonists described herein does not extend singlet oxygen lifetime. Insome cases, one or more of muscarinic antagonists described herein is aradical scavenger, which quenches photogenerated singlet oxygen specieswithin the composition. In some instances, the one or more muscarinicantagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some instances, the one or more muscarinic antagonistcomprises atropine, atropine sulfate, homatropine, scopolamine or acombination thereof. In some instances, the one or more muscarinicantagonist comprises atropine or atropine sulfate. In some instances, acomposition comprising atropine or atropine sulfate does not stabilizesinglet oxygen upon irradiation with UV. In some instances, acomposition comprising atropine or atropine sulfate quenchesphotogenerated singlet oxygen species present in the composition.

Ophthalmic Muscarinic Antagonist Concentration

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.050%,between about 0.005% to about 0.050%, between about 0.010% to about0.050%, between about 0.015% to about 0.050%, between about 0.020% toabout 0.050%, between about 0.025% to about 0.050%, between about 0.030%to about 0.050%, between about 0.035% to about 0.050%, between about0.040% to about 0.050%, or between about 0.045% to about 0.050% of theophthalmic agent, or pharmaceutically acceptable prodrug or saltthereof, by weight of the composition. In some instances, the prodrug ofthe ophthalmic agent (e.g. muscarinic antagonist) is chemicallyconverted into the ophthalmic agent (e.g. muscarinic antagonist) afterthe administration of the ophthalmic composition. In anon-limitingexample, the muscarinic antagonist prodrug has a chemical bond that iscleavable by one or more enzymes in tears. In some embodiments, theophthalmic agent is a muscarinic antagonist. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist is atropine, ora pharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate. As described herein, theophthalmic agent includes optically pure stereoisomers, opticallyenriched stereoisomers, and a racemic mixture of stereoisomers. Forexample, some ophthalmic compositions disclosed herein includes atropineor atropine sulfate in which the atropine is a racemic mixture of D- andL-isomers; and some ophthalmic compositions disclosed herein includesatropine or atropine sulfate in which the atropine is a opticallyenriched in favor of the more ophthalmically active L-isomer.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.045%,between about 0.005% to about 0.045%, between about 0.010% to about0.045%, between about 0.015% to about 0.045%, between about 0.020% toabout 0.045%, between about 0.025% to about 0.045%, between about 0.030%to about 0.045%, between about 0.035% to about 0.045%, or between about0.040% to about 0.045% of the ophthalmic agent, or pharmaceuticallyacceptable prodrug or salt thereof, by weight of the composition. Insome embodiments, the ophthalmic agent is a muscarinic antagonist. Insome embodiments, the muscarinic antagonist comprises atropine, atropinesulfate, noratropine, atropine-N-oxide, tropine, tropic acid, hyoscine,scopolomine, tropicamide, cyclopentolate, pirenzapine, homatropine, or acombination thereof. In some embodiments, the muscarinic antagonist isatropine, or a pharmaceutically acceptable salt thereof. In someembodiments, the muscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.040%,between about 0.005% to about 0.040%, between about 0.010% to about0.040%, between about 0.015% to about 0.040%, between about 0.020% toabout 0.040%, between about 0.025% to about 0.040%, between about 0.030%to about 0.040%, between about 0.035% to about 0.040% of the activeingredient, or pharmaceutically acceptable prodrug or salt thereof, byweight of the composition. In some embodiments, the ophthalmic agent isa muscarinic antagonist. In some embodiments, the muscarinic antagonistcomprises atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, hyoscine, scopolomine, tropicamide,cyclopentolate, pirenzapine, homatropine, or a combination thereof. Insome embodiments, the muscarinic antagonist is atropine, or apharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.035%,between about 0.005% to about 0.035%, between about 0.010% to about0.035%, between about 0.015% to about 0.035%, between about 0.020% toabout 0.035%, between about 0.025% to about 0.035%, or between about0.030% to about 0.035% of the ophthalmic agent, or pharmaceuticallyacceptable prodrug or salt thereof, by weight of the composition. Insome embodiments, the ophthalmic agent is a muscarinic antagonist. Insome embodiments, the muscarinic antagonist comprises atropine, atropinesulfate, noratropine, atropine-N-oxide, tropine, tropic acid, hyoscine,scopolomine, tropicamide, cyclopentolate, pirenzapine, homatropine, or acombination thereof. In some embodiments, the muscarinic antagonist isatropine, or a pharmaceutically acceptable salt thereof. In someembodiments, the muscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.030%,between about 0.005% to about 0.030%, between about 0.010% to about0.030%, between about 0.015% to about 0.030%, between about 0.020% toabout 0.030%, or between about 0.025% to about 0.030% of the activeingredient, or pharmaceutically acceptable prodrug or salt thereof, byweight of the composition. In some embodiments, the ophthalmic agent isa muscarinic antagonist. In some embodiments, the muscarinic antagonistcomprises atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, hyoscine, scopolomine, tropicamide,cyclopentolate, pirenzapine, homatropine, or a combination thereof. Insome embodiments, the muscarinic antagonist is atropine, or apharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.025%,between about 0.005% to about 0.025%, between about 0.010% to about0.025%, between about 0.015% to about 0.025%, or between about 0.020% toabout 0.025% of the ophthalmic agent, or pharmaceutically acceptableprodrug or salt thereof, by weight of the composition. In someembodiments, the ophthalmic agent is a muscarinic antagonist. In someembodiments, the muscarinic antagonist comprises atropine, atropinesulfate, noratropine, atropine-N-oxide, tropine, tropic acid, hyoscine,scopolomine, tropicamide, cyclopentolate, pirenzapine, homatropine, or acombination thereof. In some embodiments, the muscarinic antagonist isatropine, or a pharmaceutically acceptable salt thereof. In someembodiments, the muscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.020%,between about 0.005% to about 0.020%, between about 0.010% to about0.020%, or between about 0.015% to about 0.020% of the activeingredient, or pharmaceutically acceptable prodrug or salt thereof, byweight of the composition. In some embodiments, the ophthalmic agent isa muscarinic antagonist. In some embodiments, the muscarinic antagonistcomprises atropine, atropine sulfate, noratropine, atropine-N-oxide,tropine, tropic acid, hyoscine, scopolomine, tropicamide,cyclopentolate, pirenzapine, homatropine, or a combination thereof. Insome embodiments, the muscarinic antagonist is atropine, or apharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.015%,between about 0.005% to about 0.015%, or between about 0.010% to about0.015% of the ophthalmic agent, or pharmaceutically acceptable prodrugor salt thereof, by weight of the composition. In some embodiments, theophthalmic agent is a muscarinic antagonist. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist is atropine, ora pharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent between about 0.001% to about 0.010%,between about 0.005% to about 0.010%, or between about 0.008% to about0.010% of the ophthalmic agent, or pharmaceutically acceptable prodrugor salt thereof, by weight of the composition. In some embodiments, theophthalmic agent is a muscarinic antagonist. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist is atropine, ora pharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

In some embodiments, the compositions described herein have aconcentration of ophthalmic agent about 0.001%, 0.005%, 0.010%, 0.015%,0.020%, 0.025%, 0.030%, 0.035%, 0.040%, 0.045%, or 0.050% of theophthalmic agent, or pharmaceutically acceptable prodrug or saltthereof, by weight of the composition. In some embodiments, theophthalmic agent is a muscarinic antagonist. In some embodiments, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolamine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some embodiments, the muscarinic antagonist is atropine, ora pharmaceutically acceptable salt thereof. In some embodiments, themuscarinic antagonist is atropine sulfate.

Without wishing to be bound by any particular theory, it is contemplatedherein that the low concentration of the ophthalmic agent (e.g.muscarinic antagonist such as atropine or atropine sulfate) in thedisclosed ophthalmic composition provides sufficient and consistenttherapeutic benefits to an individual in need thereof, while reducing oravoiding the ocular side effects including glare from pupillary dilationand blurred vision due to loss of accommodation that are associated withophthalmic formulations containing higher concentrations of theophthalmic agent (e.g. muscarinic antagonist such as atropine oratropine sulfate).

Aqueous Solution Stability

In some embodiments, the composition described herein comprises abuffer. In some embodiments, a buffer is selected from borates,borate-polyol complexes, succinate, phosphate buffering agents, citratebuffering agents, acetate buffering agents, carbonate buffering agents,organic buffering agents, amino acid buffering agents, or combinationsthereof. In some embodiments, the composition described herein comprisesbuffer comprising deuterated water. In some embodiments, a deuteratedbuffer is selected from borates, borate-polyol complexes, succinate,phosphate buffering agents, citrate buffering agents, acetate bufferingagents, carbonate buffering agents, organic buffering agents, amino acidbuffering agents, or combinations thereof, formulated in deuteratedwater.

In some instances, borates include boric acid, salts of boric acid,other pharmaceutically acceptable borates, and combinations thereof. Insome cases, borates include boric acid, sodium borate, potassium borate,calcium borate, magnesium borate, manganese borate, and other suchborate salts.

As used herein, the term polyol includes any compound having at leastone hydroxyl group on each of two adjacent carbon atoms that are not intrans configuration relative to each other. In some embodiments, thepolyols is linear or cyclic, substituted or unsubstituted, or mixturesthereof, so long as the resultant complex is water soluble andpharmaceutically acceptable. In some instances, examples of polyolinclude, sugars, sugar alcohols, sugar acids and uronic acids. In somecases, polyols include, but are not limited to: mannitol, glycerin,xylitol and sorbitol.

In some embodiments, phosphate buffering agents include phosphoric acid;alkali metal phosphates such as disodium hydrogen phosphate, sodiumdihydrogen phosphate, trisodium phosphate, dipotassium hydrogenphosphate, potassium dihydrogen phosphate, and tripotassium phosphate,alkaline earth metal phosphates such as calcium phosphate, calciumhydrogen phosphate, calcium dihydrogen phosphate, monomagnesiumphosphate, dimagnesium phosphate (magnesium hydrogen phosphate), andtrimagnesium phosphate; ammonium phosphates such as diammonium hydrogenphosphate and ammonium dihydrogen phosphate; or a combination thereof.In some instances, the phosphate buffering agent is an anhydride. Insome instances, the phosphate buffering agent is a hydrate.

In some embodiments, borate-polyol complexes include those described inU.S. Pat. No. 6,503,497. In some instances, the borate-polyol complexescomprise borates in an amount of from about 0.01 to about 2.0% w/v, andone or more polyols in an amount of from about 0.01% to about 5.0% w/v.

In some cases, citrate buffering agents include citric acid and sodiumcitrate.

In some instances, acetate buffering agents include acetic acid,potassium acetate, and sodium acetate.

In some instances, carbonate buffering agents include sodium bicarbonateand sodium carbonate.

In some cases, organic buffering agents include Good's Buffer, such asfor example 2-(N-morpholino)ethanesulfonic acid (MES),N-(2-Acetamido)iminodiacetic acid, N-(Carbamoylmethyl)iminodiacetic acid(ADA), piperazine-N,N′-bis(2-ethanesulfonic acid (PIPES),N-(2-acetamido)-2-aminoethanesulfonic acid (ACES),β-Hydroxy-4-morpholinepropanesulfonic acid,3-Morpholino-2-hydroxypropanesulfonic acid (MOPSO), cholamine chloride,3-(N-morpholino)propanesulfonic acid (MOPS),N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES),2-[(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid(TES), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),3-(N,N-Bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO),acetamidoglycine,3-{[1,3-Dihydroxy-2-(hydroxymethyl)-2-propanyl]amino}-2-hydroxy-1-propanesulfonicacid (TAPSO), piperazine-1,4,-bis (2-hydroxypropanesulphonic acid)(POPSO), 4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid)hydrate (HEPPSO), 3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonicacid (HEPPS), tricine, glycinamide, bicine orN-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid sodium (TAPS);glycine; and diethanolamine (DEA).

In some cases, amino acid buffering agents include taurine, asparticacid and its salts (e.g., potassium salts, etc), E-aminocaproic acid,and the like.

In some instances, the composition described herein further comprises atonicity adjusting agent. Tonicity adjusting agent is an agentintroduced into a preparation such as an ophthalmic composition toreduce local irritation by preventing osmotic shock at the site ofapplication. In some instances, buffer solution and/or a pD adjustingagent that broadly maintains the ophthalmic solution at a particular ionconcentration and pD are considered as tonicity adjusting agents. Insome cases, tonicity adjusting agents include various salts, such ashalide salts of a monovalent cation. In some cases, tonicity adjustingagents include mannitol, sorbitol, dextrose, sucrose, urea, andglycerin. In some instances, suitable tonicity adjustors comprise sodiumchloride, sodium nitrate, sodium sulfate, sodium bisulfate, potassiumchloride, calcium chloride, magnesium chloride, zinc chloride, potassiumacetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodiumthiosulfate, magnesium sulfate, disodium hydrogen phosphate, sodiumdihydrogen phosphate, potassium dihydrogen phosphate, dextrose,mannitol, sorbitol, dextrose, sucrose, urea, propylene glycol, glycerin,trehalose, or a combination thereof.

In some instances, the concentration of the tonicity adjusting agent ina composition described herein is between about 0.5% and about 2.0%. Insome instances, the concentration of the tonicity adjusting agent in acomposition described herein is between about 0.7% and about 1.8%, about0.8% and about 1.55%, or about 1% and about 1.3%. In some instances, theconcentration of the tonicity adjusting agent is about 0.6%, 0.7%, 0.8%,0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, or 1.9%. Insome cases, the percentage is a weight percentage.

In some cases, the composition described herein further comprises a pDadjusting agent. In some embodiments, the pD adjusting agent used is anacid or a base. In some embodiments, the base is oxides, hydroxides,carbonates, bicarbonates and the likes. In some instances, the oxidesare metal oxides such as calcium oxide, magnesium oxide and the likes;hydroxides are of alkali metals and alkaline earth metals such as sodiumhydroxide, potassium hydroxide, calcium hydroxide and the likes or theirdeuterated equivalents, and carbonates are sodium carbonate, sodiumbicarbonates, potassium bicarbonates and the likes. In some instances,the acid is mineral acid and organic acids such as hydrochloric acid,nitric acid, phosphoric acid, acetic acid, citric acid, fumaric acid,malic acid tartaric acid and the likes or their deuterated equivalents.In some instances, the pD adjusting agent includes, but is not limitedto, acetate, bicarbonate, ammonium chloride, citrate, phosphate,pharmaceutically acceptable salts thereof and combinations or mixturesthereof. In some embodiments, the pD adjusting agent comprises DCl andNaOD.

In some instances, the composition has a pD of between about 4 and about8, about 4.5 and about 7.8, about 5 and about 7.5, or about 5.5 andabout 7. In some embodiments, the composition has a pD of less thanabout 7.5. In some embodiments, the composition has a pD of less thanabout 7.4. In some embodiments, the composition has a pD of less thanabout 7.3. In some embodiments, the composition has a pD of less thanabout 7.2. In some embodiments, the composition has a pD of less thanabout 7.1. In some embodiments, the composition has a pD of less thanabout 7. In some embodiments, the composition has a pD of less thanabout 6.9. In some embodiments, the composition has a pD of less thanabout 6.8. In some embodiments, the composition has a pD of less thanabout 6.7. In some embodiments, the composition has a pD of less thanabout 6.6. In some embodiments, the composition has a pD of less thanabout 6.5. In some embodiments, the composition has a pD of less thanabout 6.4. In some embodiments, the composition has a pD of less thanabout 6.3. In some embodiments, the composition has a pD of less thanabout 6.2. In some embodiments, the composition has a pD of less thanabout 6.1. In some embodiments, the composition has a pD of less thanabout 6. In some embodiments, the composition has a pD of less thanabout 5.9. In some embodiments, the composition has a pD of less thanabout 5.8. In some embodiments, the composition has a pD of less thanabout 5.7. In some embodiments, the composition has a pD of less thanabout 5.6. In some embodiments, the composition has a pD of less thanabout 5.5. In some embodiments, the composition has a pD of less thanabout 5.4. In some embodiments, the composition has a pD of less thanabout 5.3. In some embodiments, the composition has a pD of less thanabout 5.2. In some embodiments, the composition has a pD of less thanabout 5.1. In some embodiments, the composition has a pD of less thanabout 5. In some embodiments, the composition has a pD of less thanabout 4.9. In some embodiments, the composition has a pD of less thanabout 4.8. In some embodiments, the composition has a pD of less thanabout 4.7. In some embodiments, the composition has a pD of less thanabout 4.6. In some embodiments, the composition has a pD of less thanabout 4.5. In some embodiments, the composition has a pD of less thanabout 4.4. In some embodiments, the composition has a pD of less thanabout 4.3. In some embodiments, the composition has a pD of less thanabout 4.2. In some embodiments, the composition has a pD of less thanabout 4.1. In some embodiments, the composition has a pD of less thanabout 4. In some embodiments, the pD is the pD of the composition afterextended period of time under storage condition.

In some instances, the composition has an initial pD of between about 4and about 8, about 4.5 and about 7.8, about 5 and about 7.5, or about5.5 and about 7. In some embodiments, the composition has an initial pDof about 7.5. In some embodiments, the composition has an initial pD ofabout 7.4. In some embodiments, the composition has an initial pD ofabout 7.3. In some embodiments, the composition has an initial pD ofabout 7.2. In some embodiments, the composition has an initial pD ofabout 7.1. In some embodiments, the composition has an initial pD ofabout 7. In some embodiments, the composition has an initial pD of about6.9. In some embodiments, the composition has an initial pD of about6.8. In some embodiments, the composition has an initial pD of about6.7. In some embodiments, the composition has an initial pD of about6.6. In some embodiments, the composition has an initial pD of about6.5. In some embodiments, the composition has an initial pD of about6.4. In some embodiments, the composition has an initial pD of about6.3. In some embodiments, the composition has an initial pD of about6.2. In some embodiments, the composition has an initial pD of about6.1. In some embodiments, the composition has an initial pD of about 6.In some embodiments, the composition has an initial pD of about 5.9. Insome embodiments, the composition has an initial pD of about 5.8. Insome embodiments, the composition has an initial pD of about 5.7. Insome embodiments, the composition has an initial pD of about 5.6. Insome embodiments, the composition has an initial pD of about 5.5. Insome embodiments, the composition has an initial pD of about 5.4. Insome embodiments, the composition has an initial pD of about 5.3. Insome embodiments, the composition has an initial pD of about 5.2. Insome embodiments, the composition has an initial pD of about 5.1. Insome embodiments, the composition has an initial pD of about 5. In someembodiments, the composition has an initial pD of about 4.9. In someembodiments, the composition has an initial pD of about 4.8. In someembodiments, the composition has an initial pD of about 4.7. In someembodiments, the composition has an initial pD of about 4.6. In someembodiments, the composition has an initial pD of about 4.5. In someembodiments, the composition has an initial pD of about 4.4. In someembodiments, the composition has an initial pD of about 4.3. In someembodiments, the composition has an initial pD of about 4.2. In someembodiments, the composition has an initial pD of about 4.1. In someembodiments, the composition has an initial pD of about 4.

In some embodiments, the pD of the composition described herein isassociated with the stability of the composition. In some embodiments, astable composition comprises a pD of between about 4 and about 8, about4.5 and about 7.8, about 5 and about 7.5, or about 5.5 and about 7. Insome embodiments, a stable composition comprises a pD of less than about7.5. In some embodiments, a stable composition comprises a pD of lessthan about 7.4. In some embodiments, a stable composition comprises a pDof less than about 7.3. In some embodiments, a stable compositioncomprises a pD of less than about 7.2. In some embodiments, a stablecomposition comprises a pD of less than about 7.1. In some embodiments,a stable composition comprises a pD of less than about 7. In someembodiments, a stable composition comprises a pD of less than about 6.9.In some embodiments, a stable composition comprises a pD of less thanabout 6.8. In some embodiments, a stable composition comprises a pD ofless than about 6.7. In some embodiments, a stable composition comprisesa pD of less than about 6.6. In some embodiments, a stable compositioncomprises a pD of less than about 6.5. In some embodiments, a stablecomposition comprises a pD of less than about 6.4. In some embodiments,a stable composition comprises a pD of less than about 6.3. In someembodiments, a stable composition comprises a pD of less than about 6.2.In some embodiments, a stable composition comprises a pD of less thanabout 6.1. In some embodiments, a stable composition comprises a pD ofless than about 6. In some embodiments, a stable composition comprises apD of less than about 5.9. In some embodiments, a stable compositioncomprises a pD of less than about 5.8. In some embodiments, a stablecomposition comprises a pD of less than about 5.7. In some embodiments,a stable composition comprises a pD of less than about 5.6. In someembodiments, a stable composition comprises a pD of less than about 5.5.In some embodiments, a stable composition comprises a pD of less thanabout 5.4. In some embodiments, a stable composition comprises a pD ofless than about 5.3. In some embodiments, a stable composition comprisesa pD of less than about 5.2. In some embodiments, a stable compositioncomprises a pD of less than about 5.1. In some embodiments, a stablecomposition comprises a pD of less than about 5. In some embodiments, astable composition comprises a pD of less than about 4.9. In someembodiments, a stable composition comprises a pD of less than about 4.8.In some embodiments, a stable composition comprises a pD of less thanabout 4.7. In some embodiments, a stable composition comprises a pD ofless than about 4.6. In some embodiments, a stable composition comprisesa pD of less than about 4.5. In some embodiments, a stable compositioncomprises a pD of less than about 4.4. In some embodiments, a stablecomposition comprises a pD of less than about 4.3. In some embodiments,a stable composition comprises a pD of less than about 4.2. In someembodiments, a stable composition comprises a pD of less than about 4.1.In some embodiments, a stable composition comprises a pD of less thanabout 4.

As described elsewhere herein, in some instances, the D₂O aqueous systemstabilizes a muscarinic antagonist (e.g., atropine). In someembodiments, this is due to a lower concentration of the reactivespecies (e.g., —OD) in the D₂O aqueous system compared to theconcentration of the reactive species (e.g., —OH) in an equivalent H₂Oaqueous system. In some instances, the concentration of the reactivespecies (e.g., —OD) in the D₂O aqueous system is about one third lessthan the concentration of the reactive species (e.g., —OH) in theequivalent H₂O aqueous system. In some cases, this is due to a lower orsmaller dissociation constant of D₂O than H₂O. For example, theK_(a)(H₂O) is 1×10⁻¹⁴, whereas the K^(a)(D₂O) is 1×10⁻¹⁵. As such, D₂Ois a weaker acid than H₂O. In some cases, base catalyzed hydrolysisleads to the presence of tropine degradant from atropine. In some cases,with a lower concentration of the reactive species that causes tropinedegradant formation, atropine solution is more stable in a D₂O aqueoussystem than compared to an equivalent H₂O aqueous system. In someembodiments, the ophthalmic composition formulated with deuterated waterallows for a more stable ophthalmic composition relative to theophthalmic composition formulated with H₂O.

In some embodiments, the presence of deuterated water shifts the pKa ofthe buffer. In some embodiments, the presence of deuterated water allowsfor the ophthalmic composition to simulate the stability of a lower pHsystem. In some instances, the buffer capacity of the ophthalmiccomposition is lowered, thereby allowing a faster shift in pH. In someinstances, the lowered buffering capacity of the ophthalmic compositionwhen administered into the eye allows the ophthalmic composition toreach physiological pH at a faster rate than compared to an ophthalmiccomposition formulated in H₂O. In some instances, the ophthalmiccomposition formulated with deuterated water allows for a lower tearproduction, or less tear reflex in the eye, in comparison with anophthalmic composition formulated with H₂O.

In some instances, the composition described herein further comprises adisinfecting agent. In some cases, disinfecting agents include polymericbiguanides, polymeric quaternary ammonium compounds, chlorites,bisbiguanides, chlorite compounds (e.g. potassium chlorite, sodiumchlorite, calcium chlorite, magnesium chlorite, or mixtures thereof),and a combination thereof.

In some instances, the composition described herein further comprises apreservative. In some cases, a preservative is added at a concentrationto a composition described herein to prevent the growth of or to destroya microorganism introduced into the composition. In some instances,microorganisms refer to bacteria (e.g. Proteus mirabilis, Serratiamarcesens), virus (e.g. Herpes simplex virus, herpes zoster virus),fungus (e.g. fungi from the genus Fusarium), yeast (e.g. Candidaalbicans), parasites (e.g. Plasmodium spp., Gnathostoma spp.), protozoan(e.g. Giardia lamblia), nematodes (e.g. Onchocercus volvulus), worm(e.g. Dirofilaria immitis), and/or amoeba (e.g. Acanthameoba).

In some instances, the concentration of the preservative is betweenabout 0.0001% and about 1%, about 0.001% and about 0.8%, about 0.004%and about 0.5%, about 0.008% and about 0.1%, and about 0.01% and about0.08%. In some cases, the concentration of the preservatives is about0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.008%, 0.009%, 0.009%,0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1.0%.

In some embodiments, the preservative is selected from benzalkoniumchloride, cetrimonium, sodium perborate, stabilized oxychloro complex,SofZia (Alcon), polyquaternium-1, chlorobutanol, edetate disodium, andpolyhexamethylene biguanide.

In some embodiments, the composition described herein is stored in aplastic container. In some embodiments, the material of the plasticcontainer comprises high density polyethylene (HDPE), low densitypolyethylene (LDPE), polyethylene terephthalate (PET), polyvinylchloride (PVC), polyproylene (PP), polystyrene (PS), fluorine treatedHDPE, post-consumer resin (PCR), K-resine (SBC), or bioplastic. In someembodiments, the material of the plastic container comprises LDPE.

In some embodiments, the composition described herein is stored in aplastic container. In some embodiments, the composition stored in aplastic container has a pD of between about 4 and about 8, about 4.5 andabout 7.9, or about 4.9 and about 7.5. In some embodiments, thecomposition stored in a plastic container has a pD of less than about7.4. In some embodiments, the composition stored in a plastic containerhas a pD of less than about 7.3. In some embodiments, the compositionstored in a plastic container has a pD of less than about 7.2. In someembodiments, the composition stored in a plastic container has a pD ofless than about 7.1. In some embodiments, the composition stored in aplastic container has a pD of less than about 7. In some embodiments,the composition stored in a plastic container has a pD of less thanabout 6.9. In some embodiments, the composition stored in a plasticcontainer has a pD of less than about 6.8. In some embodiments, thecomposition stored in a plastic container has a pD of less than about6.7. In some embodiments, the composition stored in a plastic containerhas a pD of less than about 6.6. In some embodiments, the compositionstored in a plastic container has a pD of less than about 6.5. In someembodiments, the composition stored in a plastic container has a pD ofless than about 6.4. In some embodiments, the composition stored in aplastic container has a pD of less than about 6.3. In some embodiments,the composition stored in a plastic container has a pD of less thanabout 6.2. In some embodiments, the composition stored in a plasticcontainer has a pD of less than about 6.1. In some embodiments, thecomposition stored in a plastic container has a pD of less than about 6.In some embodiments, the composition stored in a plastic container has apD of less than about 5.9. In some embodiments, the composition storedin a plastic container has a pD of less than about 5.8. In someembodiments, the composition stored in a plastic container has a pD ofless than about 5.7. In some embodiments, the composition stored in aplastic container has a pD of less than about 5.6. In some embodiments,the composition stored in a plastic container has a pD of less thanabout 5.5. In some embodiments, the composition stored in a plasticcontainer has a pD of less than about 5.4. In some embodiments, thecomposition stored in a plastic container has a pD of less than about5.3. In some embodiments, the composition stored in a plastic containerhas a pD of less than about 5.2. In some embodiments, the compositionstored in a plastic container has a pD of less than about 5.1. In someembodiments, the composition stored in a plastic container has a pD ofless than about 5. In some embodiments, the composition stored in aplastic container has a pD of less than about 4.9. In some embodiments,the composition stored in a plastic container has a pD of less thanabout 4.8. In some embodiments, the composition stored in a plasticcontainer has a pD of less than about 4.7. In some embodiments, thecomposition stored in a plastic container has a pD of less than about4.6. In some embodiments, the composition stored in a plastic containerhas a pD of less than about 4.5. In some embodiments, the compositionstored in a plastic container has a pD of less than about 4.4. In someembodiments, the composition stored in a plastic container has a pD ofless than about 4.3. In some embodiments, the composition stored in aplastic container has a pD of less than about 4.2. In some embodiments,the composition stored in a plastic container has a pD of less thanabout 4.1. In some embodiments, the composition stored in a plasticcontainer has a pD of less than about 4.

In some embodiments, the composition stored in a plastic container has apotency of at least 70% after extended period of time under storagecondition. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 75% after extended period of timeunder storage condition. In some embodiments, the composition stored ina plastic container has a potency of at least 80% after extended periodof time under storage condition. In some embodiments, the compositionstored in a plastic container has a potency of at least 85% afterextended period of time under storage condition. In some embodiments,the composition stored in a plastic container has a potency of at least90% after extended period of time under storage condition. In someembodiments, the composition stored in a plastic container has a potencyof at least 93% after extended period of time under storage condition.In some embodiments, the composition stored in a plastic container has apotency of at least 95% after extended period of time under storagecondition. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 97% after extended period of timeunder storage condition. In some embodiments, the composition stored ina plastic container has a potency of at least 98% after extended periodof time under storage condition. In some embodiments, the compositionstored in a plastic container has a potency of at least 99% afterextended period of time under storage condition. In some instances, thestorage condition comprises a temperature of about 25° C., about 40° C.,or about 60° C. In some instances, the extended period of time is atleast 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, atleast 2 months, at least 3 months, at least 4 months, at least 5 months,at least 6 months, at least 8 months, at least 10 months, at least 12months, at least 18 months, or at least 24 months.

In some embodiments, the composition stored in a plastic container has apotency of at least 80% at a temperature of about 25° C., about 40° C.,or about 60° C. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 85% at a temperature of about 25°C., about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container has a potency of at least 90% at atemperature of about 25° C., about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container has a potencyof at least 93% at a temperature of about 25° C., about 40° C., or about60° C. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 95% at a temperature of about 25° C.about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container has a potency of at least 97% at atemperature of about 25° C., about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container has a potencyof at least 98% at a temperature of about 25° C., about 40° C., or about60° C. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 99% at a temperature of about 25°C., about 40° C., or about 60° C.

In some embodiments, the composition stored in a plastic container has apotency of at least 80% for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container has a potency of at least 85% for a periodof at least 1 week, at least 2 weeks, at least 3 weeks, at least 1month, at least 2 months, at least 3 months, at least 4 months, at least5 months, at least 6 months, at least 8 months, at least 10 months, atleast 12 months, at least 18 months, or at least 24 months. In someembodiments, the composition stored in a plastic container has a potencyof at least 90% for a period of at least 1 week, at least 2 weeks, atleast 3 weeks, at least 1 month, at least 2 months, at least 3 months,at least 4 months, at least 5 months, at least 6 months, at least 8months, at least 10 months, at least 12 months, at least 18 months, orat least 24 months. In some embodiments, the composition stored in aplastic container has a potency of at least 93% for a period of at least1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2months, at least 3 months, at least 4 months, at least 5 months, atleast 6 months, at least 8 months, at least 10 months, at least 12months, at least 18 months, or at least 24 months. In some embodiments,the composition stored in a plastic container has a potency of at least95% for a period of at least 1 week, at least 2 weeks, at least 3 weeks,at least 1 month, at least 2 months, at least 3 months, at least 4months, at least 5 months, at least 6 months, at least 8 months, atleast 10 months, at least 12 months, at least 18 months, or at least 24months. In some embodiments, the composition stored in a plasticcontainer has a potency of at least 97% for a period of at least 1 week,at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months,at least 3 months, at least 4 months, at least 5 months, at least 6months, at least 8 months, at least 10 months, at least 12 months, atleast 18 months, or at least 24 months. In some embodiments, thecomposition stored in a plastic container has a potency of at least 98%for a period of at least 1 week, at least 2 weeks, at least 3 weeks, atleast 1 month, at least 2 months, at least 3 months, at least 4 months,at least 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic container has apotency of at least 99% for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months.

In some embodiments, the composition stored in a plastic containercomprises less than 20% of primary degradant based on the concentrationof the ophthalmic agent after extended period of time under storagecondition. In some embodiments, the composition stored in a plasticcontainer comprises less than 15% of primary degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition stored ina plastic container comprises less than 10% of primary degradant basedon the concentration of the ophthalmic agent after extended period oftime under storage condition. In some embodiments, the compositionstored in a plastic container comprises less than 5% of primarydegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition.

In some embodiments, the composition stored in a plastic containercomprises from less than 2.5% of primary degradant to less than 0.1% ofprimary degradant based on the concentration of the ophthalmic agentafter extended period of time under storage condition. In someembodiments, the composition stored in a plastic container comprisesless than 2.5% of primary degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition stored in a plastic containercomprises less than 2.0% of primary degradant based on the concentrationof the ophthalmic agent after extended period of time under storagecondition. In some embodiments, the composition stored in a plasticcontainer comprises less than 1.5% of primary degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some embodiments, the composition stored ina plastic container comprises less than 1.0% of primary degradant basedon the concentration of the ophthalmic agent after extended period oftime under storage condition. In some embodiments, the compositionstored in a plastic container comprises less than 0.5% of primarydegradant based on the concentration of the ophthalmic agent afterextended period of time under storage condition. In some embodiments,the composition stored in a plastic container comprises less than 0.4%of primary degradant based on the concentration of the ophthalmic agentafter extended period of time under storage condition. In someembodiments, the composition stored in a plastic container comprisesless than 0.3% of primary degradant based on the concentration of theophthalmic agent after extended period of time under storage condition.In some embodiments, the composition stored in a plastic containercomprises less than 0.2% of primary degradant based on the concentrationof the ophthalmic agent after extended period of time under storagecondition. In some embodiments, the composition stored in a plasticcontainer comprises less than 0.1% of primary degradant based on theconcentration of the ophthalmic agent after extended period of timeunder storage condition. In some instances, the storage conditioncomprises a temperature of about 25° C., about 40° C., or about 60° C.In some instances, the extended period of time is at least 1 week, atleast 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, atleast 3 months, at least 4 months, at least 5 months, at least 6 months,at least 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months.

In some embodiments, the composition stored in a plastic containercomprises less than 20% of primary degradant based on the concentrationof the ophthalmic agent at a temperature of about 25° C., about 40° C.,or about 60° C. In some embodiments, the composition stored in a plasticcontainer comprises less than 15% of primary degradant based on theconcentration of the ophthalmic agent at a temperature of about 25° C.,about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container comprises less than 10% of primarydegradant based on the concentration of the ophthalmic agent at atemperature of about 25° C., about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container comprisesless than 5% of primary degradant based on the concentration of theophthalmic agent at a temperature of about 25° C., about 40° C., orabout 60° C.

In some embodiments, the composition stored in a plastic containercomprises from less than 2.5% of primary degradant to less than 0.1% ofprimary degradant based on the concentration of the ophthalmic agent ata temperature of about 25° C., about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container comprisesless than 2.5% of primary degradant based on the concentration of theophthalmic agent at a temperature of about 25° C., about 40° C., orabout 60° C. In some embodiments, the composition stored in a plasticcontainer comprises less than 2.0% of primary degradant based on theconcentration of the ophthalmic agent at a temperature of about 25° C.,about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container comprises less than 1.5% of primarydegradant based on the concentration of the ophthalmic agent at atemperature of about 25° C., about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container comprisesless than 1.0% of primary degradant based on the concentration of theophthalmic agent at a temperature of about 25° C., about 40° C., orabout 60° C. In some embodiments, the composition stored in a plasticcontainer comprises less than 0.5% of primary degradant based on theconcentration of the ophthalmic agent at a temperature of about 25° C.,about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container comprises less than 0.4% of primarydegradant based on the concentration of the ophthalmic agent at atemperature of about 25° C. about 40° C., or about 60° C. In someembodiments, the composition stored in a plastic container comprisesless than 0.3% of primary degradant based on the concentration of theophthalmic agent at a temperature of about 25° C., about 40° C., orabout 60° C. In some embodiments, the composition stored in a plasticcontainer comprises less than 0.2% of primary degradant based on theconcentration of the ophthalmic agent at a temperature of about 25° C.,about 40° C., or about 60° C. In some embodiments, the compositionstored in a plastic container comprises less than 0.1% of primarydegradant based on the concentration of the ophthalmic agent at atemperature of about 25° C., about 40° C., or about 60° C.

In some embodiments, the composition stored in a plastic containercomprises less than 20% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 15% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 10% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 5% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.

In some embodiments, the composition stored in a plastic containercomprises from less than 2.5% of primary degradant to less than 0.1% ofprimary degradant based on the concentration of the ophthalmic agent fora period of at least 1 week, at least 2 weeks, at least 3 weeks, atleast 1 month, at least 2 months, at least 3 months, at least 4 months,at least 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 2.5% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 2.0% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 1.5% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 1.0% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 0.5% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 0.4% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 0.3% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months. In some embodiments, the compositionstored in a plastic container comprises less than 0.2% of primarydegradant based on the concentration of the ophthalmic agent for aperiod of at least 1 week, at least 2 weeks, at least 3 weeks, at least1 month, at least 2 months, at least 3 months, at least 4 months, atleast 5 months, at least 6 months, at least 8 months, at least 10months, at least 12 months, at least 18 months, or at least 24 months.In some embodiments, the composition stored in a plastic containercomprises less than 0.1% of primary degradant based on the concentrationof the ophthalmic agent for a period of at least 1 week, at least 2weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3months, at least 4 months, at least 5 months, at least 6 months, atleast 8 months, at least 10 months, at least 12 months, at least 18months, or at least 24 months.

In some embodiments, the composition described herein is stored in aglass container. In some embodiments, the glass container is a glassvial, such as for example, a type I, type II or type III glass vial. Insome embodiments, the glass container is a type I glass vial. In someembodiments, the type I glass vial is a borosilicate glass vial.

In some embodiments, the composition stored in a glass container has apD of higher than about 7. In some embodiments, the composition storedin a glass container has a pD of higher than about 7.5. In someembodiments, the composition stored in a glass container has a pD ofhigher than about 8. In some embodiments, the composition stored in aglass container has a pD of higher than about 8.5. In some embodiments,the composition stored in a glass container has a pD of higher thanabout 9.

In some embodiments, the composition stored in a glass container has apotency of less than 60% at a temperature of about 25° C., about 40° C.,or about 60° C. In some embodiments, the composition stored in a glasscontainer has a potency of less than 60% for a period of at least 1week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2months, at least 3 months, at least 4 months, at least 5 months, atleast 6 months, at least 8 months, at least 10 months, at least 12months, at least 18 months, or at least 24 months.

In some embodiments, the composition stored in a glass container is lessstable than a composition stored in a plastic container.

In some embodiments, the composition is stored under in the dark. Insome instances, the composition is stored in the presence of light. Insome instances, the light is indoor light, room light, or sun light. Insome instances, the composition is stable while stored in the presenceof light.

In some embodiments, the composition described herein is formulated asan aqueous solution. In some embodiments, the aqueous solution is astable aqueous solution. In some instances, the aqueous solution isstored in a plastic container as described above. In some instances, theaqueous solution is not stored in a glass container. In some instances,the aqueous solution is stored in the dark. In some instances, theaqueous solution is stored in the presence of light. In some instances,the aqueous solution is stable in the presence of light.

In a specific embodiment, the ophthalmically acceptable formulationsalternatively comprise a cyclodextrin. Cyclodextrins are cyclicoligosaccharides containing 6, 7, or 8 glucopyranose units, referred toas α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin respectively.Cyclodextrins have a hydrophilic exterior, which enhances water-soluble,and a hydrophobic interior which forms a cavity. In an aqueousenvironment, hydrophobic portions of other molecules often enter thehydrophobic cavity of cyclodextrin to form inclusion compounds.Additionally, cyclodextrins are also capable of other types ofnonbonding interactions with molecules that are not inside thehydrophobic cavity. Cyclodextrins have three free hydroxyl groups foreach glucopyranose unit, or 18 hydroxyl groups on α-cyclodextrin, 21hydroxyl groups on β-cyclodextrin, and 24 hydroxyl groups onγ-cyclodextrin. In some embodiments, one or more of these hydroxylgroups are reacted with any of a number of reagents to form a largevariety of cyclodextrin derivatives, including hydroxypropyl ethers,sulfonates, and sulfoalkylethers. Shown below is the structure ofβ-cyclodextrin and the hydroxypropyl-β-cyclodextrin (HPβCD).

In some embodiments, the use of cyclodextrins in the pharmaceuticalcompositions described herein improves the solubility of the drug.Inclusion compounds are involved in many cases of enhanced solubility;however other interactions between cyclodextrins and insoluble compoundsalso improves solubility. Hydroxypropyl-β-cyclodextrin (HPβCD) iscommercially available as a pyrogen free product. It is a nonhygroscopicwhite powder that readily dissolves in water. HPβCD is thermally stableand does not degrade at neutral pH. Thus, cyclodextrins improve thesolubility of a therapeutic agent in a composition or formulation.Accordingly, in some embodiments, cyclodextrins are included to increasethe solubility of the ophthalmically acceptable ophthalmic agents withinthe formulations described herein. In other embodiments, cyclodextrinsin addition serve as controlled release excipients within theformulations described herein.

By way of example only, cyclodextrin derivatives for use includeα-cyclodextrin, β-cyclodextrin, γ-cyclodextrin,hydroxyethyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, sulfatedβ-cyclodextrin, sulfated α-cyclodextrin, sulfobutyl etherβ-cyclodextrin.

The concentration of the cyclodextrin used in the compositions andmethods disclosed herein varies according to the physiochemicalproperties, pharmacokinetic properties, side effect or adverse events,formulation considerations, or other factors associated with thetherapeutically ophthalmic agent, or a salt or prodrug thereof, or withthe properties of other excipients in the composition. Thus, in certaincircumstances, the concentration or amount of cyclodextrin used inaccordance with the compositions and methods disclosed herein will vary,depending on the need. When used, the amount of cyclodextrins needed toincrease solubility of the ophthalmic agent and/or function as acontrolled release excipient in any of the formulations described hereinis selected using the principles, examples, and teachings describedherein.

Other stabilizers that are useful in the ophthalmically acceptableformulations disclosed herein include, for example, fatty acids, fattyalcohols, alcohols, long chain fatty acid esters, long chain ethers,hydrophilic derivatives of fatty acids, polyvinyl pyrrolidones,polyvinyl ethers, polyvinyl alcohols, hydrocarbons, hydrophobicpolymers, moisture-absorbing polymers, and combinations thereof. In someembodiments, amide analogues of stabilizers are also used. In furtherembodiments, the chosen stabilizer changes the hydrophobicity of theformulation, improves the mixing of various components in theformulation, controls the moisture level in the formula, or controls themobility of the phase.

In other embodiments, stabilizers are present in sufficient amounts toinhibit the degradation of the ophthalmic agent. Examples of suchstabilizing agents, include, but are not limited to: glycerol,methionine, monothioglycerol, EDTA, ascorbic acid, polysorbate 80,polysorbate 20, arginine, heparin, dextran sulfate, cyclodextrins,pentosan polysulfate and other heparinoids, divalent cations such asmagnesium and zinc, or combinations thereof.

Additional useful stabilization agents for ophthalmically acceptableformulations include one or more anti-aggregation additives to enhancestability of ophthalmic formulations by reducing the rate of proteinaggregation. The anti-aggregation additive selected depends upon thenature of the conditions to which the ophthalmic agents, for example amuscarinic antagonist (e.g. atropine or its pharmaceutically acceptablesalts), are exposed. For example, certain formulations undergoingagitation and thermal stress require a different anti-aggregationadditive than a formulation undergoing lyophilization andreconstitution. Useful anti-aggregation additives include, by way ofexample only, urea, guanidinium chloride, simple amino acids such asglycine or arginine, sugars, polyalcohols, polysorbates, polymers suchas polyethylene glycol and dextrans, alkyl saccharides, such as alkylglycoside, and surfactants.

Other useful formulations optionally include one or more ophthalmicallyacceptable antioxidants to enhance chemical stability where required.Suitable antioxidants include, by way of example only, ascorbic acid,methionine, sodium thiosulfate and sodium metabisulfite. In oneembodiment, antioxidants are selected from metal chelating agents, thiolcontaining compounds and other general stabilizing agents.

Still other useful compositions include one or more ophthalmicallyacceptable surfactants to enhance physical stability or for otherpurposes. Suitable nonionic surfactants include, but are not limited to,polyoxyethylene fatty acid glycerides and vegetable oils, e.g.,polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylenealkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.

In some embodiments, the ophthalmically acceptable pharmaceuticalformulations described herein are stable with respect to compounddegradation (e.g. less than 30% degradation, less than 25% degradation,less than 20% degradation, less than 15% degradation, less than 10%degradation, less than 8% degradation, less than 5% degradation, lessthan 3% degradation, less than 2% degradation, or less than 5%degradation) over a period of any of at least about 1 day, at leastabout 2 days, at least about 3 days, at least about 4 days, at leastabout 5 days, at least about 6 days, at least about 1 week, at leastabout 2 weeks, at least about 3 weeks, at least about 4 weeks, at leastabout 5 weeks, at least about 6 weeks, at least about 7 weeks, at leastabout 8 weeks, at least about 3 months, at least about 4 months, atleast about 5 months, or at least about 6 months under storageconditions (e.g. room temperature). In other embodiments, theformulations described herein are stable with respect to compounddegradation over a period of at least about 1 week. Also describedherein are formulations that are stable with respect to compounddegradation over a period of at least about 1 month.

In other embodiments, an additional surfactant (co-surfactant) and/orbuffering agent is combined with one or more of the pharmaceuticallyacceptable vehicles previously described herein so that the surfactantand/or buffering agent maintains the product at an optimal pD forstability. Suitable co-surfactants include, but are not limited to; a)natural and synthetic lipophilic agents, e.g., phospholipids,cholesterol, and cholesterol fatty acid esters and derivatives thereof;b) nonionic surfactants, which include for example, polyoxyethylenefatty alcohol esters, sorbitan fatty acid esters (Spans),polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene (20)sorbitan monooleate (Tween 80), polyoxyethylene (20) sorbitanmonostearate (Tween 60), polyoxyethylene (20)sorbitan monolaurate (Tween20) and other Tweens, sorbitan esters, glycerol esters, e.g., Myrj andglycerol triacetate (triacetin), polyethylene glycols, cetyl alcohol,cetostearyl alcohol, stearyl alcohol, polysorbate 80, poloxamers,poloxamines, polyoxyethylene castor oil derivatives (e.g., Cremophor®RH40, Cremphor A25, Cremphor A20, Cremophor® EL) and other Cremophors,sulfosuccinates, alkyl sulphates (SLS); PEG glyceryl fatty acid esterssuch as PEG-8 glyceryl caprylate/caprate (Labrasol), PEG-4 glycerylcaprylate/caprate (Labrafac Hydro WL 1219), PEG-32 glyceryl laurate(Gelucire 444/14), PEG-6 glyceryl mono oleate (Labrafil M 1944 CS),PEG-6 glyceryl linoleate (Labrafil M 2125 CS); propylene glycol mono-and di-fatty acid esters, such as propylene glycol laurate, propyleneglycol caprylate/caprate; Brij® 700, ascorbyl-6-palmitate, stearylamine,sodium lauryl sulfate, polyoxethyleneglycerol triricinoleate, and anycombinations or mixtures thereof; c) anionic surfactants include, butare not limited to, calcium carboxymethylcellulose, sodiumcarboxymethylcellulose, sodium sulfosuccinate, dioctyl, sodium alginate,alkyl polyoxyethylene sulfates, sodium lauryl sulfate, triethanolaminestearate, potassium laurate, bile salts, and any combinations ormixtures thereof; and d) cationic surfactants such ascetyltrimethylammonium bromide, and lauryldimethylbenzyl-ammoniumchloride.

In a further embodiment, when one or more co-surfactants are utilized inthe ophthalmically acceptable formulations of the present disclosure,they are combined, e.g., with a pharmaceutically acceptable vehicle andis present in the final formulation, e.g., in an amount ranging fromabout 0.1% to about 20%, from about 0.5% to about 10%.

In one embodiment, the surfactant has an HLB value of 0 to 20. Inadditional embodiments, the surfactant has an HLB value of 0 to 3, of 4to 6, of 7 to 9, of 8 to 18, of 13 to 15, of 10 to 18.

pD

In some embodiments, the pD of a composition described herein isadjusted (e.g., by use of a buffer and/or a pD adjusting agent) to anophthalmically compatible pD range of from about 4 to about 8, about 4.5to about 7.5, or about 5 to about 7. In some embodiments, the ophthalmiccomposition has a pD of from about 5.0 to about 7.0. In someembodiments, the ophthalmic composition has a pD of from about 5.5 toabout 7.0. In some embodiments, the ophthalmic composition has a pD offrom about 6.0 to about 7.0.

In some embodiments, useful formulations include one or more pDadjusting agents or buffering agents. Suitable pD adjusting agents orbuffers include, but are not limited to acetate, bicarbonate, ammoniumchloride, citrate, phosphate, deuterated forms of acetate, bicarbonate,ammonium chloride, citrate, phosphate, pharmaceutically acceptable saltsthereof and combinations or mixtures thereof. In some embodiments, thepD adjusting agents or buffers include deuterated hydrochloric acid(DCI), deuterated sodium hydroxide (NaOD), deuterated acetic acid(CD₃COOD), or deuterated citric acid (C₆D₈O₇).

In one embodiment, when one or more buffers are utilized in theformulations of the present disclosure, they are combined, e.g., with apharmaceutically acceptable vehicle and are present in the finalformulation, e.g., in an amount ranging from about 0.1% to about 20%,from about 0.5% to about 10%. In certain embodiments of the presentdisclosure, the amount of buffer included in the gel formulations are anamount such that the pD of the gel formulation does not interfere withthe body's natural buffering system.

In one embodiment, diluents are also used to stabilize compounds becausethey provide a more stable environment. In some instances, saltsdissolved in buffered solutions (which also provides pD control ormaintenance) are utilized as diluents in the art, including, but notlimited to a phosphate buffered saline solution.

In some embodiments, the pD is calculated according to the formuladisclosed in Glasoe et al., “Use of glass electrodes to measureacidities in deuterium oxide,” J. Physical Chem. 64(1): 188-190(1960).In some embodiment, the pD is calculated as pD=pH*+0.4, in which pH* isthe measured or observed pH of the ophthalmic composition formulated ina solution comprising deuterated water (e.g., D₂O).

In some embodiments, the ophthalmic aqueous, gel, or ointmentcomposition described herein has a pD of between about 4 and about 8,between about 4.5 and about 8, between about 4.9 and about 7.9, betweenabout 5.4 and about 7.9, between about 5.9 and about 7.9, between about6.4 and about 7.9, or between about 7.4 and about 7.9. In someembodiments, the ophthalmic aqueous, gel, or ointment compositiondescribed herein has a pD of between about 4.5-7.5, between about 5.0and about 7.5, between about 5.5 and about 7.5, between about 6.0 andabout 7.5, or between about 7.0 and about 7.5. In some embodiments, theophthalmic aqueous, gel, or ointment composition described herein has apD of between about 4.5-7.0, between about 5.0 and about 7.0, betweenabout 5.5 and about 7.0, between about 6.0 and about 7.0, or betweenabout 6.5 and about 7.0. In some embodiments, the ophthalmic aqueous,gel, or ointment composition described herein has a pD of between about4.9-7.4, between about 5.4 and about 7.4, between about 5.9 and about7.4, between about 6.4 and about 7.4, or between about 6.9 and about7.4. In some embodiments, the ophthalmic aqueous, gel, or ointmentcomposition described herein has a pD of between about 4.5-6.5, betweenabout 5.0 and about 6.5, between about 5.5 and about 6.5, or betweenabout 6.0 and about 6.5. In some embodiments, the ophthalmic aqueous,gel, or ointment composition described herein has a pD of between about4.9-6.9, between about 5.4 and about 6.9, between about 5.9 and about6.9, or between about 6.4 and about 6.9. In some embodiments, theophthalmic aqueous, gel, or ointment composition described herein has apD of between about 4.5-6.0, between about 5.0 and about 6.0, or betweenabout 5.5 and about 6.0. In some embodiments, the ophthalmic aqueous,gel, or ointment composition described herein has a pD of between about4.9-6.4, between about 5.4 and about 6.4, or between about 5.9 and about6.4. In some embodiments, the ophthalmic aqueous, gel, or ointmentcomposition described herein has a pD of between about 4.5-5.5, orbetween about 5.0 and about 5.5. In some embodiments, the ophthalmicaqueous, gel, or ointment composition described herein has a pD ofbetween about 4.9-5.9, or between about 5.4 and about 5.9. In someembodiments, the ophthalmic aqueous, gel, or ointment compositiondescribed herein has a pD of between about 4.5-5.0. In some embodiments,the ophthalmic aqueous, gel, or ointment composition described hereinhas a pD of between about 4.9-5.4.

In some embodiments, the ophthalmic composition is an ophthalmic aqueouscomposition. In some instances, the ophthalmic aqueous composition has apD of between about 4 and about 8, about 4.5 and about 7.8, about 5 andabout 7.5, or about 5.5 and about 7. In some embodiments, the ophthalmicaqueous composition has a pD of about 7.5. In some embodiments, theophthalmic aqueous composition has a pD of about 7.4. In someembodiments, the ophthalmic aqueous composition has a pD of about 7.3.In some embodiments, the ophthalmic aqueous composition has a pD ofabout 7.2. In some embodiments, the ophthalmic aqueous composition has apD of about 7.1. In some embodiments, the ophthalmic aqueous compositionhas a pD of about 7. In some embodiments, the ophthalmic aqueouscomposition has a pD of about 6.9. In some embodiments, the ophthalmicaqueous composition has a pD of about 6.8. In some embodiments, theophthalmic aqueous composition has a pD of about 6.7. In someembodiments, the ophthalmic aqueous composition has a pD of about 6.6.In some embodiments, the ophthalmic aqueous composition has a pD ofabout 6.5. In some embodiments, the ophthalmic aqueous composition has apD of about 6.4. In some embodiments, the ophthalmic aqueous compositionhas a pD of about 6.3. In some embodiments, the ophthalmic aqueouscomposition has a pD of about 6.2. In some embodiments, the ophthalmicaqueous composition has a pD of about 6.1. In some embodiments, theophthalmic aqueous composition has a pD of about 6. In some embodiments,the ophthalmic aqueous composition has a pD of about 5.9. In someembodiments, the ophthalmic aqueous composition has a pD of about 5.8.In some embodiments, the ophthalmic aqueous composition has a pD ofabout 5.7. In some embodiments, the ophthalmic aqueous composition has apD of about 5.6. In some embodiments, the ophthalmic aqueous compositionhas a pD of about 5.5. In some embodiments, the ophthalmic aqueouscomposition has a pD of about 5.4. In some embodiments, the ophthalmicaqueous composition has a pD of about 5.3. In some embodiments, theophthalmic aqueous composition has a pD of about 5.2. In someembodiments, the ophthalmic aqueous composition has a pD of about 5.1.In some embodiments, the ophthalmic aqueous composition has a pD ofabout 5. In some embodiments, the ophthalmic aqueous composition has apD of about 4.9. In some embodiments, the ophthalmic aqueous compositionhas a pD of about 4.8. In some embodiments, the ophthalmic aqueouscomposition has a pD of about 4.7. In some embodiments, the ophthalmicaqueous composition has a pD of about 4.6. In some embodiments, theophthalmic aqueous composition has a pD of about 4.5. In someembodiments, the ophthalmic aqueous composition has a pD of about 4.4.In some embodiments, the ophthalmic aqueous composition has a pD ofabout 4.3. In some embodiments, the ophthalmic aqueous composition has apD of about 4.2. In some embodiments, the ophthalmic aqueous compositionhas a pD of about 4.1. In some embodiments, the ophthalmic aqueouscomposition has a pD of about 4. In some embodiments, the pD is aninitial pD of the ophthalmic aqueous composition. In some embodiments,the pD is the pD of the ophthalmic aqueous composition after extendedperiod of time under storage condition.

In some instances, the ophthalmic aqueous composition has an initial pDof between about 4 and about 8, about 4.5 and about 7.8, about 5 andabout 7.5, or about 5.5 and about 7. In some embodiments, the ophthalmicaqueous composition has an initial pD of about 7.5. In some embodimes,the ophthalmic aqueous composition has an initial pD of about 7.4. Insome embodiments, the ophthalmic aqueous composition has an initial pDof about 7.3. In some embodiments, the ophthalmic aqueous compositionhas an initial pD of about 7.2. In some embodiments, the ophthalmicaqueous composition has an initial pD of about 7.1. In some embodiments,the ophthalmic aqueous composition has an initial pD of about 7. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 6.9. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 6.8. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 6.7. In some embodiments, theophthalmic aqueous composition has an initial pD of about 6.6. In someembodiments the ophthalmic aqueous composition has an initial pD ofabout 6.5. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 6.4. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 6.3. In some embodiments, theophthalmic aqueous composition has an initial pD of about 6.2. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 6.1. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 6. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 5.9. In some embodiments, theophthalmic aqueous composition has an initial pD of about 5.8. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 5.7. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 5.6. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 5.5. In some embodiments, theophthalmic aqueous composition has an initial pD of about 5.4. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 5.3. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 5.2. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 5.1. In some embodiments, theophthalmic aqueous composition has an initial pD of about 5. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 4.9. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 4.8. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 4.7. In some embodiments, theophthalmic aqueous composition has an initial pD of about 4.6. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 4.5. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 4.4. In some embodiments, the ophthalmic aqueouscomposition has an initial pD of about 4.3. In some embodiments, theophthalmic aqueous composition has an initial pD of about 4.2. In someembodiments, the ophthalmic aqueous composition has an initial pD ofabout 4.1. In some embodiments, the ophthalmic aqueous composition hasan initial pD of about 4.

In some instances, the ophthalmic aqueous composition has a pD ofbetween about 4 and about 8, about 4.5 and about 7.8, about 5 and about7.5, or about 5.5 and about 7. In some embodiments, the ophthalmicaqueous composition has a pD of less than about 7.5. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 7.4. In some embodiments, the ophthalmic aqueous composition has apD of less than about 7.3. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 7.2. In some embodiments, theophthalmic aqueous composition has a pD of less than about 7.1. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 7. In some embodiments, the ophthalmic aqueous composition has apD of less than about 6.9. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 6.8. In some embodiments, theophthalmic aqueous composition has a pD of less than about 6.7. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 6.6. In some embodiments, the ophthalmic aqueous composition has apD of less than about 6.5. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 6.4. In some embodiments, theophthalmic aqueous composition has a pD of less than about 6.3. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 6.2. In some embodiments, the ophthalmic aqueous composition has apD of less than about 6.1. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 6. In some embodiments, theophthalmic aqueous composition has a pD of less than about 5.9. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 5.8. In some embodiments, the ophthalmic aqueous composition has apD of less than about 5.7. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 5.6. In some embodiments, theophthalmic aqueous composition has a pD of less than about 5.5. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 5.4. In some embodiments, the ophthalmic aqueous composition has apD of less than about 5.3. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 5.2. In some embodiments, theophthalmic aqueous composition has a pD of less than about 5.1. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 5. In some embodiments, the ophthalmic aqueous composition has apD of less than about 4.9. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 4.8. In some embodiments, theophthalmic aqueous composition has a pD of less than about 4.7. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 4.6. In some embodiments, the ophthalmic aqueous composition has apD of less than about 4.5. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 4.4. In some embodiments, theophthalmic aqueous composition has a pD of less than about 4.3. In someembodiments, the ophthalmic aqueous composition has a pD of less thanabout 4.2. In some embodiments, the ophthalmic aqueous composition has apD of less than about 4.1. In some embodiments, the ophthalmic aqueouscomposition has a pD of less than about 4. In some embodiments, the pDis the pD of the ophthalmic aqueous composition after extended period oftime under storage condition.

In some embodiments, the pD of the ophthalmic aqueous compositiondescribed herein is associated with the stability of the ophthalmicaqueous composition. In some embodiments, a stable composition comprisesa pD of between about 4 and about 8, about 4.5 and about 7.8, about 5and about 7.5, or about 5.5 and about 7. In some embodiments, a stablecomposition comprises a pD of less than about 7.5. In some embodiments,a stable composition comprises a pD of less than about 7.4. In someembodiments, a stable composition comprises a pD of less than about 7.3.In some embodiments, a stable composition comprises a pD of less thanabout 7.2. In some embodiments, a stable composition comprises a pD ofless than about 7.1. In some embodiments, a stable composition comprisesa pD of less than about 7. In some embodiments, a stable compositioncomprises a pD of less than about 6.9. In some embodiments, a stablecomposition comprises a pD of less than about 6.8. In some embodiments,a stable composition comprises a pD of less than about 6.7. In someembodiments, a stable composition comprises a pD of less than about 6.6.In some embodiments, a stable composition comprises a pD of less thanabout 6.5. In some embodiments, a stable composition comprises a pD ofless than about 6.4. In some embodiments, a stable composition comprisesa pD of less than about 6.3. In some embodiments, a stable compositioncomprises a pD of less than about 6.2. In some embodiments, a stablecomposition comprises a pD of less than about 6.1. In some embodiments,a stable composition comprises a pD of less than about 6. In someembodiments, a stable composition comprises a pD of less than about 5.9.In some embodiments, a stable composition comprises a pD of less thanabout 5.8. In some embodiments, a stable composition comprises a pD ofless than about 5.7. In some embodiments, a stable composition comprisesa pD of less than about 5.6. In some embodiments, a stable compositioncomprises a pD of less than about 5.5. In some embodiments, a stablecomposition comprises a pD of less than about 5.4. In some embodiments,a stable composition comprises a pD of less than about 5.3. In someembodiments, a stable composition comprises a pD of less than about 5.2.In some embodiments, a stable composition comprises a pD of less thanabout 5.1. In some embodiments, a stable composition comprises a pD ofless than about 5. In some embodiments, a stable composition comprises apD of less than about 4.9. In some embodiments, a stable compositioncomprises a pD of less than about 4.8. In some embodiments, a stablecomposition comprises a pD of less than about 4.7. In some embodiments,a stable composition comprises a pD of less than about 4.6. In someembodiments, a stable composition comprises a pD of less than about 4.5.In some embodiments, a stable composition comprises a pD of less thanabout 4.4. In some embodiments, a stable composition comprises a pD ofless than about 4.3. In some embodiments, a stable composition comprisesa pD of less than about 4.2. In some embodiments, a stable compositioncomprises a pD of less than about 4.1. In some embodiments, a stablecomposition comprises a pD of less than about 4.

In some embodiments, the D₂O aqueous system stabilizes a muscarinicantagonist (e.g., atropine). In some embodiments, this is due to a lowerconcentration of the reactive species (e.g., —OD) in the D₂O aqueoussystem compared to the concentration of the reactive species (e.g., —OH)in an equivalent H₂O aqueous system. In some instances, theconcentration of the reactive species (e.g., —OD) in the D₂O aqueoussystem is about one third less than the concentration of the reactivespecies (e.g., —OH) in the equivalent H₂O aqueous system. In some cases,this is due to a lower or smaller dissociation constant of D₂O than H₂O.For example, the K_(a)(H₂O) is 1×10⁻¹⁴, whereas the K_(a)(D₂O) is1×110⁻¹⁵. As such, D₂O is a weaker acid than H₂O. In some cases, basecatalyzed hydrolysis leads to the presence of tropine degradant fromatropine. In some cases, with a lower concentration of the reactivespecies that causes tropine degradant formation, atropine solution ismore stable in a D₂O aqueous system than compared to an equivalent H₂Oaqueous system. In some embodiments, the ophthalmic compositionformulated with deuterated water allows for a more stable ophthalmiccomposition relative to the ophthalmic composition formulated with H₂O.

In some embodiments, the presence of deuterated water shifts the pKa ofthe buffer. In some embodiments, the presence of deuterated water allowsfor the ophthalmic composition to simulate the stability of a lower pHsystem. In some instances, the buffer capacity of the ophthalmiccomposition is lowered, thereby allowing a faster shift in pH. In someinstances, the lowered buffering capacity of the ophthalmic compositionwhen administered into the eye allows the ophthalmic composition toreach physiological pH at a faster rate than compared to an ophthalmiccomposition formulated in H₂O. In some instances, the ophthalmiccomposition formulated with deuterated water allows for a lower tearproduction, or less tear reflex in the eye, in comparison with anophthalmic composition formulated with H₂O.

In some embodiment, the ophthalmic gel or ointment composition describedherein has a pD of about 4, about 4.1, about 4.2, about 4.3, about 4.4,about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7,about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0,about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about7.7, about 7.8, or about 7.9.

In some embodiment, the pD of the ophthalmic aqueous, gel, or ointmentcomposition described herein is suitable for sterilization (e.g., byfiltration or aseptic mixing or heat treatment and/or autoclaving (e.g.,terminal sterilization)) of ophthalmic formulations described herein. Asused in in the present disclosure, the term “aqueous composition”includes compositions that are based on D₂O.

In some embodiments, the pharmaceutical formulations described hereinare stable with respect to pD over a period of any of at least about 1day, at least about 2 days, at least about 3 days, at least about 4days, at least about 5 days, at least about 6 days, at least about 1week, at least about 2 weeks, at least about 3 weeks, at least about 4weeks, at least about 5 weeks, at least about 6 weeks, at least about 7weeks, at least about 8 weeks, at least about 1 month, at least about 2months, at least about 3 months, at least about 4 months, at least about5 months, at least about 6 months, at least about 7 months, at leastabout 8 months, at least about 9 months, at least about 10 months, atleast about 11 months, at least about 12 months, at least about 18months, at least about 24 months, at least about 3 years, at least about4 years, at least about 5 years, at least about 6 years, at least about7 years, at least about 8 years, at least about 9 years, at least about10 years, or more. In other embodiments, the formulations describedherein are stable with respect to pD over a period of at least about 1week. In other embodiments, the formulations described herein are stablewith respect to pD over a period of at least about 2 weeks. In otherembodiments, the formulations described herein are stable with respectto pD over a period of at least about 3 weeks. In other embodiments, theformulations described herein are stable with respect to pD over aperiod of at least about 1 month. Also described herein are formulationsthat are stable with respect to pD over a period of at least about 2months, at least about 3 months, at least about 4 months, at least about5 months, at least about 6 months, at least about 12 months, at leastabout 18 months, at least about 2 years, or more.

Aqueous Solution Dose-to-Dose Uniformity

Typical ophthalmic aqueous solutions are packaged in eye drop bottlesand administered as drops. For example, a single administration (i.e. asingle dose) of an ophthalmic aqueous solution includes a single drop,two drops, three drops or more into the eyes of the patient. In someembodiments, one dose of the ophthalmic aqueous solution describedherein is one drop of the aqueous solution composition from the eye dropbottle.

In some cases, described herein include ophthalmic aqueous compositionswhich provide a dose-to-dose uniform concentrations. In some instances,the dose-to-dose uniform concentration does not present significantvariations of drug content from one dose to another. In some instances,the dose-to-dose uniform concentration does provide consistent drugcontent from one dose to another.

In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 50%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 40%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 30%.In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 20%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 10%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 5%.

In some embodiments, the dose-to-dose ophthalmic agent concentrationvariation is based on 10 consecutive doses. In some embodiments, thedose-to-dose ophthalmic agent concentration variation is based on 8consecutive doses. In some embodiments, the dose-to-dose ophthalmicagent concentration variation is based on 5 consecutive doses. In someembodiments, the dose-to-dose ophthalmic agent concentration variationis based on 3 consecutive doses. In some embodiments, the dose-to-doseophthalmic agent concentration variation is based on 2 consecutivedoses.

A nonsettling formulation should not require shaking to disperse druguniformly. A “no-shake” formulation is potentially advantageous overformulations that require shaking for the simple reason that patients'shaking behavior is a major source of variability in the amount of drugdosed. It has been reported that patients often times do not or forgetto shake their ophthalmic compositions that requires shaking beforeadministering a dose, despite the instructions to shake that wereclearly marked on the label. On the other hand, even for those patientswho do shake the product, it is normally not possible to determinewhether the shaking is adequate in intensity and/or duration to renderthe product uniform. In some embodiments, the ophthalmic gelcompositions and ophthalmic ointment compositions described herein are“no-shake” formulations that maintained the dose-to-dose uniformitydescribed herein.

To evaluate the dose-to-dose uniformity, drop bottles or tubescontaining the ophthalmic aqueous compositions, the ophthalmic gelcompositions, or ophthalmic ointment compositions are stored upright fora minimum of 12 hours prior to the start of the test. To simulate therecommended dosing of these products, predetermined number of drops orstrips are dispensed from each commercial bottles or tubes atpredetermined time intervals for an extended period of time or until noproduct was left in the bottle or tube. All drops and strips aredispensed into tared glass vials, capped, and stored at room temperatureuntil analysis. Concentrations of a muscarinic antagonist such asatropine in the expressed drops were determined using a reverse-phaseHPLC method.

Aqueous Solution Viscosity

In some embodiments, the composition has a Brookfield RVDV viscosity offrom about 10 to about 50,000 cps at about 20° C. and sheer rate of 1s⁻¹. In some embodiments, the composition has a Brookfield RVDVviscosity of from about 100 to about 40,000 cps at about 20° C. andsheer rate of 1 s⁻¹. In some embodiments, the composition has aBrookfield RVDV viscosity of from about 500 to about 30,000 cps at about20° C. and sheer rate of 1 s⁻¹. In some embodiments, the composition hasa Brookfield RVDV viscosity of from about 1000 to about 20,000 cps atabout 20° C. and sheer rate of 1 s⁻¹. In some embodiments, thecomposition has a Brookfield RVDV viscosity of from about 2000 to about10,000 cps at about 20° C. and sheer rate of 1 s⁻¹. In some embodiments,the composition has a Brookfield RVDV viscosity of from about 4000 toabout 8000 cps at about 20° C. and sheer rate of 1 s⁻¹.

In some embodiments, the ophthalmic aqueous formulation contains aviscosity enhancing agent sufficient to provide a viscosity of betweenabout 500 and 50.000 centipoise, between about 750 and 50,000centipoise; between about 1000 and 50,000 centipoise; between about 1000and 40,000 centipoise; between about 2000 and 30,000 centipoise; betweenabout 3000 and 20,000 centipoise; between about 4000 and 10,000centipoise, or between about 5000 and 8000 centipoise.

In some embodiments, the compositions described herein are low viscositycompositions at body temperature. In some embodiments, low viscositycompositions contain from about 1% to about 10% of a viscosity enhancingagent (e.g., gelling components such as polyoxyethylene-polyoxypropylenecopolymers). In some embodiments, low viscosity compositions containfrom about 2% to about 10% of a viscosity enhancing agent (e.g., gellingcomponents such as polyoxyethylene-polyoxypropylene copolymers). In someembodiments, low viscosity compositions contain from about 5% to about10% of a viscosity enhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, lowviscosity compositions are substantially free of a viscosity enhancingagent (e.g., gelling components such as polyoxyethylene-polyoxypropylenecopolymers). In some embodiments, a low viscosity ophthalmic agentcomposition described herein provides an apparent viscosity of fromabout 100 cP to about 10,000 cP. In some embodiments, a low viscosityophthalmic agent composition described herein provides an apparentviscosity of from about 500 cP to about 10,000 cP. In some embodiments,a low viscosity ophthalmic agent composition described herein providesan apparent viscosity of from about 1000 cP to about 10,000 cP.

Osmolarity

In some embodiments, a composition disclosed herein is formulated inorder to not disrupt the ionic balance of the eye. In some embodiments,a composition disclosed herein has an ionic balance that is the same asor substantially the same as the eye. In some embodiments, a compositiondisclosed herein does not does not disrupt the ionic balance of the eye.

As used herein, “practical osmolarity/osmolality” or “deliverableosmolarity/osmolality” means the osmolarity/osmolality of a compositionas determined by measuring the osmolarity/osmolality of the ophthalmicagent and all excipients except the gelling and/or the thickening agent(e.g., poly oxyethylene-polyoxypropylene copolymers,carboxymethylcellulose or the like). The practical osmolarity of acomposition disclosed herein is measured by a suitable method, e.g., afreezing point depression method as described in Viegas et. al., Int. J.Pharm., 1998, 160, 157-162. In some instances, the practical osmolarityof a composition disclosed herein is measured by vapor pressureosmometry (e.g., vapor pressure depression method) that allows fordetermination of the osmolarity of a composition at higher temperatures.In some instances, vapor pressure depression method allows fordetermination of the osmolarity of a composition comprising a gellingagent (e.g., a thermoreversible polymer) at a higher temperature whereinthe gelling agent is in the form of a gel.

In some embodiments, the osmolarity at a target site of action (e.g.,the eye) is about the same as the delivered osmolarity of a compositiondescribed herein. In some embodiments, a composition described hereinhas a deliverable osmolarity of about 150 mOsm/L to about 500 mOsm/L,about 250 mOsm/L to about 500 mOsm/L, about 250 mOsm/L to about 350mOsm/L, about 280 mOsm/L to about 370 mOsm/L or about 250 mOsm/L toabout 320 mOsm/L.

The practical osmolality of an ophthalmic composition disclosed hereinis from about 100 mOsm/kg to about 1000 mOsm/kg, from about 200 mOsm/kgto about 800 mOsm/kg, from about 250 mOsm/kg to about 500 mOsm/kg, orfrom about 250 mOsm/kg to about 320 mOsm/kg, or from about 250 mOsm/kgto about 350 mOsm/kg or from about 280 mOsm/kg to about 320 mOsm/kg. Insome embodiments, a composition described herein has a practicalosmolarity of about 100 mOsm/L to about 1000 mOsm/L, about 200 mOsm/L toabout 800 mOsm/L, about 250 mOsm/L to about 500 mOsm/L, about 250 mOsm/Lto about 350 mOsm/L, about 250 mOsm/L to about 320 mOsm/L, or about 280mOsm/L to about 320 mOsm/L.

In some embodiments, suitable tonicity adjusting agents include, but arenot limited to any pharmaceutically acceptable sugar, salt or anycombinations or mixtures thereof, such as, but not limited to dextrose,glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes.In some instances, the tonicity adjusting agent is selected from sodiumchloride, sodium nitrate, sodium sulfate, sodium bisulfate, potassiumchloride, calcium chloride, magnesium chloride, zinc chloride, potassiumacetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodiumthiosulfate, magnesium sulfate, disodium hydrogen phosphate, sodiumdihydrogen phosphate, potassium dihydrogen phosphate, dextrose,mannitol, sorbitol, dextrose, sucrose, urea, propylene glycol, glycerin,trehalose, or a combination thereof.

In some embodiment, the ophthalmic compositions described herein includeone or more salts in an amount required to bring osmolality of thecomposition into an acceptable range. Such salts include those havingsodium, potassium or ammonium cations and chloride, citrate, ascorbate,borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfiteanions; suitable salts include sodium chloride, potassium chloride,sodium thiosulfate, sodium bisulfite and ammonium sulfate.

Sterility

In some embodiments, the compositions are sterilized. Included withinthe embodiments disclosed herein are means and processes forsterilization of a pharmaceutical composition disclosed herein for usein humans. The goal is to provide a safe pharmaceutical product,relatively free of infection causing micro-organisms. The U. S. Food andDrug Administration has provided regulatory guidance in the publication“Guidance for Industry: Sterile Drug Products Produced by AsepticProcessing” available at: http://www.fda.gov/cder/guidance/5882fnl.htm,which is incorporated herein by reference in its entirety.

As used herein, sterilization means a process used to destroy or removemicroorganisms that are present in a product or packaging. Any suitablemethod available for sterilization of objects and compositions is used.Available methods for the inactivation of microorganisms include, butare not limited to, the application of extreme heat, lethal chemicals,or gamma radiation. In some embodiments, a process for the preparationof an ophthalmic formulation comprises subjecting the formulation to asterilization method selected from heat sterilization, chemicalsterilization, radiation sterilization or filtration sterilization. Themethod used depends largely upon the nature of the device or compositionto be sterilized. Detailed descriptions of many methods of sterilizationare given in Chapter 40 of Remington: The Science and Practice ofPharmacy published by Lippincott, Williams & Wilkins, and isincorporated by reference with respect to this subject matter.

Filtration

Filtration sterilization is a method used to remove but not destroymicroorganisms from solutions. Membrane filters are used to filterheat-sensitive solutions. Such filters are thin, strong, homogenouspolymers of mixed cellulosic esters (MCE), polyvinylidene fluoride (PVF;also known as PVDF), or polytetrafluoroethylene (PTFE) and have poresizes ranging from 0.1 to 0.22 □m. Solutions of various characteristicsare optionally filtered using different filter membranes. For example,PVF and PTFE membranes are well suited to filtering organic solventswhile aqueous solutions are filtered through PVF or MCE membranes.Filter apparatus are available for use on many scales ranging from thesingle point-of-use disposable filter attached to a syringe up tocommercial scale filters for use in manufacturing plants. The membranefilters are sterilized by autoclave or chemical sterilization.Validation of membrane filtration systems is performed followingstandardized protocols (Microbiological Evaluation of Filters forSterilizing Liquids, Vol 4, No. 3. Washington, D.C.: Health IndustryManufacturers Association, 1981) and involve challenging the membranefilter with a known quantity (ca. 10⁷/cm²) of unusually smallmicroorganisms, such as Brevundimonas diminuta (ATCC 19146).

Pharmaceutical compositions are optionally sterilized by passing throughmembrane filters. Formulations comprising nanoparticles (U.S. Pat. No.6,139,870) or multilamellar vesicles (Richard et al., InternationalJournal of Pharmaceutics (2006), 312(1-2):144-50) are amenable tosterilization by filtration through 0.22 □m filters without destroyingtheir organized structure.

In some embodiments, the methods disclosed herein comprise sterilizingthe formulation (or components thereof) by means of filtrationsterilization. In ophthalmic gel compositions that includesthermosetting polymers, filtration is carried out below (e.g. about 5°C.) the gel temperature (Tgel) of a formulation described herein andwith viscosity that allows for filtration in a reasonable time using aperistaltic pump (e.g. below a theoretical value of 100 cP).

Accordingly, provided herein are methods for sterilization of ophthalmicformulations that prevent degradation of polymeric components (e.g.,thermosetting and/or other viscosity enhancing agents) and/or theophthalmic agent during the process of sterilization. In someembodiments, degradation of the ophthalmic agent (e.g., a muscarinicantagonist such as atropine or atropine sulfate) is reduced oreliminated through the use of specific pD ranges for buffer componentsand specific proportions of viscosity enhancing agents in theformulations. In some embodiments, the choice of an appropriateviscosity enhancing agents or thermosetting polymer allows forsterilization of formulations described herein by filtration. In someembodiments, the use of an appropriate thermosetting polymer or otherviscosity enhancing agents in combination with a specific pD range forthe formulation allows for high temperature sterilization offormulations described with substantially no degradation of thetherapeutic agent or the polymeric excipients. An advantage of themethods of sterilization provided herein is that, in certain instances,the formulations are subjected to terminal sterilization via autoclavingwithout any loss of the ophthalmic agent and/or excipients and/orviscosity enhancing agents during the sterilization step and arerendered substantially free of microbes and/or pyrogens.

Radiation Sterilization

One advantage of radiation sterilization is the ability to sterilizemany types of products without heat degradation or other damage. Theradiation commonly employed is beta radiation or alternatively, gammaradiation from a ⁶⁰Co source. The penetrating ability of gamma radiationallows its use in the sterilization of many product types, includingsolutions, compositions and heterogeneous mixtures. The germicidaleffects of irradiation arise from the interaction of gamma radiationwith biological macromolecules. This interaction generates chargedspecies and free-radicals. Subsequent chemical reactions, such asrearrangements and cross-linking processes, result in the loss of normalfunction for these biological macromolecules. The formulations describedherein are also optionally sterilized using beta irradiation.

Sterilization by Heat

Many methods are available for sterilization by the application of highheat. One method is through the use of a saturated steam autoclave. Inthis method, saturated steam at a temperature of at least 121° C. isallowed to contact the object to be sterilized. The transfer of heat iseither directly to the microorganism, in the case of an object to besterilized, or indirectly to the microorganism by heating the bulk of anaqueous solution to be sterilized. This method is widely practiced as itallows flexibility, safety and economy in the sterilization process.

Microorganisms

In some embodiments, the compositions are substantially free ofmicroorganisms. Acceptable bioburden or sterility levels are based onapplicable standards that define therapeutically acceptablecompositions, including but not limited to United States PharmacopeiaChapters <1111> et seq. For example, acceptable sterility (e.g.,bioburden) levels include about 10 colony forming units (cfu) per gramof formulation, about 50 cfu per gram of formulation, about 100 cfu pergram of formulation, about 500 cfu per gram of formulation or about 100cfu per gram of formulation. In some embodiments, acceptable bioburdenlevels or sterility for formulations include less than 10 cfu/mL, lessthan 50 cfu/mL, less than 500 cfu/mL or less than 1000 cfu/mL microbialagents. In addition, acceptable bioburden levels or sterility includethe exclusion of specified objectionable microbiological agents. By wayof example, specified objectionable microbiological agents include butare not limited to Escherichia coli (E. coli). Salmonella sp.,Pseudomonas aeruginosa (P. aeruginosa) and/or other specific microbialagents.

An important component of the sterility assurance quality control,quality assurance and validation process is the method of sterilitytesting. Sterility testing, by way of example only, is performed by twomethods. The first is direct inoculation wherein a sample of thecomposition to be tested is added to growth medium and incubated for aperiod of time up to 21 days. Turbidity of the growth medium indicatescontamination. Drawbacks to this method include the small sampling sizeof bulk materials which reduces sensitivity, and detection ofmicroorganism growth based on a visual observation. An alternativemethod is membrane filtration sterility testing. In this method, avolume of product is passed through a small membrane filter paper. Thefilter paper is then placed into media to promote the growth ofmicroorganisms. This method has the advantage of greater sensitivity asthe entire bulk product is sampled. The commercially available MilliporeSteritest sterility testing system is optionally used for determinationsby membrane filtration sterility testing. For the filtration testing ofcreams or ointments Steritest filter system No. TLHVSL210 are used. Forthe filtration testing of emulsions or viscous products Steritest filtersystem No. TLAREM210 or TDAREM210 are used. For the filtration testingof pre-filled syringes Steritest filter system No. TTTHASY210 are used.For the filtration testing of material dispensed as an aerosol or foamSteritest filter system No. TTHVA210 are used. For the filtrationtesting of soluble powders in ampoules or vials Steritest filter systemNo. TTHADA210 or TTHADV210 are used.

Testing for E. coli and Salmonella includes the use of lactose brothsincubated at 30-35° C. for 24-72 hours, incubation in MacConkey and/orEMB agars for 18-24 hours, and/or the use of Rappaport medium. Testingfor the detection of P. aeruginosa includes the use of NAC agar. UnitedStates Pharmacopeia Chapter <62> further enumerates testing proceduresfor specified objectionable microorganisms.

In certain embodiments, the ophthalmic formulation described herein hasless than about 60 colony forming units (CFU), less than about 50 colonyforming units, less than about 40 colony forming units, or less thanabout 30 colony forming units of microbial agents per gram offormulation. In certain embodiments, the ophthalmic formulationsdescribed herein are formulated to be isotonic with the eye.

Endotoxins

An additional aspect of the sterilization process is the removal ofby-products from the killing of microorganisms (hereinafter, “Product”).The process of depyrogenation removes pyrogens from the sample. Pyrogensare endotoxins or exotoxins which induce an immune response. An exampleof an endotoxin is the lipopolysaccharide (LPS) molecule found in thecell wall of gram-negative bacteria. While sterilization procedures suchas autoclaving or treatment with ethylene oxide kill the bacteria, theLPS residue induces a proinflammatory immune response, such as septicshock. Because the molecular size of endotoxins varies widely, thepresence of endotoxins is expressed in “endotoxin units” (EU). One EU isequivalent to 100 picograms of E. coli LPS. In some cases, humansdevelop a response to as little as 5 EU/kg of body weight. The bioburden(e.g., microbial limit) and/or sterility (e.g., endotoxin level) isexpressed in any units as recognized in the art. In certain embodiments,ophthalmic compositions described herein contain lower endotoxin levels(e.g. <4 EU/kg of body weight of a subject) when compared toconventionally acceptable endotoxin levels (e.g., 5 EU/kg of body weightof a subject). In some embodiments, the ophthalmic formulation has lessthan about 5 EU/kg of body weight of a subject. In other embodiments,the ophthalmic formulation has less than about 4 EU/kg of body weight ofa subject. In additional embodiments, the ophthalmic formulation hasless than about 3 EU/kg of body weight of a subject. In additionalembodiments, the ophthalmic formulation has less than about 2 EU/kg ofbody weight of a subject.

In some embodiments, the ophthalmic formulation has less than about 5EU/kg of formulation. In other embodiments, the ophthalmic formulationhas less than about 4 EU/kg of formulation. In additional embodiments,the ophthalmic formulation has less than about 3 EU/kg of formulation.In some embodiments, the ophthalmic formulation has less than about 5EU/kg Product. In other embodiments, the ophthalmic formulation has lessthan about 1 EU/kg Product. In additional embodiments, the ophthalmicformulation has less than about 0.2 EU/kg Product. In some embodiments,the ophthalmic formulation has less than about 5 EU/g of unit orProduct. In other embodiments, the ophthalmic formulation has less thanabout 4 EU/g of unit or Product. In additional embodiments, theophthalmic formulation has less than about 3 EU/g of unit or Product. Insome embodiments, the ophthalmic formulation has less than about 5 EU/mgof unit or Product. In other embodiments, the ophthalmic formulation hasless than about 4 EU/mg of unit or Product. In additional embodiments,the ophthalmic formulation has less than about 3 EU/mg of unit orProduct. In certain embodiments, ophthalmic formulations describedherein contain from about 1 to about 5 EU/mL of formulation. In certainembodiments, ophthalmic formulations described herein contain from about2 to about 5 EU/mL of formulation, from about 3 to about 5 EU/mL offormulation, or from about 4 to about 5 EU/mL of formulation.

In certain embodiments, ophthalmic compositions described herein containlower endotoxin levels (e.g. <0.5 EU/mL of formulation) when compared toconventionally acceptable endotoxin levels (e.g., 0.5 EU/mL offormulation). In some embodiments, the ophthalmic formulation has lessthan about 0.5 EU/mL of formulation. In other embodiments, theophthalmic formulation has less than about 0.4 EU/mL of formulation. Inadditional embodiments, the ophthalmic formulation has less than about0.2 EU/mL of formulation.

Pyrogen detection, by way of example only, is performed by severalmethods. Suitable tests for sterility include tests described in UnitedStates Pharmacopoeia (USP) <71> Sterility Tests (23rd edition, 1995).The rabbit pyrogen test and the Limulus amebocyte lysate test are bothspecified in the United States Pharmacopeia Chapters <85> and <151>(USP23/NF 18, Biological Tests, The United States PharmacopeialConvention, Rockville, Md., 1995). Alternative pyrogen assays have beendeveloped based upon the monocyte activation-cytokine assay. Uniformcell lines suitable for quality control applications have been developedand have demonstrated the ability to detect pyrogenicity in samples thathave passed the rabbit pyrogen test and the Limulus amebocyte lysatetest (Taktak et al, J. Pharm. Pharmacol. (1990), 43:578-82). In anadditional embodiment, the ophthalmic formulation is subject todepyrogenation. In a further embodiment, the process for the manufactureof the ophthalmic formulation comprises testing the formulation forpyrogenicity. In certain embodiments, the formulations described hereinare substantially free of pyrogens.

Ophthalmic Muscarinic Antagonist-Mucus Penetrating Particle (MPP)Composition

Mucus-penetrating particles (MPPs) are particles that rapidly traversemucus (e.g. human mucus). In some cases, MPPs comprise of a nanoparticlewith a particle size of between about 200 nm and 500 nm. In someinstances, the nanoparticle is further coated with a mucus penetratingagent. In some instances, a composition described herein is formulatedwith MPPs for mucus penetration. In some instances, an ophthalmic agentcomposition described herein is formulated with MPPs for mucuspenetration. In some instances, the ophthalmic agent is a muscarinicantagonist. In some instances, a muscarinic antagonist compositiondescribed herein is formulated with MPPs for mucus penetration. In someinstances, a muscarinic antagonist comprises atropine, atropine sulfate,noratropine, atropine-N-oxide, tropine, tropic acid, atropinemethonitrate, diphenhydramine, dimenhydrinate, dicyclomine, flavoxate,oxybutynin, tiotropium, hyoscine, scopolomine (L-hyoscine), hydroxyzine,ipratropium, tropicamide, cyclopentolate, pirenzapine, homatropine,solifenacin, darifenacin, benzatropine, mebeverine, procyclidine,aclidinium bromide, trihexyphenidyl/benzhexol, or tolterodine. In someinstances, a muscarinic antagonist is atropine or its pharmaceuticallyacceptable salt thereof. In some instances, a muscarinic antagonist isatropine sulfate. In some instances, an atropine composition describedherein is formulated with MPPs for mucus penetration. In some instances,an atropine sulfate composition described herein is formulated with MPPsfor mucus penetration. In a non-limiting example, the MMPs for use inthe disclosed composition is obtained from Kala Pharmaceuticals, Inc.(100 Beaver Street #201, Waltham, Mass. 02453).

In some embodiments, the nanoparticle comprises of any suitablematerial, such as an organic material, an inorganic material, a polymer,or combinations thereof. In some instances, the nanoparticle comprisesof inorganic material, such as for example, a metal (e.g., Ag, Au, Pt,Fe, Cr, Co, Ni, Cu, Zn, and other transition metals), a semiconductor(e.g., silicon, silicon compounds and alloys, cadmium selenide, cadmiumsulfide, indium arsenide, and indium phosphide), or an insulator (e.g.,ceramics such as silicon oxide). In some instances, the nanoparticlecomprises organic materials such as a synthetic polymer and/or a naturalpolymer. Examples of synthetic polymers include non-degradable polymerssuch as polymethacrylate and degradable polymers such as polylacticacid, polyglycolic acid and copolymers thereof. Examples of naturalpolymers include hyaluronic acid, chitosan, and collagen.

In some embodiments, the nanoparticle is coated with a mucus penetratingagent. In some instances, the mucus penetrating agent comprises anysuitable material, such as a hydrophobic material, a hydrophilicmaterial, and/or an amphiphilic material. In some instances, the mucuspenetrating agent is a polymer. In some instances, the polymer asynthetic polymer (i.e., a polymer not produced in nature). In otherembodiments, the polymer is a natural polymer (e.g., a protein,polysaccharide, rubber). In certain embodiments, the polymer is asurface active polymer. In certain embodiments, the polymer is anon-ionic polymer. In certain embodiments, the polymer is a non-ionicblock copolymer. In some embodiments, the polymer is a diblockcopolymer, a triblock copolymer, e.g., e.g., where one block is ahydrophobic polymer and another block is a hydrophilic polymer. In someembodiments, the polymer is charged or uncharged.

Additional examples of suitable polymers include, but are not limitedto, polyamines, polyethers, polyamides, polyesters, polycarbamates,polyureas, polycarbonates, polystyrenes, polyimides, polysulfones,polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines,polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles,and polyarylates. Non-limiting examples of specific polymers includepoly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA),poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid)(PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lacticacid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA),poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone),poly(D,L-lactide-co-caprolactone-co-glycolide),poly(D,L-lactide-co-PEO-co-D,L-lactide),poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylate,polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA),poly(ethylene glycol), poly-L-glutamic acid, poly(hydroxy acids),polyanhydrides, polyorthoesters, poly(ester amides), polyamides,poly(ester ethers), polycarbonates, polyalkylenes such as polyethyleneand polypropylene, polyalkylene glycols such as poly(ethylene glycol)(PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such aspoly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinylethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halidessuch as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes,polystyrene (PS), polyurethanes, derivatized celluloses such as alkylcelluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters,nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose,polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA),poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate),poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate),poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate),poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropylacrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) (jointlyreferred to herein as “polyacrylic acids”), and copolymers and mixturesthereof, polydioxanone and its copolymers, polyhydroxyalkanoates,polypropylene fumarate), polyoxymethylene, poloxamers,poly(ortho)esters, poly(butyric acid), poly(valeric acid),poly(lactide-co-caprolactone), and trimethylene carbonate,polyvinylpyrrolidone.

In some cases, an ophthalmic agent (e.g. a muscarinic antagonist such asatropine or atropine sulfate) is present in the MPP formulation at aconcentration of between about 0.001 wt % and about 0.05 wt %, betweenabout 0.005% to about 0.050%, between about 0.010% to about 0.050%,between about 0.015% to about 0.050%, between about 0.020% to about0.050%, between about 0.025% to about 0.050%, between about 0.030% toabout 0.050%, between about 0.035% to about 0.050%, between about 0.040%to about 0.050%, or between about 0.045% to about 0.050% of theophthalmic agent, or pharmaceutically acceptable prodrug or saltthereof, by weight of the composition. In some instances, additionalagents such as buffers, pD adjusting agents, and/or preservatives areformulated in the MPP formulation.

In some instances, ophthalmic agent-MPP composition is formulated usingany suitable method. In some embodiments, a milling process is used toreduce the size of a solid material to form particles in the micrometerto nanometer size range. In some cases, dry and wet milling processessuch as jet milling, cryo-milling, ball milling, media milling, andhomogenization are known and are used in methods described herein.Generally, in a wet milling process, a suspension of the material to beused as the nanoparticle is mixed with milling media with or withoutexcipients to reduce particle size. Dry milling is a process wherein thematerial to be used as the nanoparticle is mixed with milling media withor without excipients to reduce particle size. In a cryo-millingprocess, a suspension of the material to be used as the nanoparticle ismixed with milling media with or without excipients under cooledtemperatures.

In some embodiments, any suitable grinding medium is used for milling.In some embodiments, a ceramic and/or polymeric material and/or a metalis used. Examples of suitable materials include zirconium oxide, siliconcarbide, silicon oxide, silicon nitride, zirconium silicate, yttriumoxide, glass, alumina, alpha-alumina, aluminum oxide, polystyrene,poly(methyl methacrylate), titanium, steel. In some cases, a grindingmedium has any suitable size. For example, the grinding medium has anaverage diameter of at least about 0.1 mm, at least about 0.2 mm, atleast about 0.5 mm, at least about 0.8 mm, at least about 1 mm, at leastabout 2 mm, or at least about 5 mm. In some cases, the grinding mediumhas an average diameter of less than or equal to about 5 mm, less thanor equal to about 2 mm, less than or equal to about 1 mm, less than orequal to about 0.8, less than or equal to about 0.5 mm, or less than orequal to about 0.2 mm. Combinations of the above-referenced ranges arealso possible (e.g., an average diameter of at least about 0.5millimeters and less than or equal to about 1 mm). Other ranges are alsopossible.

In some embodiments, any suitable solvent are used for milling. In somecases, the choice of solvent is depend on factors such as the solidmaterial (e.g., a muscarinic antagonist such as atropine) being milled,the particular type of stabilizer/mucus penetrating agent being used(e.g., one that renders the particle mucus penetrating), the grindingmaterial be used, among other factors. In some cases, suitable solventsare ones that do not substantially dissolve the solid material or thegrinding material, but dissolve the stabilizer/mucus penetrating agentto a suitable degree. Non-limiting examples of solvents include, but arenot limited to, water, buffered solutions, other aqueous solutions,alcohols (e.g., ethanol, methanol, butanol), and mixtures thereof thatoptionally include other components such as pharmaceutical excipients,polymers, pharmaceutical agents, salts, preservative agents, viscositymodifiers, tonicity modifier, taste masking agents, antioxidants, pDmodifier, and other pharmaceutical excipients. In other embodiments, anorganic solvent is used. In some cases, a pharmaceutical agent (e.g. amuscarinic antagonist such as atropine) has any suitable solubility inthese or other solvents, such as a solubility in one or more of theranges described above for aqueous solubility or for solubility in acoating solution.

In some instances, a MPP is a MPP as described in WO2013/166385. In someinstances, a MPP is a MPP as described in Lai et al., “Rapid transportof large polymeric nanoparticles in fresh undiluted human mucus,” PNAS104(5):1482-1487(2007). In some instances, an ophthalmic agent-MPPcomposition is formulated using a method as described in WO2013/166385.In some instances, an ophthalmic agent-MPP composition is formulatedusing a method as described in Lai et al., “Rapid transport of largepolymeric nanoparticles in fresh undiluted human mucus,” PNAS104(5):1482-1487 (2007). In some instances, the ophthalmic agent is amuscarinic antagonist such as atropine or atropine sulfate.

Muscarinic Antagonist-Ophthalmic Delivery Devices and Delivery System

In some embodiments, a muscarinic antagonist described herein isdelivered to a target site by an ophthalmic delivery device. In somecases, the ophthalmic delivery device is configured for controlledsustained release of a muscarinic antagonist. In some instances, themuscarinic antagonist comprises atropine, atropine sulfate, noratropine,atropine-N-oxide, tropine, tropic acid, hyoscine, scopolomine,tropicamide, cyclopentolate, pirenzapine, homatropine, or a combinationthereof. In some cases, the muscarinic antagonist comprises atropine oratropine sulfate.

In some embodiments, an ophthalmic delivery device comprises a punctalplug, a scleral patch, a scleral ring, a Cul-de sac insert, asubconjunctival/episcleral implant, an intravitreal implant, or anon-invasive delivery device. In some instances, anon-invasive deliverydevice comprises topical ophthalmic drug delivery device (TODD) or acontact lens. In some instances, the ophthalmic delivery device is abiodegradable ophthalmic delivery device. In other instances, theophthalmic delivery device is a non-biodegradable ophthalmic deliverydevice. In some cases, the biodegradable ophthalmic delivery device isconfigured for controlled sustained release of a muscarinic antagonist.In other cases, the non-biodegradable ophthalmic delivery device isconfigured for controlled sustained release of a muscarinic antagonist.

In some instances, an ophthalmic delivery device comprises a core orreservoir which comprises a muscarinic antagonist (e.g., atropine oratropine sulfate) and is configured for a controlled sustained releaseof the muscarinic antagonist. In some cases, the muscarinic antagonistis formulated within the core or reservoir as a solution, a gel, or in asolid form. In other embodiments, a muscarinic antagonist (e.g.,atropine or atropine sulfate) is dispersed (e.g., uniformly) within thematerial of the ophthalmic delivery device, and is configured for acontrolled sustained release of the muscarinic antagonist. In someinstances, the ophthalmic delivery device is a punctal plug, a scleralpatch, a scleral ring, a Cul-de sac insert, a subconjunctival/episcleralimplant, an intravitreal implant, or anon-invasive delivery device.

Punctal Plug

A punctal plug or tear duct plug is an ocular device that in some casesis inserted into the tear duct (or puncta) of an eye. In some instances,a punctal plug is used for the delivery of an ophthalmic composition,for example, an ophthalmic composition described herein. In some cases,a punctal plug is used for the delivery of a muscarinic antagonistformulated in deuterated water. In additional cases, a punctal plug isused for the delivery of atropine or atropine sulfate formulated indeuterated water.

In some instances, a punctal plug is used for controlled sustainedrelease of a muscarinic antagonist (e.g., atropine or atropine sulfate).In some cases, the period of controlled sustained release is, forexample, up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30,45, 60 days or longer. In some instances, the period of controlledsustained release is, for example, up to 7 days. In some cases, theperiod of controlled sustained release is, for example, up to 14 days.In some cases, the period of controlled sustained release is, forexample, up to 1 month.

In some embodiments, a punctal plug comprises a core or reservoir whichcomprises a muscarinic antagonist (e.g., atropine or atropine sulfate)and is configured fora controlled sustained release of the muscarinicantagonist. In other embodiments, a muscarinic antagonist (e.g.,atropine or atropine sulfate) is dispersed within the punctal plugmaterial, and is configured for a controlled sustained release of themuscarinic antagonist.

In some embodiments, a punctal plug described herein utilizes adiffusion mechanism for the del very of a muscarinic antagonist (e.g.,atropine or atropine sulfate) In some instances, the configuration ofthe punctal plug is tubular with its cylindrical wall closed bytransverse end walls to define a reservoir for the muscarinic antagonist(either in liquid or gel form). In some cases, at least the cylindricalw all is a membrane permeable by diffusion so that the muscarinicantagonist is released continuously at a controlled rate through themembrane into the tear fluid.

Exemplary materials for a permeable membrane for the diffusion mechanisminclude insoluble microporous materials of polycarbonates, polyvinylchlorides, polyamides, copolymers of polyvinyl chloride andacrylonitrile, polysulphones, polyvinylidene fluorides, polyvinylfluorides, polychloroethers, polyformaldehydes, acrylic resins,polyurethanes, polyimides, polybenzimadozoles, poly vinyl acetates,polyethers, cellulose esters, porous rubbers, cross-linked poly(ethyleneoxide), cross-linked polyvinyl pyrrolidone, cross-linked poly(vinylalcohol) and polystyrenes.

In some embodiments, a punctal plug described herein utilizes an osmosismechanism for the delivery of a muscarinic antagonist (e.g., atropine oratropine sulfate) In some cases, the configuration of the punctal plugis tubular with domed end walls, and the device comprises a transverseimpermeable elastic membrane dividing the tubular interior of the deviceinto a first compartment and a second compartment; the first compartmentis bounded by a semi-permeable membrane and the impermeable elasticmembrane, and the second compartment is bounded by an impermeablematerial and the elastic membrane. In some cases, a drug releaseaperture is included in the impermeable end wall of the device. When thedevice is placed in the aqueous environment of the eye water diffusesinto the first compartment and stretches the elastic membrane to expandthe first compartment and contract the second compartment so that thedrug is forced through the drug release aperture.

Examples of materials for an osmotic semi-permeable membrane includecellulose acetate and its derivatives, partial and completely hydrolyzedethylene-vinyl acetate copolymers, highly plasticized polyvinylchloride, homo- and copolymers of polyvinyl acetate, polyesters ofacrylic acid and methacrylic acid, polyvinyl alkyl ethers, polyvinylfluoride; silicone polycarbonates, aromatic nitrogen-containingpolymeric membranes, polymeric epoxides, copolymers of an alkylene oxideand alkyl glycidyl ether, polyurethanes, polyglycolic or polyacetic acidand derivatives thereof, derivatives of polystyrene such as poly(sodiumstyrenesulfonate) and poly(vinyl benzyltrimethyl-ammonium chloride),ethylene-vinyl acetate copolymers.

In some embodiments, a punctal plug described herein utilizes abioerosion mechanism for the delivery of a muscarinic antagonist (e.g.,atropine or atropine sulfate). In some cases, the configuration of thepunctal plug is rod-like being constituted from a matrix of bioerodiblematerial in which the drug is dispersed. Contact of the device with tearfluid results in controlled sustained release of the drug by bioerosionof the matrix. In such cases, the drug is dispersed uniformly throughoutthe matrix but it is believed a more controlled release is obtained ifthe drug is superficially concentrated in the matrix.

Examples of bioerodible matrix materials include polyesters of thegeneral formula —O—(W)—CO— and mixture thereof wherein W is a loweralkylene of 1 to 7 carbons and may include a member selected from thegroup of alkylenes of the formula —CH₂—, or —CH—CH₂—, and Y has a valuesuch that the molecular weight of the polymer is from about 4,000 to100,000. The polymers are polymerization-condensation products ofmonobasic hydroxy acid of the formula C_(n)H_(2n)(OH)COOH wherein n hasa value of 1 to 7, preferably 1 or 2 and the acid is especially lacticacid or glycolic acid. Also included are copolymers derived frommixtures of these acids. Bioerodible materials also includepoly(orthoesters). These materials have the following general formula:

wherein R₁ is an alkylene of 4 to 12 carbons, a cycloalkylene of 5 to 6carbons substituted with an alkylene of 1 to 7 carbons and analkyleneoxy of 1 to 7 carbons, and R₂ is a lower alkyl of 1 to 7carbons.

Additional bioerodible matrix materials include: (1) Polyanhydrides suchas poly(p-carboxyphenoxy) alkyl (e.g. p-carboxyphenoxypropane) orpolymeric fatty acid dimer (e.g. poly-dodecanedioic acid) compounds andfurther co-polymers with sebacic acid, or phthalic acid such asdisclosed in Chasin et al., Polyanhydrides for Controlled Drug Delivery,Biopharm., February 1988, 33-46; and Lee et al. (1988), The Use ofBioerodible Polymers and 5 fluorouracil in Glaucoma Filtration Surgery,Invest. Ophthalmol. Vis Sci., 29, 1692-1697; (2) Poly(alkyl-2-cyanoacrylates) such as poly (hexyl-2-cyanoacrylate) asdescribed by Douglas et al. (1987). Nanoparticles in Drug Delivery. CRCCrit. Rev. Therap. Drug Carr. System., 3, 233-261; and (3) Polyaminoacids such as copolymers of leucine and methyl glutamate.

In some cases, a punctal plug described herein comprises a solidnon-erodible rod with pores. In some instances, the release of amuscarinic antagonist takes place via diffusion through the pores. Insuch instances, controlled release is further regulated by gradualdissolution of solid dispersed drug within this matrix as a result ofinward diffusion of aqueous solutions.

Examples of materials for use as non-erodible rods include polymers suchas hydroxyethylmethacrylate and co-polymers with methacrylic acid,methylmethacrylate, N-vinyl 2-pyrrolidone, allyl methacrylate, ethyleneglycol dimethacrylate, ethylene dimethacrylate, or 1,1,1trimethylolpropane trimethacrylate, and dimethyl diphenyl methylvinylpolysiloxane.

In some instances, the body of the plug is wholly or partiallytransparent or opaque. Optionally, the body includes a tint or pigmentthat makes the plug easier to see when it is placed in a punctum.

In some cases, the surface of the plug body is wholly or partiallycoated. In some cases, the coating provides one or more oflubriciousness to aid insertion, muco-adhesiveness to improve tissuecompatibility, and texture to aid in anchoring the plug within thepunctum. Examples of suitable coatings include, without limitation,gelatin, collagen, hydroxyethyl methacrylate, PVP, PEG, heparin,chondroitin sulphate, hyaluronic acid, synthetic and natural proteins,and polysaccharides, thiomers, thiolated derivatives of polyacrylic acidand chitosan, polyacrylic acid, carboxymethyl cellulose and the like andcombinations thereof.

In some embodiments, a punctal plug described herein is a punctal plugdescribed in U.S. Pat. No. 5,147,647; U.S. Publication No. 2012/0277694;or 2010/0256557.

In some instances, the size of the opening of the punctal plug is fromabout 0.05 mm to about 2.5 mm. In some instances, it is from about 0.1mm to about 2.0 mm, or from about 0.15 mm to about 1 mm.

In some embodiments, the amount of a muscarinic antagonist (e.g.,atropine or atropine sulfate) used in the plugs depends upon themuscarinic antagonist selected, the desired doses to be delivered viathe punctal plug, the desired release rate, and the melting points ofthe muscarinic antagonist and muscarinic antagonist-containing material.

Scleral Patch or Scleral Ring

In some embodiments, a muscarinic antagonist described herein isdelivered to an eye through a scleral patch or a scleral ring. In someinstances, a scleral patch or a scleral ring is a biodegradable scleralpatch or scleral ring. In other instances, a scleral patch or a scleralring is a non-biodegradable scleral patch or scleral ring. In additionalinstances, a scleral patch or a scleral ring is formulated forcontrolled sustained release of one or more of a muscarinic antagonistdescribed herein. In some cases, a scleral patch comprises amulti-layered patch in which one or more layer within the patchcomprises a muscarinic antagonist described herein. In some cases, ascleral ring comprises a core or reservoir which comprises a muscarinicantagonist (e.g., atropine or atropine sulfate), and the muscarinicantagonist is formulated within the core or reservoir as a solution, agel, or in a solid form. In other embodiments, a muscarinic antagonist(e.g., atropine or atropine sulfate) is dispersed (e.g., uniformly)within the material of the scleral patch or the scleral ring.

Cul-De Sac Inserts

In some embodiments, a muscarinic antagonist described herein isdelivered to an eye through a Cul-de sac insert. In some instances, theCul-de sac insert comprises a single-layered device comprisingmuscarinic antagonist dispersed within the insert material, ormultilayered, solid or semisolid consistency insert. In some instances,the Cul-de sac insert is a biodegradable insert. In other instances, theCul-de sac insert is a non-biodegradable insert. In additionalinstances, a Cul-de sac insert is formulated for controlled sustainedrelease of one or more of a muscarinic antagonist described herein. Insome instances, a Cul-de sac insert comprises a membrane-bound ocularinsert, which comprises of two outer layers of a copolymer such asethylene-vinyl acetate copolymer (EVA) and an inner laver comprising amuscarinic antagonist. In some instances, the muscarinic antagonistwithin the inner layer is formulated as a gel or as a solution. Anexemplary membrane-bound ocular insert is Ocuserts from Alza Corp.

In some cases, a Cul-de sac insert comprises an ocular film or sheath(mucoadhesive film or sheath or collagen shields), a coil, a polymerrod, HEMA hydrogel, or polysulfone capillary fiber. In some instances, aCul-de sac insert comprises rod-shaped water soluble insert comprisingof hydroxypropyl cellulose, a muscarinic antagonist, and one or moreadditional excipients. In some instances, the Cul-de sac insertcomprising a rod-shaped water soluble insert is a biodegradable insert.An example comprises Lacrisert (Merck).

Subconjunctival/Episcleral Implant

In some embodiments, a muscarinic antagonist described herein isdelivered to an eye through a subconjunctival/episcleral implant. Insome instances, a subconjunctival/episcleral implant is a biodegradableimplant. In other instances, a subconjunctival/episcleral implant isanon-biodegradable implant. In additional instances, asubconjunctival/episcleral implant is formulated for controlledsustained release of one or more of a muscarinic antagonist describedherein. In some cases, a subconjunctival/episcleral implant comprises acore or reservoir which comprises a muscarinic antagonist (e.g.,atropine or atropine sulfate), and the muscarinic antagonist isformulated within the core or reservoir as a solution, a gel, or in asolid form. In other embodiments, a muscarinic antagonist (e.g.,atropine or atropine sulfate) is dispersed (e.g., uniformly) within thematerial of the subconjunctival/episcleral implant. Exemplarysubconjunctival/episcleral implants include LX201 (Lux BiosciencesInc.), an episcleral implant from 3T Ophthalmics, or a subconjunctivalinsert from Pfizer.

Intravitreal Implants

In some embodiments, a muscarinic antagonist described herein isdelivered to an eye through an intravitreal implant. In some instances,an intravitreal implant is a biodegradable implant. In other instances,an intravitreal implant is a non-biodegradable implant. In additionalinstances, an intravitreal implant is formulated for controlledsustained release of one or more of a muscarinic antagonist describedherein. In some cases, an intravitreal implant comprises a core orreservoir which comprises a muscarinic antagonist (e.g., atropine oratropine sulfate), and the muscarinic antagonist is formulated withinthe core or reservoir as a solution, a gel, or in a solid form. In otherembodiments, a muscarinic antagonist (e.g., atropine or atropinesulfate) is dispersed (e.g., uniformly) within the material of theintravitreal implant. Exemplary intravitreal implant comprises Durasert™technology system (pSivida Corp.) (such as Vitrasert® and Retisert® fromBausch & Lomb Inc, and Iluvien® from Alimera sciences), Novadur™technology system (such as Ozurdex® from Allergan). I-Vation™ technologysystem (such as a delivery system developed from SurModics, Inc.), andNT-501 from Neurotech Pharmaceuticals.

Non-Invasive Delivery System

In some embodiments, a non-invasive delivery system comprises a topicalophthalmic agent delivery device. In some embodiments, a muscarinicantagonist described herein is delivered to an eye through a topicalophthalmic agent delivery device. In some instances, the topicalophthalmic agent delivery device comprises a soft elastomer drug depotthat floats atop the sclera under the eyelid. In some instances, thetopical ophthalmic agent delivery device is a biodegradable deliverydevice. In other instances, the topical ophthalmic agent delivery deviceis anon-biodegradable delivery device. In some cases, the topicalophthalmic agent delivery device is impregnated with a muscarinicantagonist described herein. In other cases, a muscarinic antagonist isdisperse (e.g., uniformly) in the topical ophthalmic agent deliverydevice. In some instances, the topical ophthalmic agent delivery deviceis formulated for controlled sustained release of the muscarinicantagonist. In some instances, an exemplary delivery device is a topicalophthalmic drug delivery device (TODD) from Amorphex Therapeutics.

In some embodiments, anon-invasive delivery system comprises a contactlens. In some embodiments, a muscarinic antagonist described herein isdelivered to an eye through a contact lens. In some instances, thecontact lens is impregnated with a muscarinic antagonist, for example,in which the muscarinic antagonist is dispersed, e.g., as colloidalstructure, within the lens. In other instances, the contact lens isfurther combined with a muscarinic antagonist layer, and is configuredfor controlled sustained release to the eye. Exemplary polymers, e.g.,hydrogel copolymers, for making a contact lens include at least onehydrophilic monomer and a crosslinking agent (a crosslinker beingdefined as a monomer having multiple polymerizable functionalities).Representative, hydrophilic monomers include unsaturated carboxylicacids, such as methacrylic acid and acrylic acid; (meth)acrylicsubstituted alcohols, such as 2-hydroxyethylmethacrylate and2-hydroxyethylacrylate; vinyl lactams, such as N-vinyl pyrrolidone; and(meth)acrylamides, such as methacrylamide and N,N-dimethylacrylamide.Typical crosslinking agents include polyvinyl, typically di- ortri-vinyl monomers, such as di- or tri(meth)acrylates ofdiethyleneglycol, triethyleneglycol, butyleneglycol and hexane-1,6-diol;and divinylbenzene. A specific example of a hydrogel-forming monomermixture is polymacon, composed primarily of 2-hydroxyethylmethacrylatewith a small amount of diethyleneglycol dimethacrylate as a crosslinkingmonomer. Optionally, the monomer mixture may include asilicone-containing monomer in order to form a silicone hydrogelcopolymer. Examples of silicone-containing monomers include: monomersincluding a single activated unsaturated radical, such asmethacryloxypropyl tris(trimethylsiloxy)silane, pentamethyldisiloxanylmethylmethacrylate, tris(trimethylsiloxy)methacryloxy propylsilane,methyldi(trimethylsiloxy)methacryloxymethyl silane,3-[tris(trimethylsiloxy)silyl]propylvinyl carbamate, and3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; andmultifunctional ethylenically “end-capped” siloxane-containing monomers,especially difunctional monomers having two activated unsaturatedradicals. A specific example of a silicone hydrogel-forming monomermixture is balafilcon, based on N-vinyl pyrrolidone and theaforementioned vinyl carbonate and carbamate monomers, disclosed in U.S.Pat. No. 5,260,000.

Ophthalmic Gel Muscarinic Antagonist Composition

Gels have been defined in various ways. For example, the United StatesPharmacopoeia defines gels as semisolid systems consisting of eithersuspensions made up of small inorganic particles or large organicmolecules interpenetrated by a liquid. Gels include a single-phase or atwo-phase system. A single-phase gel consists of organic macromoleculesdistributed uniformly throughout a liquid in such a manner that noapparent boundaries exist between the dispersed macromolecules and theliquid. Some single-phase gels are prepared from syntheticmacromolecules (e.g., carbomer) or from natural gums, (e.g.,tragacanth). In some embodiments, single-phase gels are generallyaqueous, but will also be made using alcohols and oils. Two-phase gelsconsist of a network of small discrete particles.

In some embodiments, gels are also classified as being hydrophobic orhydrophilic. In certain embodiments, the base of a non-limiting exampleof a hydrophobic gel includes a liquid paraffin with polyethylene orfatty oils gelled with colloidal silica, or aluminum or zinc soaps. Incontrast, the base of a non-limiting example of a hydrophilic gelincludes water, glycerol, or propylene glycol gelled with a suitablegelling agent (e.g., tragacanth, starch, cellulose derivatives,carboxyvinyl polymers, and magnesium-aluminum silicates). In certainembodiments, the rheology of the compositions disclosed herein is pseudoplastic, plastic, thixotropic, or dilatant.

In some embodiments, the ophthalmic composition is an ophthalmic gel,and wherein the ophthalmically acceptable carrier comprises water and atleast one viscosity-enhancing agent. In some embodiments, theviscosity-enhancing agent is selected from cellulose-based polymers,polyoxyethylene-polyoxypropylene triblock copolymers, dextran-basedpolymers, polyvinyl alcohol, dextrin, polyvinylpyrrolidone, polyalkyleneglycols, chitosan, collagen, gelatin, hyaluronic acid, or combinationsthereof.

In some embodiment, the ophthalmic gel composition described herein is asemi-solid or id in a gelled state before it is topically administered(e.g. at room temperature). For example, suitable viscosity-enhancingagents for such gels include by way of example only, gelling agents andsuspending agents. In one embodiment, the enhanced viscosity formulationdoes not include a buffer. In other embodiments, the enhanced viscosityformulation includes a pharmaceutically acceptable buffer. Sodiumchloride or other tonicity agents are optionally used to adjusttonicity, if necessary.

By way of example only, the ophthalmically acceptable viscosity agentincludes hydroxypropyl methylcellulose, hydroxyethyl cellulose,polyvinylpyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodiumchondroitin sulfate, sodium hyaluronate. Other viscosity enhancingagents compatible with the targeted ocular site include, but are notlimited to, acacia (gum arabic), agar, aluminum magnesium silicate,sodium alginate, sodium stearate, bladder wrack, bentonite, carbomer,carrageenan, Carbopol, xanthan, cellulose, microcrystalline cellulose(MCC), ceratonia, chitin, carboxymethylated chitosan, chondrus,dextrose, furcellaran, gelatin. Ghatti gum, guar gum, hectorite,lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch,wheat starch, rice starch, potato starch, gelatin, sterculia gum,xanthum gum, gum tragacanth, ethyl cellulose, ethylhydraxethylcellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethylcellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose,poly(hydroxyethyl methacrylate), oxypolygelatin, pectin, polygeline,povidone, propylene carbonate, methyl vinyl ether/maleic anhydridecopolymer (PVM/MA), poly(methoxyethyl methacrylate),poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose,hydroxypropylmethyl-cellulose (HPMC), sodium carboxymethyl-cellulose(CMC), silicon dioxide, polyvinylpyrrolidone (PVP: povidone), Splenda®(dextrose, maltodextrin and sucralose) or combinations thereof. Inspecific embodiments, the viscosity-enhancing excipient is a combinationof MCC and CMC. In another embodiment, the viscosity-enhancing agent isa combination of carboxymethylated chitosan, or chitin, and alginate.The combination of chitin and alginate with the ophthalmic agentsdisclosed herein acts as a controlled release formulation, restrictingthe diffusion of the ophthalmic agents from the formulation. Moreover,the combination of carboxymethylated chitosan and alginate is optionallyused to assist in increasing the permeability of the ophthalmic agentsin the eye.

In some embodiments is an enhanced viscosity formulation, comprisingfrom about 0.1 mM and about 100 mM of an ophthalmic agent, apharmaceutically acceptable viscosity agent, and water for injection,the concentration of the viscosity agent in the water being sufficientto provide an enhanced viscosity formulation with a final viscosity fromabout 100 to about 100,000 cP. In certain embodiments, the viscosity ofthe gel is in the range from about 100 to about 50,000 cP, about 100 cPto about 1,000 cP, about 500 cP to about 1500 cP, about 1000 cP to about3000 cP, about 2000 cP to about 8,000 cP, about 4,000 cP to about 50,000cP, about 10,000 cP to about 500.000 cP, about 15,000 cP to about1,000,000 cP. In other embodiments, when an even more viscous medium isdesired, the biocompatible gel comprises at least about 35%, at leastabout 45%, at least about 55%, at least about 65%, at least about 70%,at least about 75%, or even at least about 80% or so by weight of theophthalmic agent. In highly concentrated samples, the biocompatibleenhanced viscosity formulation comprises at least about 25%, at leastabout 35%, at least about 45%, at least about 55%, at least about 65%,at least about 75%, at least about 85%, at least about 90% or at leastabout 95% or more by weight of the ophthalmic agent.

In one embodiment, the pharmaceutically acceptable enhanced viscosityophthalmically acceptable formulation comprises at least one ophthalmicagent and at least one gelling agent. Suitable gelling agents for use inpreparation of the gel formulation include, but are not limited to,celluloses, cellulose derivatives, cellulose ethers (e.g.,carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose,hydroxymethylcellulose, hydroxypropylmethylcellulose,hydroxypropylcellulose, methylcellulose), guar gum, xanthan gum, locustbean gum, alginates (e.g., alginic acid), silicates, starch, tragacanth,carboxyvinyl polymers, carrageenan, paraffin, petrolatum and anycombinations or mixtures thereof. In some other embodiments,hydroxypropylmethylcellulose (Methocel®) is utilized as the gellingagent. In certain embodiments, the viscosity enhancing agents describedherein are also utilized as the gelling agent for the gel formulationspresented herein.

In some embodiments, the ophthalmic gel composition described herein isan in situ gel formulation. In some instances, the in situ gel formationis based on increased pre-corneal residence time of the ophthalmiccomposition which improves ocular bioavailability, corneal mucoadhesion,lysosomal interaction and ionic gelation, improved corneal absorption,thermal gelation, or a combination thereof. In some instances, the insitu gel formulation is activated by pH, temperature, ion, UV, orsolvent exchange.

In some instances, the ophthalmic gel composition comprises a muscarinicantagonist and one or more gelling agents. In some instances, thegelling agent includes, but is not limited to, poloxamer (e.g. Poloxamer407), tetronics, ethyl (hydroxyethyl) cellulose, cellulose acetatephthalate (CAP), carbopol (e.g. Carbopol 1342P NF, Carbopol 980 NF),alginates (e.g. low acetyl gellan gum (Gelrite®)), gellan, hyaluronicacid, pluronics (e.g. Pluronic F-127), chitosan, polyvinyl alcohol(PVA), polyvinylpyrrolidone (PVP), dextran, hydroxy propyl methylcellulose (HPMC), hydroxyethylcellulose (HEC), methylcellulose (MC),thiolated xyloglucan, polymethacrylic acid (PMMA), polyethylene glycol(PEG), pseudolatexes, xyloglucans, or combinations thereof.

In some instances, the in situ gel formation further comprises apermeation enhancer. In some instances, the permeation enhancer includessurfactants (e.g. non-ionic surfactants), benzalkonium chloride, EDTA,surface-active heteroglycosides, calcium chelators, hydroxyl propyl betacyclodextrin (HP beta CD), bile salts, and the like.

In some embodiments, other gel formulations are useful depending uponthe particular ophthalmic agent, other pharmaceutical agent orexcipients/additives used, and as such are considered to fall within thescope of the present disclosure. For example, othercommercially-available glycerin-based gels, glycerin-derived compounds,conjugated, or crosslinked gels, matrices, hydrogels, and polymers, aswell as gelatins and their derivatives, alginates, and alginate-basedgels, and even various native and synthetic hydrogel andhydrogel-derived compounds are all expected to be useful in theophthalmic agent formulations described herein. In some embodiments,ophthalmically acceptable gels include, but are not limited to, alginatehydrogels SAF®-Gel (ConvaTec, Princeton, N.J.), Duoderm® Hydroactive Gel(ConvaTec), Nu-gel® (Johnson & Johnson Medical, Arlington, Tex.).Carrasyn® (V) Acemannan Hydrogel (Carrington Laboratories, Inc., Irving,Tex.); glycerin gels Elta® Hydrogel (Swiss-American Products, Inc.,Dallas, Tex.) and K-Y® Sterile (Johnson & Johnson). In furtherembodiments, biodegradable biocompatible gels also represent compoundspresent in ophthalmically acceptable formulations disclosed anddescribed herein.

In some embodiments, the viscosity-enhancing agent is a cellulose-basedpolymer selected from cellulose gum, alkylcellulose, hydroxyl-alkylcellulose, hydroxyl-alkyl alkylcellulose, carboxy-alkyl cellulose, orcombinations thereof. In some embodiments, the viscosity-enhancing agentis hydroxyl-alkyl alkylcellulose. In some embodiment, theviscosity-enhancing agent is hydroxypropyl methylcellulose.

In certain embodiments, the enhanced viscosity formulation ischaracterized by a phase transition between room temperature and bodytemperature (including an individual with a serious fever, e.g., up toabout 42° C.). In some embodiments, the phase transition occurs at 1° C.below body temperature, at 2° C. below body temperature, at 3° C. belowbody temperature, at 4° C. below body temperature, at 6° C. below bodytemperature, at 8° C. below body temperature, or at 10° C. below bodytemperature. In some embodiments, the phase transition occurs at about15° C. below body temperature, at about 20° C. below body temperature orat about 25° C. below body temperature. In specific embodiments, thegelation temperature (Tgel) of a formulation described herein is about20° C., about 25° C., or about 30° C. In certain embodiments, thegelation temperature (Tgel) of a formulation described herein is about35° C., or about 40° C. Included within the definition of bodytemperature is the body temperature of a healthy individual, or anunhealthy individual, including an individual with a fever (up to ˜42°C.). In some embodiments, the pharmaceutical compositions describedherein are liquids at about room temperature and are administered at orabout room temperature.

Copolymers polyoxypropylene and polyoxyethylene (e.g.polyoxyethylene-polyoxypropylene triblock copolymers) form thermosettinggels when incorporated into aqueous solutions. These polymers have theability to change from the liquid state to the gel state at temperaturesclose to body temperature, therefore allowing useful formulations thatare applied to the targeted ocular site. The liquid state-to-gel statephase transition is dependent on the polymer concentration and theingredients in the solution.

In some embodiments, the amount of thermosetting polymer in anyformulation described herein is about 10%, about 15%, about 20%, about25%, about 30%, about 35% or about 40% of the total weight of theformulation. In some embodiments, the amount of thermosetting polymer ina w formulation described herein is about 10%, about 11%, about 12%,about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about19%, about 20%, about 21%, about 22%, about 23%, about 24% or about 25%of the total weight of the formulation. In some embodiments, the amountof thermosetting polymer (e.g., Poloxamer 407) in any formulationdescribed herein is about 7.5% of the total weight of the formulation.In some embodiments, the amount of thermosetting polymer (e.g.,Poloxamer 407) in any formulation described herein is about 10% of thetotal weight of the formulation. In some embodiments, the amount ofthermosetting polymer (e.g., Poloxamer 407) in any formulation describedherein is about 11% of the total weight of the formulation. In someembodiments, the amount of thermosetting polymer (e.g., Poloxamer 407)in any formulation described herein is about 12% of the total weight ofthe formulation. In some embodiments, the amount of thermosettingpolymer (e.g., Poloxamer 407) in any formulation described herein isabout 13% of the total weight of the formulation. In some embodiments,the amount of thermosetting polymer (e.g., Poloxamer 407) in anyformulation described herein is about 14% of the total weight of theformulation. In some embodiments, the amount of thermosetting polymer(e.g., Poloxamer 407) in any formulation described herein is about 15%of the total weight of the formulation. In some embodiments, the amountof thermosetting polymer (e.g., Poloxamer 407) in any formulationdescribed herein is about 16% of the total weight of the formulation. Insome embodiments, the amount of thermosetting polymer (e.g., Poloxamer407) in any formulation described herein is about 17% of the totalweight of the formulation. In some embodiments, the amount ofthermosetting polymer (e.g., Poloxamer 407) in any formulation describedherein is about 18% of the total weight of the formulation. In someembodiments, the amount of thermosetting polymer (e.g., Poloxamer 407)in any formulation described herein is about 19% of the total weight ofthe formulation. In some embodiments, the amount of thermosettingpolymer (e.g., Poloxamer 407) in any formulation described herein isabout 20% of the total weight of the formulation. In some embodiments,the amount of thermosetting polymer (e.g., Poloxamer 407) in anyformulation described herein is about 21% of the total weight of theformulation. In some embodiments, the amount of thermosetting polymer(e.g., Poloxamer 407) in any formulation described herein is about 23%of the total weight of the formulation. In some embodiments, the amountof thermosetting polymer (e.g., Poloxamer 407) in any formulationdescribed herein is about 25% of the total weight of the formulation. Insome embodiments, the amount of thickening agent (e.g., a gelling agent)in any formulation described herein is about 1%, about 5%, about 10%, orabout 15% of the total weight of the formulation. In some embodiments,the amount of thickening agent (e.g., a gelling agent) in anyformulation described herein is about 0.5%, about 1%, about 1.5%, about2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, or about 5%of the total weight of the formulation.

In an alternative embodiment, the thermogel is a PEG-PLGA-PEG triblockcopolymer (Jeong et al, Nature (1997), 388:860-2; Jeong et al, J.Control. Release (2000), 63:155-63; Jeong et al, Adv. Drug Delivery Rev.(2002), 54:37-51). The polymer exhibits sol-gel behavior over aconcentration of about 5% w/w to about 40% w/w. Depending on theproperties desired, the lactide/glycolide molar ratio in the PLGAcopolymer ranges from about 1:1 to about 20:1. The resulting copolymersare soluble in water and form a free-flowing liquid at room temperature,but form a hydrogel at body temperature. A commercially availablePEG-PLGA-PEG triblock copolymer is RESOMER RGP t50106 manufactured byBoehringer Ingelheim. This material is composed of a PLGA copolymer of50:50 poly(DL-lactide-co-glycolide) and is 10% w/w of PEG and has amolecular weight of about 6000.

Additional biodegradable thermoplastic polyesters include AtriGel®(provided by Atrix Laboratories, Inc.) and/or those disclosed, e.g., inU.S. Pat. Nos. 5,324,519; 4,938,763; 5,702,716; 5,744,153; and5,990,194; wherein the suitable biodegradable thermoplastic polyester isdisclosed as a thermoplastic polymer. Examples of suitable biodegradablethermoplastic polyesters include polylactides, polyglycolides,polycaprolactones, copolymers thereof, terpolymers thereof, and anycombinations thereof. In some such embodiments, the suitablebiodegradable thermoplastic polyester is a polylactide, a polyglycolide,a copolymer thereof, a terpolymer thereof, or a combination thereof. Inone embodiment, the biodegradable thermoplastic polyester is 50/50poly(DL-lactide-co-glycolide) having a carboxy terminal group; ispresent in about 30 wt. % to about 40 wt. % of the composition; and hasan average molecular weight of about 23,000 to about 45,000.Alternatively, in another embodiment, the biodegradable thermoplasticpolyester is 75/25 poly (DL-lactide-co-glycolide) without a carboxyterminal group; is present in about 40 wt. % to about 50 wt. % of thecomposition; and has an average molecular weight of about 15,000 toabout 24,000. In further or alternative embodiments, the terminal groupsof the poly(DL-lactide-co-glycolide) are either hydroxyl, carboxyl, orester depending upon the method of polymerization. Polycondensation oflactic or glycolic acid provides a polymer with terminal hydroxyl andcarboxyl groups. Ring-opening polymerization of the cyclic lactide orglycolide monomers with water, lactic acid, or glycolic acid providespolymers with the same terminal groups. However, ring-opening of thecyclic monomers with a monofunctional alcohol such as methanol, ethanol,or 1-dodecanol provides a polymer with one hydroxyl group and one esterterminal groups. Ring-opening polymerization of the cyclic monomers witha diol such as 1,6-hexanediol or polyethylene glycol provides a polymerwith only hydroxyl terminal groups.

Since the polymer systems of thermosetting gels dissolve more completelyat reduced temperatures, methods of solubilization include adding therequired amount of polymer to the amount of water to be used at reducedtemperatures. Generally after wetting the polymer by shaking, themixture is capped and placed in a cold chamber or in a thermostaticcontainer at about 0-10° C. in order to dissolve the polymer. Themixture is stirred or shaken to bring about a more rapid dissolution ofthe thermosetting gel polymer. The ophthalmic agent and variousadditives such as buffers, salts, and preservatives are subsequentlyadded and dissolved. In some instances the pharmaceutically agent issuspended if it is insoluble in water. The pD is modulated by theaddition of appropriate buffering agents.

Ophthalmic Ointment Muscarinic Antagonist Composition

An ointment is a homogeneous, viscous, semi-solid preparation, mostcommonly a greasy, thick oil (e.g. oil 80%-water 20%) with a highviscosity, intended for external application to the skin or mucousmembranes. Ointments have a water number that defines the maximum amountof water that it contains. They are used as emollients or for theapplication of active ingredients to the skin for protective,therapeutic, or prophylactic purposes and where a degree of occlusion isdesired. Ointments are used topically on a variety of body surfaces.These include the skin and the mucous membranes of the eye (an eyeointment), vulva, anus, and nose

The vehicle of an ointment is known as the ointment base. The choice ofa base depends upon the clinical indication for the ointment. Thedifferent types of ointment bases are: hydrocarbon bases, e.g. hardparaffin, soft paraffin, microcrystalline wax and ceresine; absorptionbases, e.g. wool fat, beeswax; water soluble bases, e.g. macrogels 200,300, 400; emulsifying bases, e.g. emulsifying wax, cetrimide; vegetableoils, e.g. olive oil, coconut oil, sesame oil, almond oil and peanutoil.

Ointments are formulated using hydrophobic, hydrophilic, orwater-emulsifying bases to provide preparations that are immiscible,miscible, or emulsifiable with skin secretions. In some embodiments,they are also derived from hydrocarbon (fatty), absorption,water-removable, or water-soluble bases. The active agents are dispersedin the base, and later they get divided after the drug penetration intothe target sites (e.g. membranes, skins, etc.).

The present disclosure recognizes that it is sometimes difficult toincorporate into the ointment a drug of low concentration withsufficient dose-to-dose uniformity for effectively treating a disorderor disease. In some embodiments, poly(ethylene-glycols), polyethoxylatedcastor oils (Cremophor® EL), alcohols having 12 to 20 carbon atoms or amixture of two or more of said components are effective excipients fordispersing and/or dissolving effective amounts of ophthalmic drugs, inparticular of ascormycins and staurosporine derivatives, in an ointmentbase, in particular in an ointment base substantially comprisingoleaginous and hydrocarbon components, and that the resulting ointmentsare excellently tolerated by the skin and by ocular tissue.

The present disclosure further recognizes that ophthalmic drugs, such asa muscarinic antagonist (e.g. atropine or its pharmaceuticallyacceptable salts), incorporated in the ointment compositions describesherein target the choroid and/or retina in a patient when thecompositions are topically administered to the ocular surface, inparticular to the sclera of said patient. In some embodiments, anophthalmic ointment composition includes an ophthalmic drug, an ointmentbase and an agent for dispersing and/or dissolving said drug in theointment base, selected from a poly(ethylene-glycol), a polyethoxylatedcastor oil, an alcohol having 12 to 20 carbon atoms and a mixture of twoor more of said components.

In some embodiments, the ointment bases include ophthalmicallyacceptable oil and fat bases, such as natural wax e.g. white and yellowbees wax, carnauba wax, wool wax (wool fat), purified lanolin, anhydrouslanolin; petroleum wax e.g. hard paraffin, microcrystalline wax;hydrocarbons e.g. liquid paraffin, white and yellow soft paraffin, whitepetrolatum, yellow petrolatum; or combinations thereof.

The above mentioned oil and fat bases are described in more detail, forinstance, in the British Pharmacopoeia, Edition 2001, or the EuropeanPharmacopoeia, 3rd Edition.

In some embodiments, the ointment base is present in amounts of about 50to about 95, preferably of 70 to 90% by weight based on the total weightof the composition.

A preferred ointment base comprises a combination of one or more of oneor more natural waxes like those indicated above, preferably wool wax(wool fat), and one or more hydrocarbons like those indicated above,preferably a soft paraffin or a petrolatum, more preferably incombination with liquid paraffin.

A special embodiment of the aforementioned ointment base comprises e.g.5 to 1⁷ parts by weight of wool fat, and 50 to 65 parts by weight ofwhite petrolatum as well as 20 to 30 parts by weight of liquid paraffin.

In some embodiments, the agent for dispersing and/or dissolving theophthalmic drug in the ointment base is selected from apoly(ethylene-glycol), a polyethoxylated castor oil, an alcohol having12 to 20 carbon atoms and a mixture of two or more of said components.The agent is preferably used in amounts of 1 to 20 percent, morepreferably 1 to 10 percent by weight of the entire semisolid ophthalmiccomposition.

Alcohols having 12 to 20 carbon atoms include particularly stearylalcohol (C18H37OH), cetyl alcohol (C16H33OH) and mixtures thereof.Preferred are so-called cetostearyl alcohols, mixtures of solid alcoholssubstantially consisting of stearyl and cetyl alcohol and preferablycomprising not less than 40 percent by weight of stearyl alcohol and asum of stearyl alcohol and cetyl alcohol amounting to at least 90percent by weight, and compositions comprising not less than 80 percentby weight of cetylstearyl alcohol and an emulsifier, in particularsodium cetostearyl sulfate and/or sodium lauryl sulfate, preferably inamounts not less than 7 percent by weight of emulsifier.

Polyethoxylated castor oils are reaction products of natural orhydrogenated castor oils and ethylene glycol. In some instances, suchproducts are obtained in known manner, e.g. by reaction of a natural orhydrogenated castor oil or fractions thereof with ethylene oxide, e.g.in a molar ratio of from about 1:30 to about 1:60, with optional removalof free polyethylene glycol components from the product, e.g. inaccordance with the methods disclosed in German Auslegeschriften1,182,388 and 1,518,819. Especially suitable and preferred is a productcommercially available under the trade name Cremophor® EL having amolecular weight (by steam osmometry)=ca. 1630, a saponification no.=ca.65-70, an acid no.=ca. 2, an iodine no.=ca. 28-32 and an nD 25=ca.1.471. Also suitable for use in this category is, for instance, Nikkol®HCO-60, a reaction product of hydrogenated castor oil and ethylene oxideexhibiting the following characteristics: acid no.=ca. 0.3;saponification no.=ca. 47.4; hydroxy value=ca. 42.5. pH (5%)=ca. 4.6;Color APHA=ca. 40; m.p.=ca. 36.0° C., Freezing point=ca. 32.4° C.; H₂Ocontent (%, KF)=ca. 0.03.

Poly(ethylene-glycols) are used in some embodiments as the agent fordispersing and/or dissolving the ophthalmic drug in the ointment baseaccording to the present disclosure. Suitable poly(ethylene-glycol)s aretypically mixtures of polymeric compounds of the general formulaH—(OCH2-CH2)nOH, wherein the index n typically range from 4 to 230 andthe mean molecular weight from about 200 to about 10000. Preferably n isa number from about 6 to about 22 and the mean molecular weight betweenabout 300 and about 1000, more preferably n ranges from about 6 to about13 and the mean molecular weight from about 300 to about 600, mostpreferably n has a value of about 8.5 to about 9 and the relativemolecular weight is about 400. Suitable poly(ethylene-glycols) arereadily available commercially, for example poly(ethylene-glycols)having a mean molecular weight of about 200, 300, 400, 600, 100), 1500,2000, 3000, 4000, 6000, 8000 and 10000.

The poly(ethylene-glycols), in particular the preferred types describedin the foregoing paragraph, are preferably used in amounts of 1 to 10,more preferably 1 to 5 percent by weight of the entire semisolidophthalmic composition.

An especially preferred embodiment of the compositions according to theinstant disclosure comprises an agent for dispersing and/or dissolvingof the drug in the ointment base which is selected from apoly(ethylene-glycol), a polyethoxylated castor oil and preferably amixture of said components.

Gel/Ointment Viscosity

In some embodiments, the composition has a Brookfield RVDV viscosity offrom about 10,000 to about 300,000 cps at about 20° C. and sheer rate of1 s⁻¹. In some embodiments, the composition has a Brookfield RVDVviscosity of from about 15,000 to about 200,000 cps at about 20° C. andsheer rate of 1 s⁻¹. In some embodiments, the composition has aBrookfield RVDV viscosity of from about 50,000 to about 150,000 cps atabout 20° C. and sheer rate of 1 s⁻¹. In some embodiments, thecomposition has a Brookfield RVDV viscosity of from about 70,000 toabout 130,000 cps at about 20° C. and sheer rate of 1 s⁻¹. In someembodiments, the composition has a Brookfield RVDV viscosity of fromabout 90,000 to about 110,000 cps at about 20° C. and sheer rate of 1s⁻¹.

In some embodiments, the ophthalmic gel formulation contains a viscosityenhancing agent sufficient to provide a viscosity of between about 500and 1,000,000 centipoise, between about 750 and 1,000,000 centipoise;between about 1000 and 1,000,000 centipoise; between about 1000 and400,000 centipoise; between about 2000 and 100.000 centipoise; betweenabout 3000 and 50,000 centipoise; between about 4000 and 25,000centipoise; between about 5000 and 20,000 centipoise; or between about6000 and 15,000 centipoise. In some embodiments, the ophthalmic gelformulation contains a viscosity enhancing agent sufficient to provide aviscosity of between about 50,0000 and 1,000,000 centipoise.

In some embodiments, the compositions described herein are low viscositycompositions at body temperature. In some embodiments, low viscositycompositions contain from about 1% to about 10% of a viscosity enhancingagent (e.g., gelling components such as polyoxyethylene-polyoxypropylene copolymers). In some embodiments, lowviscosity compositions contain from about 2% to about 10% of a viscosityenhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, lowviscosity compositions contain from about 5% to about 10% of a viscosityenhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, lowviscosity compositions are substantially free of a viscosity enhancingagent (e.g., gelling components such as polyoxyethylene-polyoxypropylenecopolymers). In some embodiments, a low viscosity ophthalmic agentcomposition described herein provides an apparent viscosity of fromabout 100 cP to about 10,000 cP. In some embodiments, a low viscosityophthalmic agent composition described herein provides an apparentviscosity of from about 500 cP to about 10,000 cP. In some embodiments,a low viscosity ophthalmic agent composition described herein providesan apparent viscosity of from about 1000 cP to about 10,000 cP.

In some embodiments, the compositions described herein are viscouscompositions at body temperature. In some embodiments, viscouscompositions contain from about 10% to about 25% of a viscosityenhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, theviscous compositions contain from about 14% to about 22% of a viscosityenhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, theviscous compositions contain from about 15% to about 21% of a viscosityenhancing agent (e.g., gelling components such aspolyoxyethylene-polyoxypropylene copolymers). In some embodiments, aviscous ophthalmic composition described herein provides an apparentviscosity of from about 100,000 cP to about 1,000,000 cP. In someembodiments, a viscous ophthalmic composition described herein providesan apparent viscosity of from about 150,000 cP to about 500,000 cP. Insome embodiments, a viscous ophthalmic composition described hereinprovides an apparent viscosity of from about 250,000 cP to about 500,000cP. In some of such embodiments, a viscous ophthalmic composition is aliquid at room temperature and gels at about between room temperatureand body temperature (including an individual with a serious fever,e.g., up to about 42° C.). In some embodiments, a viscous ophthalmiccomposition is administered as monotherapy for treatment of anophthalmic disease or condition described herein.

In some embodiments, the viscosity of the gel formulations presentedherein is measured by any means described. For example, in someembodiments, an LVDV-II+CP Cone Plate Viscometer and a Cone SpindleCPE-40 is used to calculate the viscosity of the gel formulationdescribed herein. In other embodiments, a Brookfield (spindle and cup)viscometer is used to calculate the viscosity of the gel formulationdescribed herein. In some embodiments, the viscosity ranges referred toherein are measured at room temperature. In other embodiments, theviscosity ranges referred to herein are measured at body temperature(e.g., at the average body temperature of a healthy human).

Gel/Ointment Dose-To-Dose Uniformity

Typical ophthalmic gels are packaged in eye drop bottles andadministered as drops. For example, a single administration (i.e. asingle dose) of an ophthalmic gel includes a single drop, two drops,three drops or more into the eyes of the patient. Furthermore, typicalophthalmic ointments are packaged in tubes or other squeezablecontainers with a dispensing nozzle through which strips of the ointmentare delivered. For example, a single administration (i.e. a single dose)of an ophthalmic ointment includes a single strip, or multiple stripsinto the eyes of the patient. In some embodiments, one dose of theophthalmic gel described herein is one drop of the gel composition fromthe eye drop bottle. In some embodiments, one dose of the ophthalmicointment is one strip of the ointment composition dispensed through thenozzle of a dispersing tube.

In some cases, described herein include ophthalmic gel compositionswhich provide a dose-to-dose uniform concentrations. In some instances,the dose-to-dose uniform concentration does not present significantvariations of drug content from one dose to another. In some instances,the dose-to-dose uniform concentration does provide consistent drugcontent from one dose to another.

In some cases, described herein include ophthalmic ointment compositionswhich provide a dose-to-dose uniform concentrations. In some instances,the dose-to-dose uniform concentration does not present significantvariations of drug content from one dose to another. In some instances,the dose-to-dose uniform concentration does provide consistent drugcontent from one dose to another.

In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 50%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 40%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 30%.In some embodiments, the composition has a dose-to-dose ophthalmic agentconcentration variation of less than 20%. In some embodiments, thecomposition has a dose-to-dose ophthalmic agent concentration variationof less than 10%. In some embodiments, the composition has adose-to-dose ophthalmic agent concentration variation of less than 5%.

In some embodiments, the dose-to-dose ophthalmic agent concentrationvariation is based on 10 consecutive doses. In some embodiments, thedose-to-dose ophthalmic agent concentration variation is based on 8consecutive doses. In some embodiments, the dose-to-dose ophthalmicagent concentration variation is based on 5 consecutive doses. In someembodiments, the dose-to-dose ophthalmic agent concentration variationis based on 3 consecutive doses. In some embodiments, the dose-to-doseophthalmic agent concentration variation is based on 2 consecutivedoses.

A nonsettling formulation should not require shaking to disperse druguniformly. A “no-shake” formulation is potentially advantageous overformulations that require shaking for the simple reason that patients'shaking behavior is a major source of variability in the amount of drugdosed. It has been reported that patients often times do not or forgetto shake their ophthalmic compositions that requires shaking beforeadministering a dose, despite the instructions to shake that wereclearly marked on the label. On the other hand, even for those patientswho do shake the product, it is normally not possible to determinewhether the shaking is adequate in intensity and/or duration to renderthe product uniform. In some embodiments, the ophthalmic gelcompositions and ophthalmic ointment compositions described herein are“no-shake” formulations that maintained the dose-to-dose uniformitydescribed herein.

To evaluate the dose-to-dose uniformity, drop bottles or tubescontaining the ophthalmic aqueous compositions, the ophthalmic gelcompositions, or ophthalmic ointment compositions are stored upright fora minimum of 12 hours prior to the start of the test. To simulate therecommended dosing of these products, predetermined number of drops orstrips are dispensed from each commercial bottles or tubes atpredetermined time intervals for an extended period of time or until noproduct was left in the bottle or tube. All drops and strips aredispensed into tared glass vials, capped, and stored at room temperatureuntil analysis. Concentrations of a muscarinic antagonist such asatropine in the expressed drops were determined using a reverse-phaseHPLC method.

Methods of Treatment

Disclosed herein are methods of arresting myopia development byadministering to an eye of an individual in need thereof an effectiveamount of an ophthalmic composition as described above. Also disclosedherein are methods of preventing myopia development by administering toan eye of an individual in need thereof an effective amount of anophthalmic composition as described above.

In some embodiments, the ophthalmic aqueous formulations describedherein are packaged in eye drop bottles and administered as drops. Forexample, a single administration (i.e. a single dose) of an ophthalmicaqueous formulation includes a single drop, two drops, three drops ormore into the eyes of the patient. In some embodiments, the ophthalmicgel formulations described herein are packaged in eye drop bottles andadministered as drops. For example, a single administration (i.e. asingle dose) of an ophthalmic gel includes a single drop, two drops,three drops or more into the eyes of the patient. In some embodiments,the ophthalmic ointment formulations described herein are packaged intubes or other squeezable containers with a dispensing nozzle throughwhich strips of the ointment are delivered. For example, a singleadministration (i.e. a single dose) of an ophthalmic ointment includes asingle strip, or multiple strips into the eyes of the patient. In someembodiments, one dose of the ophthalmic aqueous formulation describedherein is one drop of the aqueous composition from the eye drop bottle.In some embodiments, one dose of the ophthalmic gel described herein isone drop of the gel composition from the eye drop bottle. In someembodiments, one dose of the ophthalmic ointment is one strip of theointment composition dispensed through the nozzle of a dispersing tube.

In some embodiments of the disclosed method, the ophthalmic compositionis stored below room temperature prior to first use. In some embodimentsof the disclosed method, the ophthalmic composition is stored at betweenabout 2° C. to about 10° C. prior to first use. In some embodiments ofthe disclosed method, the ophthalmic composition is stored at about 20°C., about 3° C., about 4° C., about 5° C., about 6° C., about 7° C.,about 8° C. about 9° C., or about 10° C. prior to first use. In someembodiments of the disclosed method, the ophthalmic composition isstored at between about 4° C. to about 8° C. prior to first use.

In some embodiments of the disclosed method, the ophthalmic compositionis stored at room temperature after first use. In some embodiments ofthe disclosed method, the ophthalmic composition is stored at betweenabout 16° C. to about 26° C. after to first use. In some embodiments ofthe disclosed method, the ophthalmic composition is stored at about 16°C., about 17° C., about 18° C., about 19° C., about 20° C., about 21°C., about 22° C., about 23° C., about 24° C., about 25° C., or about 26°C. after to first use.

In some embodiments, the ophthalmic aqueous formulations areadministered as follows: the lower lid of the eye to be administered waspulled down and a predetermined amount of the aqueous formulation (e.g.1-3 drops) is applied to the inside of the eyelid. The ophthalmic tip ofthe dispensing mechanism does not touch any surface to avoidcontamination and/or injury.

In some embodiments, the ophthalmic gel formulations are administered asfollows: the lower lid of the eye to be administered was pulled down anda predetermined amount of gel (e.g. 1-3 drops) is applied to the insideof the eyelid. The ophthalmic tip of the dispensing mechanism does nottouch any surface to avoid contamination and/or injury.

In some embodiments, the ophthalmic ointment formulations areadministered as follows: the lower lid of the eye to be administered waspulled down and a small amount of ointment (approximately 0.25 inches)was applied to the inside of the eyelid. The ophthalmic tip of thedispensing mechanism does not touch any surface to avoid contaminationand/or injury.

In some embodiments, the ophthalmic composition is administered atpredetermined time intervals over an extended period of time. In someembodiments, the ophthalmic composition is administered once every day.In some embodiments, the ophthalmic composition is administered everyother day. In some embodiments, the ophthalmic composition isadministered over 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 moths,1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9years, 10 years, 11 years, or 12-15 years.

In some embodiments, the ophthalmic composition is administered in doseshaving a dose-to-dose ophthalmic agent concentration variation of lessthan 50%, less than 40%, less than 30%, less than 20%, less than 10%, orless than 5%.

The number of times a composition is administered to an individual inneed thereof depends on the discretion of a medical professional, thedisorder, the severity of the disorder, and the individual's response tothe formulation. In some embodiments, a composition disclosed herein isadministered once to an individual in need thereof with a mild acutecondition. In some embodiments, a composition disclosed herein isadministered more than once to an individual in need thereof with amoderate or severe acute condition. In the case wherein the patient'scondition does not improve, upon the doctor's discretion theadministration of an ophthalmic agent is administered chronically, thatis, for an extended period of time, including throughout the duration ofthe patient's life in order to ameliorate or otherwise control or limitthe symptoms of the patient's disease or condition.

In the case wherein the patient's condition does not improve, upon thedoctor's discretion the administration of the ophthalmic agent isadministered chronically, that is, for an extended period of time,including throughout the duration of the patient's life in order toameliorate or otherwise control or limit the symptoms of the patient'sdisease or condition.

In the case wherein the patient's status does improve, upon the doctor'sdiscretion the administration of the ophthalmic agent is givencontinuously; alternatively, the dose of drug being administered istemporarily reduced or temporarily suspended for a certain length oftime (i.e., a “drug holiday”). The length of the drug holiday variesbetween 2 days and 1 year, including by way of example only, 2 days, 3days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days,180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days,and 365 days. The dose reduction during a drug holiday is from 10%-100%,including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40% 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

Once improvement of the patient's ophthalmic conditions has occurred, amaintenance ophthalmic agent dose is administered if necessary.Subsequently, the dosage or the frequency of administration, or both, isoptionally reduced, as a function of the symptoms, to a level at whichthe improved disease, disorder or condition is retained. In certainembodiments, patients require intermittent treatment on a long-termbasis upon any recurrence of symptoms.

The amount of ophthalmic agent that will correspond to such an amountwill vary depending upon factors such as the particular compound,disease condition and its severity, according to the particularcircumstances surrounding the case, including, e.g., the specificophthalmic agent being administered, the route of administration, thecondition being treated, the target area being treated, and the subjector host being treated. The desired dose is presented in a single dose oras divided doses administered simultaneously (or over a short period oftime) or at appropriate intervals.

In some embodiments, the initial administration is a particularophthalmic agent and the subsequent administration a differentformulation or ophthalmic agent.

Kits/Articles of Manufacture

The disclosure also provides kits for preventing or arresting myopiadevelopment. Such kits generally will comprise one or more of theophthalmic compositions disclosed herein, and instructions for using thekit. The disclosure also contemplates the use of one or more of theophthalmic compositions, in the manufacture of medicaments for treating,abating, reducing, or ameliorating the symptoms of a disease,dysfunction, or disorder in a mammal, such as a human that has, issuspected of having, or at risk for developing myopia.

In some embodiments, kits include a carrier, package, or container thatis compartmentalized to receive one or more containers such as vials,tubes, and the like, each of the container(s) including one of theseparate elements to be used in a method described herein. Suitablecontainers include, for example, bottles, vials, syringes, and testtubes. In other embodiments, the containers are formed from a variety ofmaterials such as glass or plastic.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical products arealso presented herein. See, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558and 5,033,252. Examples of pharmaceutical packaging materials include,but are not limited to, drop bottles, tubes, pumps, bags, vials,containers, syringes, bottles, and any packaging material suitable for aselected formulation and intended mode of administration and treatment.A wide array of ophthalmic compositions provided herein are contemplatedas are a variety of treatments for any disease, disorder, or conditionthat benefits by controlled release administration of an ophthalmicagent to the eye.

In some embodiments, a kit includes one or more additional containers,each with one or more of various materials (such as rinses, wipes,and/or devices) desirable from a commercial and user standpoint for useof a formulation described herein. Such materials also include labelslisting contents and/or instructions for use and package inserts withinstructions for use. A set of instructions is optionally included. In afurther embodiment, a label is on or associated with the container. Inyet a further embodiment, a label is on a container when letters,numbers or other characters forming the label are attached, molded oretched into the container itself; a label is associated with a containerwhen it is present within a receptacle or carrier that also holds thecontainer, e.g., as a package insert. In other embodiments a label isused to indicate that the contents are to be used for a specifictherapeutic application. In yet another embodiment, a label alsoindicates directions for use of the contents, such as in the methodsdescribed herein.

In certain embodiments, the ophthalmic compositions are presented in adispenser device which contains one or more unit dosage forms containinga compound provided herein. In a further embodiment, the dispenserdevice is accompanied by instructions for administration. In yet afurther embodiment, the dispenser is also accompanied with a noticeassociated with the container in form prescribed by a governmentalagency regulating the manufacture, use, or sale of pharmaceuticals,which notice is reflective of approval by the agency of the form of thedrug for human or veterinary administration. In another embodiment, suchnotice, for example, is the labeling approved by the U.S. Food and DrugAdministration for prescription drugs, or the approved product insert.In yet another embodiment, compositions containing a compound providedherein formulated in a compatible pharmaceutical carrier are alsoprepared, placed in an appropriate container, and labeled for treatmentof an indicated condition.

EXAMPLES Example 1—Ophthalmic Formulations

Exemplary compositions for preparation of ophthalmic formulations aredescribed in Tables 1-8.

TABLE 1 Aqueous Solution Formulation (Atropine) Quantity ConcentrationIngredient (mg/g) (wt %) Atropine 0.01-0.5 0.001-0.05 (wt %) Bufferagent and/or pD — q.s. for pD = 4.2-7.9 adjusting agent (e.g., boratesand/or DCl) Preservative (e.g. — q.s. to prevent the growth benzalkoniumchloride, of or to destroy microorganism cetrimonium sodium introducedinto the solution perborate, etc.) Tonicity and/or — q.s. to 0.5-2.0 wt% Osmolarity adjustor (e.g. NaCl, mannitol, etc) Deuterated Water — q.s.to 100 wt %

TABLE 2 Aqueous Solution Formulation (Atropine Sulfate) QuantityIngredient (mg/g) Concentration (wt %) Atropine sulfate 0.01-0.50.001-0.05 (wt %) Buffer agent and/or — q.s. for pD = 4.2-7.9 pDadjusting agent (e.g., borates and/or DCl) Preservative — q.s. toprevent the growth of (e.g, benzalkonium or to destroy microorganismchloride, cetrimonium introduced into the solution sodium perborate,etc.) Tonicity and/or — q.s. to 0.5-2.0 wt % Osmolarity adjustor (e.g.NaCl, mannitol, etc) Deuterated Water — q.s. to 100 wt %

TABLE 3 Aqueous Solution Formulation ( Atropine Sulfate) QuantityIngredient (mg/g) Concentration (wt %) Atropine sulfate 0.05-0.150.005-0. 015 (wt %) Buffer agent and/or — q.s. for pD = 4.2-7.9 pDadjusting agent (e.g., borates and/or DCl) Preservative — q.s. toprevent the growth of (e.g. benzalkonium or to destroy microorganismchloride, cetrimonium introduced into the solution sodium perborate,etc.) Tonicity and/or — q.s. to 0.5-2.0 wt % Osmolarity adjustor (e.g.NaCl, mannitol, etc) Deuterated Water — q.s. to 100 wt %

TABLE 4 Mucus Penetrating Particle Formulation (Atropine) QuantityIngredient (mg/g) Concentration (wt %) Atropine 0.01-0.5 0.001-0.05 (wt%) Buffer agent and/or — q.s. for pD = 4.2-7.9 pD adjusting agent (e.g.,borates and/or DCl) Preservative — q.s. to prevent the growth of (e.g,benzalkonium or to destroy microorganism chloride, cetrimoniumintroduced into the solution sodium perborate, etc.) Mucus penetrating —q.s. to formulate atropine at particles 0.001-0.05 wt % Deuterated Water— q.s. to 100 wt %

TABLE 5 Mucus Penetrating Particle Formulation (Atropine Sulfate)Quantity Ingredient (mg/g) Concentration (wt %) Atropine sulfate0.01-0.5 0.001-0.05 (wt %) Buffer agent and/or — q.s. for pD = 4.2-7.9pD adjusting agent (e.g., borates and/or DCl) Preservative — q.s. toprevent the growth of or (e.g. benzalkonium to destroy microorganismchloride, cetrimonium introduced into the solution sodium perborate,etc.) Mucus penetrating — q.s. to formulate atropine at particles0.001-0.05 wt % Deuterated Water — q.s. to 100 wt %

TABLE 6 Cellulose Gel Formulation (Atropine Sulfate) Quantity Ingredient(mg/g) Concentration (wt %) Atropine Sulfate 0.01-0.5 0.001-0.05 (wt %)Viscosity enhancing   10-50    1-5 (wt %) agent (e.g. hydroxy- propylmethylcellulose) Buffer agent and/or — q.s. for pD = 4.2-7.9 pDadjusting agent (e.g., sodium acetate and/or DCl) Stabilizer (e.g. EDTA,— q.s. for low degradation of cyclodextrin, etc.) atropine sulfate (e.g.less than 10%, 5% or 1% degradation) Osmolarity modifier — q.s. 150-500mOsm/L (e.g. NaCl) Deuterated Water — q.s. to 100 wt %

TABLE 7 Thermosetting Gel Formulation (Atropine Sulfate) QuantityIngredient (mg/g) Concentration (wt %) Atropine sulfate 0.01-0.50.001-0.05 (wt %) Viscosity enhancing  100-250   10-25 (wt %) agent(e.g. poloxamer 407) Buffer agent and/or — q.s. for pH = 4.2-7.9 pDadjusting agent (e.g., sodium acetate and/or DCl) Stabilizer (e.g. EDTA,— q.s. for low degradation of cycled extrin, etc.) atropine sulfate(e.g. less than 10%, 5% or 1% degradation) Osmolarity modifier — q.s.150-500 mOsm/L (e.g. NaCl) Deuterated Water — q.s. to 100 wt %

TABLE 8 Ointment Formulation (Atropine Sulfate) Quantity (g)Concentration in for 1000 mL 1000 mL aqueous Ingredient solutionsolution Atropine sulfate 0.01-0.5 0.001-0.05 (wt %) Dispersing agent  10-200    1-20 (wt %) (e.g. polyethylene- glycol, and/or poly-ethoxylated castor oil and/or C12-C20 alcohol Buffering agent pD q.s.for pD = 4.2-7.9 adjusting agent (e.g. DCl) Stabilizer q.s. for lowdegradation of (e.g. EDTA, atropine sulfate (e.g. less thancyclodextrin, etc.) 10%, 5% or 1% degradation) Osmolarity modifier q.s.150-500 mOsm/L (e.g. NaCl) Ointment base q.s. to 100 wt % (e.g. wool waxand/or petrolatum and/or liquid paraffin)

Example 2—Preparation of an Aqueous Solution Formulation Containing0.01% Atropine in D₂O

Stock 1% Solution

In a 100 mL solution, 1 gram of atropine, and 0.77 g of NaCl (and otheringredients/components preferably in their dry state) are added alongwith a quantity sufficient to equal 100 mL sterile deuterated water forinjection. The solution is mixed in an appropriately sized beaker with astir bar on a hot plate until all of the solid powders have dissolvedand the solution has become clear with no visible particles. Next, thestir bar is removed, and the solution is poured into a filter bottle andvacuum filtered through a 0.22 micron polyethersulfone membrane filterinto a sterile bottle. The filter top is removed from the sterile stockbottle and the stock bottle is capped for storage with a sterile bottlecap.

Diluted 0.01% Solution

0.3 mL of the 1% solution was combined with a quantity sufficient toachieve 30 mL total of sterile 0.9% Sodium Chloride For Injection USP.The solution was thoroughly mixed. The pH of the solution was recorded.A 0.22 micron filter was placed on the tip of the syringe and thesolution was aliquoted into separate sterile containers.

Example 3—Preparation of an Aqueous Solution Formulation Containing0.01% Atropine Sulfate

Stock 1% Solution

In a 100 mL solution, 1 gram of atropine sulfate, and 0.77 g of NaCl(and other ingredients/components preferably in their dry state) wereadded along with a quantity sufficient to equal 100 mL sterile water forinjection. The solution was mixed in an appropriately sized beaker witha stir bar on a hot plate until all of the solid powders had dissolvedand the solution became clear with no visible particles. Next, the stirbar was removed, and the solution was poured into a filter bottle andvacuum filtered through a 0.22 micron polyethersulfone membrane filterinto a sterile bottle. The filter top was removed from the sterile stockbottle and the stock bottle was capped for storage with a sterile bottlecap.

Diluted 0.01% Solution

0.3 mL of the 1% solution was combined with a quantity sufficient toachieve 30 mL total of sterile 0.9% Sodium Chloride For Injection USP.The solution was thoroughly mixed. The pH of the solution was recorded.A 0.22 micron filter was placed on the tip of the syringe and thesolution was aliquoted into separate sterile containers.

Example 4—Stability Analysis

Five 0.01% atropine sulfate solutions were prepared from the 1% atropinesulfate stock solution (preparation as described in Example 2). The pHof the five solutions was 5.87, 5.97, 5.90, 6.24, and 6.16 for solutions1-5, respectively. Each solution was thoroughly mixed. A 0.22 micronfilter was placed on the tip of the syringe and the solution wasaliquoted into separate sterile containers according to Table 9.

TABLE 9 Container Filling Outline Volume of 0.01% Total Atropine SulfateDrug Containers Type of Container Product in Container Filled SterileEyedroppers 5-mL 12 Sterile Glass Vials 5-mL 12

The samples were then stored at different conditions for stabilityanalysis. The samples were analyzed at different time points up to 2months. The storage conditions include: 40° C. with 75% relativehumidity (RH) (samples were transferred from 2-8° C. condition after 3days), 25° C. with 60% RH, and 60° C. The time points were 1 week, 2weeks, 1 month, and 2 months. At each of the time point, one plasticeyedropper (LDPE plastic) and one glass vial from each of the storedcondition were removed and allowed to equilibrate to ambient conditions.Once equilibrated, both the plastic eyedropper and the glass vials wereinverted 3 times. The solution in the eyedroppers was transferred to anHPLC vial in a drop wise fashion through the dropper. The solution inthe glass vial was aliquoted into an HPLC vial using a glass Pasteurpipette. The samples were then tested for purity and potency using theUPLC method listed in Table 10.

TABLE 10 UPLC Method Parameters Parameter Condition Column EMD, Hiber HRPurospherSTAR C-18, 100 × 2.1 mm, 2 μm Mobile Phase/Diluent 87:13, 50 mMPotassium Phosphate:Acetonitrile, pH 3.5 Flow Isocratic Flow Rate  0.5mL/min Detection Wavelength  210 nm Column Temperature  30 ± 3° C.Autosampler Temperature  5 ± 3° C. Run Time  6.0 minutes InjectionVolume   10 μL* Needle Wash Solution 90/10 Water:Acetonitrile *Modifiedfrom original method to maintain sensitivity at 100 ug/mL nominal.

Table 11 lists the stability data for the 0.01% atropine sulfatesolutions.

TABLE 11 Stability Data for 0.01% Atropine Sulfate Solutions ContainerStorage t = 0 t = 1 week t = 2 week¹ t = 1 month² t = 2 month³ Analys 

  Type Condition Purit 

  Potency pH Purity Potency Purity Potency Purity Potency pH PurityPotency pH 1 Eyedropper, 25° C./ 99.5 99.8 5.9 ND ND 99.1 99.9 ND ND ND95.4 97.4 6.3 LDPE 60% RH (Plastic) 40° C./ ND ND 96.2 97.3 95.1 95.65.2 ND ND ND 75% RH 60° C. 80.8 83.3 86.2 88.6 88.3 91.5 4.2 ND ND NDGlass Vial 25° C./ 99.8 100.4 ND ND ND 92.2 93.1 80.7 80.5 7.8 73.0 74.57.3 60% RH 40° C./ ND ND 73.6 74.1 50.1 50.2 7.4 ND ND ND 75% RH 60° C.43.1 43.9 28.3 28.4 ND ND ND ND ND ND 2 Eyedropper, 25° C./ 99.7 99.96.0 ND ND 99.1 99.6 ND ND ND 97.0 99.1 6.1 LDPE 60% RH (Plastic) 40° C./ND ND 96.6 97.2 95.5 95.8 5.6 ND ND ND 75% RH 60° C. 89.4 92.2 92.2 94.090.6 94.4 4.1 ND ND ND Glass Vial 25° C./ 99.8 100.2 ND ND ND 92.6 92.982.5 82.2 7.6 80.2 81.6 7.3 60% RH 40° C./ ND ND 74.7 75.1 59.1 59.0 7.2ND ND ND 75% RH 60° C. 54.2 55.2 37.3 37.4 ND ND ND ND ND ND 3Eyedropper, 25° C./ 99.3 96.3 5.9 ND ND 98.7 96.1 ND ND ND 95.8 94.8 6.3LDPE 60% RH (Plastic) 40° C./ ND ND 96.7 93.1 94.8 91.8 5.5 ND ND ND 75%RH 60° C. 88.8 89.0 88.0 86.8 88.6 87.7 4.1 ND ND ND Glass Vial 25° C./99.4 98.4 ND ND ND 94.1 91.2 85.0 81.9 7.5 79.3 78.3 7.3 60% RH 40° C./ND ND 72.2 74.6 61.3 63.0 7.2 ND ND ND 75% RH 60° C. 48.6 51.1 34.1 34.9ND ND ND ND ND ND 4 Eyedropper, 25° C./ 99.8 99.6 6.2 ND ND 99.1 98.8 NDND ND 96.4 97.6 6.3 LDPE 60% RH (Plastic) 40° C./ ND ND 96.3 97.0 94.594.2 5.6 ND ND ND 75% RH 60° C. 90.5 93.0 89.3 90.6 84.2 85.8 4.2 ND NDND Glass Vial 25° C./ 99.8 98.8 ND ND ND 90.7 90.0 76.9 75.1 7.6 72.571.6 7.4 60% RH 40° C./ ND ND 71.0 68.7 57.0 56.7 7.2 ND ND ND 75% RH60° C. 52.4 52.1 29.7 28.6 ND ND ND ND ND ND 5 Eyedropper, 25° C./ 99.6100.5 6.2 ND ND 99.3 100.4 ND ND ND 97.8 100.5 6.2 LDPE 60% RH (Plastic)40°C./ ND ND 95.9 96.7 96.8 97.6 5.5 ND ND ND 75% RH 60° C. 91.2 94.691.4 93.6 90.3 92.8 4.2 ND ND ND Glass Vial 25° C./ 99.8 100.7 ND ND ND90.5 91.3 79.3 79.7 7.8 72.8 74.6 7.3 60% RH 40° C./ ND ND 71.3 71.956.0 56.4 7.3 ND ND ND 75% RH 60° C. 46.3 47.4 29.5 29.6 ND ND ND ND NDND ¹The 25° C. and the 60° C. samples were pulled at 15 days, the 40° C.samples were pulled at 11 days. ²The 25° C. and the 60° C. samples werepulled at 28 days, the 40° C. samples were pulled at 24 days. ³The 25°C. and the 60° C. sauples were pulled at 46 days.

indicates data missing or illegible when filed

A change in the pH of the 0.01% Atropine Sulfate solutions was observedover the course of the stability study. The plastic (LDPE) eyedroppersmaintained pH around 6.2 when stored at 25° C. for 2 months. However atthe same time point, the pH of the 0.01% atropine has increased to 7.2when stored in glass vials. Additionally, when stored at elevatedtemperatures (e.g. 40° C. and 60° C.), the pH in the plastic (LDPE)eyedroppers dropped to approximately 4-5, while the pH maintained around7.2 when stored in the glass vials.

There was also a significant difference in the rate of degradation forAtropine Sulfate (0.01%) when stored in plastic (LDPE) eyedroppersversus Type I glass vials. However, in both containers there was anincrease of an early eluting related substance at relative retentiontime (RRT)=0.87-0.89. In some cases, this early eluting relatedsubstance is referred to as primary degradant. In some instances, theprimary degradant is referred to as RRT 0.87-0.89. This relatedsubstance is likely to be the first parameter to fail specificationregardless of the container. The amount of this related substance wastracked at each time point and is listed in Table 12.

TABLE 12 Area (%) of the Main Degradation Species for 0.01% AtropineSulfate (RRT 0.87-0.89) Temperature t = t = t = t = Analyst ° C. t = 0 1week 2 week 1 month 2 months 1 25 0.08 NA 0.92 NA 3.98 40 NA NA 3.744.78 NA 60 NA 17.78 13.49 11.51 NA 2 25 0.07 NA 0.88 NA 2.46 40 NA NA3.26 4.37 NA 60 NA 9.38 7.67 9.13 NA 3 25 0.07 NA 1.05 NA 2.88 40 NA NA2.98 4.85 NA 60 NA 9.59 11.57 10.55 NA 4 25 0.08 NA 0.92 NA 3.09 40 NANA 3.43 5.32 NA 60 NA 8.30 10.46 15.49 NA 5 25 0.08 NA 0.64 NA 1.66 40NA NA 3.96 3.07 NA 60 NA 7.61 8.35 9.7 NA Average 25° C. 0.08 NA 0.88 NA2.81 Average 40° C. NA NA 3.47 4.48 NA Average 60° C. NA 10.53 10.3111.28 NA

Arrhenius based shelf life predictions were calculated using the relatedsubstance data from Table 12. These predictions are based on anassumption that the degradation is first order (linear). Thesepredictions are illustrated in FIGS. 1 and 2 . FIG. 1 shows the shelflife prediction of 0.01% atropine sulfate solution with a primarydegradant RRT 0.87-0.89, and a n.m.t. of 0.5% area, based on dataobtained from samples stored at 25° C. and 40° C. The pH range of theatropine sulfate solution is from 5.9-6.2. FIG. 2 shows the shelf lifeprediction of 0.01% atropine sulfate solution with a primary degradantRRT 0.87-0.89, and a n.m.t. of 0.5% area, based on data obtained fromsamples stored at 25° C. and 60° C. The pH range of the atropine sulfatesolution is from 5.9-6.2.

Example 5-1% Atropine Sulfate (Bausch+Lomb) Sample Analysis

The 1% atropine sulfate sample was obtained from Bausch+Lomb (Lot198421). For comparison the pH of the 1% Atropine Sulfate drug productwas determined in the neat solution as well as a sample that was dilutedto the current nominal concentration (0.01% Atropine Sulfate) using thevehicle. Additionally a sample was diluted to the nominal concentrationwith method diluent. Both samples diluted to the nominal concentrationwere analyzed using the RP-UPLC method (Table 10). The results arelisted in Table 13.

TABLE 13 pH and Purity of the Bausch + Lomb Atropine Sulfate SamplePurity Sample pH (% area) 1% Atropine Sulfate 4.89 ND 0.01% AtropineSulfate, 6.16 99.6% diluted with Vehicle 0.01% Atropine Sulfate, ND99.6% diluted with Diluent Vehicle 7.94 ND ND = not determined

Example 6—Dose Uniformity (10-Dose)

To evaluate the dose-to-dose uniformity, drop bottles containing theophthalmic aqueous composition are stored upright for a predeterminedperiod of time (e.g. 12 hours) prior to the start of the test. Tosimulate the recommended dosing of the product, 10 drops of the aqueouscomposition are dispensed from each bottle at predetermined timeintervals (e.g. consecutively, every 1 minute, every 10 minutes, everyhour or every 24 hours). All drops are dispensed into tared glass vials,capped, and stored at room temperature until analysis. Concentrations ofatropine in the expressed drops are determined using a reverse-phaseHPLC method.

Example 7—Dose Uniformity (5-Dose)

To evaluate the dose-to-dose uniformity, drop bottles containing theophthalmic aqueous composition are stored upright for a predeterminedperiod of time (e.g. 12 hours) prior to the start of the test. Tosimulate the recommended dosing of the product, 5 drops of the aqueouscomposition are dispensed from each bottle at predetermined timeintervals (e.g. consecutively, every 1 minute, every 10 minutes, everyhour or every 24 hours). All drops are dispensed into tared glass vials,capped, and stored at room temperature until analysis. Concentrations ofatropine in the expressed drops are determined using a reverse-phaseHPLC method.

Example 8—Dose Uniformity (2-Dose)

To evaluate the dose-to-dose uniformity, drop bottles containing theophthalmic aqueous composition are stored upright for a predeterminedperiod of time (e.g. 12 hours) prior to the start of the test. Tosimulate the recommended dosing of the product, 2 drops of the aqueouscomposition are dispensed from each bottle at predetermined timeintervals (e.g. consecutively, every 1 minute, every 10 minutes, everyhour or every 24 hours). All drops are dispensed into tared glass vials,capped, and stored at room temperature until analysis. Concentrations ofatropine in the expressed drops are determined using a reverse-phaseHPLC method.

Example 9—Formulation Stability Comparison

Atropine sulfate monohydrate (MP Bio; Lot Number 7825K) and tropic acid(Sigma Aldrich; Lot Number STBD6457V) were used for this experiment.Eight formulations illustrated in Table 14A were analyzed at t=0, 2weeks, and 4 weeks. A RP-HPLC method was used to carry out the analysis.

TABLE 14A Atropine sulfate formulations Atropine Benzalkonium SulfateChloride Sodium Acetic Citric Formulation Monohydrate (BAK) ChlorideAcid Acid pH/pD Aqueous 1 0.010 0.01 0.90 0.01 — 4.2 SWFI 2 0.025 0.010.90 0.01 — 4.2 SWFI 3 0.010 0.01 0.90 0.01 — 4.8 SWFI 4 0.025 0.01 0.900.01 — 4.8 SWFI 5 0.010 0.01 0.90 — 0.04 5.8 SWFI 6 0.025 0.01 0.90 —0.04 5.8 SWFI 7 0.010 0.01 0.90 0.01 — 5.2 D₂O (pD) 8 0.010 0.01 0.90 —0.04 6.2 D₂O (pD)

The values are % w/v. The formulations were prepared at 100 mL scale involumetric glassware. The pD of Formulation 7 and Formulation 8 are 5.2and 6.2, respectively. In some instances, the pD is calculated aspD=0.4+pH*, in which pH* is the measured or observed pH of the solutionformulated in a solution containing deuterated water.

Table 14B illustrates analysis time points for the formulations listedin Table 14A.

TABLE 14B Schedule for atropine sulfate formulation testing Storage TimePoint Condition Initial (Horizontal) (t=0) 2 Week 4 Week 25° C./60% RH XX X 40° C./75% RH X X 60° C. X X

Table 15 illustrates the atropine sulfate purity data associated witheach of the eight formulations. Purity, is indicated as percentage ofarea under the curve.

TABLE 15 Atropine sulfate purity as Area-% Solvent Condition t = 0 t = 2weeks t = 4 weeks¹ Formulation 1 25/60 97.39 97.76 98.20 pH 4.2 40/7597.25 97.04 60° C. 94.98 93.87 Formulation 2 25/60 98.85 99.03 99.08 pH4.2 40/75 98.50 98.32 60° C. 97.47 96.65 Formulation 3 25/60 98.16 98.1698.45 pH 4.8 40/75 97.98 97.35 60° C/ 95.94 94.65 Formulation 4 25/6098.81 98.75 98.46 pH 4.8 40/75 98.26 98.01 60° C. 96.22 94.04Formulation 5 25/60 98.16 97.92 97.54 pH 5.8 40/75 95.88 93.51 60° C.80.94 66.83 Formulation 6 25/60 99.08 98.91 98.46 pH 5.8 40/75 97.6596.20 60° C. 89.15 80.68 F ormulation 7 25/60 98.93 99.07 98.39 pD 5.240/75 98.51 97.55 60° C. 96.70 94.01 F ormulation 8 25/60 98.93 98.9598.51 pD 6.2 40/75 98.53 97 44 60° C. 95.97 92.72 ¹Some chromatographicinterference were observed to occur late in the run (~27-32 minutes) formany of the t = 4 week stability samples and in some instances isproposed to be system related.

After four weeks of storage at 60° C. in some instances the atropinesulfate concentration have an impact on the stability for theformulations containing acetic acid at pH 4.2. For example, atropinesulfate concentration at 0.025% w/v (Formulation 2) showed a 2.8%increase in % purity at pH 4.2 compared to the atropine sulfateconcentration at 0.010% w/v (Formulation 1). This trend was not observedfor the acetic acid formulations at pH 4.8 (Formulations 3 and 4);rather a 0.6% decrease in % purity was observed for the higher doses.

The dose dependent stability trend that was observed at pH=4.2 was alsoseen in the formulations containing citric acid at pH 5.8 (Formulations5 and 6). After for weeks of storage at 60° C. there is approximately14% less degradation in the higher does than observed in the lower dose.

At both the high and the low doses, more degradation is observed in theformulations that start at a higher pH. This degradation ispredominantly the growth of tropic acid. In some instances, bufferspecies plays a role in the observed degradation between the differentpH values.

The percentage of tropic acid observed for each of the formulations att=4 weeks and at 60° C. areas follow:

Formulation 1—Tropic acid observed is 0.54%.

Formulation 2—Tropic acid observed is 0.93%.

Formulation 3—Tropic acid observed is 1.58%.

Formulation 4—Tropic acid observed is 3.03%.

Formulation 5—Tropic acid observed is 29.13%.

Formulation 6—Tropic acid observed is 16.84%.

Formulation 7—Tropic acid observed is 1.07%.

Formulation 8—Tropic acid observed is 4.03%.

In some embodiments, switching the water source to deuterated water(D₂O) has an impact on stabilizing the growth of the tropic acid peakfor the formulation containing acetic acid at pD 5.2 (Formulation 7),see FIG. 4 . In addition, in the formulation containing citric acid atpD 6.2 (Formulation 8), the deuterated water also stabilizes atropinesulfate, see FIG. 5 .

Table 16 illustrates tropic acid as area under the curve for each of theeight formulations. Tropic acid is a degradant of atropine sulfate. Insome instances, LOQ was previously found to be 0.05% for the RP-HPLCmethod.

TABLE 16 Tropic acid as area-% Solvent Condition t = 0 t = 2 weeks t = 4weeks Formulation 1 25/60 <LOQ 0.08 <LOQ pH 4.2 40/75 0.10 0.10 60° C.0.37 0.51 Formulation 2 25/60 <LOQ 0.05 <LOQ pH 4.2 40/75 0.11 0.12 60°C. 0.46 0.93 Formulation 3 25/60 <LOQ 0.12 0.05 pH 4.8 40/75 0.19 0.2760° C. 0.90 1.58 Formulation 4 25/60 <LOQ 0.10 0.13 pH 4.8 40/75 0.310.53 60° C. 1.84 3.03 Formulation 5 25/60 <LOQ 0.40 0.71 pH 5.8 40/752.22 4.35 60° C. 16.62 29.13 Formulation 6 25/60 <LOQ 0.24 0.42 pH 5.840/75 1.30 2.44 60° C. 9.32 16.84 Formulation 7 25/60 <LOQ 0.07 0.08 pD5.2 40/75 0.14 0.24 60° C. 0.71 1.07 Formulation 8 25/60 <LOQ 0.11 0.14pD 6.2 40/75 0.33 0.65 60° C. 2.32 4.03

Table 17 illustrates percentage of potency of atropine in the eightformulations.

TABLE 17 % Potency Solvent Condition t = 0 t = 2 weeks t = 4 weeksFormulation 1 25/60 109.4 116.3 112 8 pH 4.2 40/75 111.0 112.4 60° C.112.8 114.8 Formulation 2 25/60 102.9 107.1 109.7 pH 4.2 40/75 108.4109.6 60° C. 109.4 111.0 Formulation 3 25/60 106.3 108.0 109.6 pH 4.840/75 108 1 110.0 60° C. 108.0 109.9 Formulation 4 25/60 102.5 107.9109.2 pH 4.8 40/75 107.4 108.9 60° C. 107.9 108.8 Formulation 5 25/60105.0 105.9 107.1 pH 5.8 40/75 103.8 103.5 60° C. 90.2 77.7 Formulation6 25/60 107.2 107.1 109.1 pH 5.8 40/75 106.8 107.1 60° C. 99.0 93.7Formulation 7 25/60 107.3 111.3 112.9 pD 5.2 40/75 111.6 113.5 60° C.111.8 113.5 Formulation 8 25/60 99.0 103.0 105.0 pD 6.2 40/75 104.9104.7 60° C. 101.6 103.0

After 4 weeks of storage, the observed potency values were elevated fromthe t=0 and 2 week time points, with the exception of Formulations 5 and6 at 60° C. where the potencies dropped due to degradation. In someinstances, these potency values are within the error of the HPLC method,but appear to be trending upward. Mass balance was calculated for the60° C. data and results were consistent across the formulations andlevels of degradation, although skewed lower due to the higher thananticipated potency values at 4 weeks, see FIG. 3 .

Table 18 illustrates pH or pD stability of the eight formulations.

TABLE 18 pH/pD Stability Solvent Condition t = 0 t = 2 weeks t = 4 weeksFormulation 1 25/60 4.21 3.93 4.02 (pH) 40/75 3.86 3.96 60° C. 3 71 3.86Formulation 2 25/60 4.26 4.11 4.25 (pH) 40/75 4.04 4.17 60° C. 3.93 4.10Formulation 3 25/60 4.85 4.44 4.61 (pH) 40/75 4.41 4.54 60° C. 4.32 4.40Formulation 4 25/60 4.98 4.93 5.05 (pH) 40/75 4.89 4.98 60° C. 4.77 4.77Formulation 5 25/60 5.87 5.93 6.03 (pH) 40/75 5.96 5.96 60° C. 5.82 5.78Formulation 6 25/60 5.80 5.69 5.77 (pH) 40/75 5.65 5.67 60° C. 5.54 5.50Formulation 7 25/60 5.31 5.10 5.24 (pD) 40/75 5.08 5.15 60° C. 5.00 4.93Formulation 8 25/60 6.25 5.72 5.88 (pD) 40/75 5.74 5.78 60° C. 5.58 5.50

The italicized values are pD values for a deuterated sample. In someembodiments, the pD of the deuterated samples are pD=pH_(reading)+0.4(Glasoe, et al. “Use of glass electrodes to measure acidities indeuterium oxide” J. Physical Chem. 64(1): 188-190 (1960)).

At the two lower temperatures, the pH values at t=4 week are slightlyelevated from the t=2 week time point. These data were generated using anew glass pH probe. In some instances, the observed differences are dueto the probe differences or additional variables such as for example,the age of the standard buffers or temperature gradients within thelaboratory environment. The downward pH trend for each formulation withincreasing temperatures at t=4 week is consistent with previous data andis consistent with the increase in the amount of tropic acid present inthe stability sample.

Example 10—Determination of Shelf Life and Activation Energy

Activation energy was calculated for the eight formulations disclosed inExample 9 and comparison with a reference standard was made withFormulations 4-7.

Table 19 illustrates the activation energy (Ea) calculation. The Eaminimum is 17.8 Kcal/mol, the Ea maximum is 21.3 Kcal/mol, and the Eamean is 19.5 Kcal/mol. Mean is +/−3* stdev. FIGS. 6 and 7 illustrate thepoor correlation between RS and tropic acid with Formulation 4 andFormulation 7, respectively. FIGS. 8 and 9 illustrate improvedcorrelation between RS and tropic acid with Formulation 5 andFormulation 6, respectively. At a lower pH (e.g. pH 4.8 or lower), therewas a poor correlation observed (Formulation 4 and Formulation 7). Thiswas due to a slowed hydrolysis and increased alternative degradationpathways. At a higher pH (e.g., pH 5.8 or higher), an improved or bettercorrelation was observed (Formulation 5 and Formulation 6). This was dueto the hydrolysis of atropine as the primary degradant. It is noted thatthe activation energy is for the specific acid catalyzed degradation totropic acid—the predominant degradation product and degradationmechanism operating at pH 5.8 or higher.

TABLE 19 Activation energy for total related substance (RS) and tropicacid. Total RS Tropic Acid 1 Poor Corr Poor Corr 2 12.2 Poor Corr 3 PoorCorr 18.3 4 16.8 18.1 5 19.8 19.7 6 19.2 20.0 7 13.2 15.5 8 Poor Corr18.9 Mean 16.2 18.4 Kcal/mole Stdev  3.4  1.6 RSD 21% 9%

Table 20 illustrates the rate of RS or tropic acid formation per week at40° C.

TABLE 20 Rate 40° C. Rate 40° C. (total RS (Tropic acid Formulation%/wk) %/wk) Formulation 5 0.01% Atr Citrate pH 5.8 1.16 1.09 Formulation 6 0.025% Atr Citrate pH 5.8 0.72 0.61  Formulation 8 0.01%Atr Citrate pD 6.2 D₂O 0.163

Table 21 illustrates the activation energy and predicted shelf life at30° C. calculated based on Table 20. It is assumed for the calculationthat tropic acid and total RS is 5% (self-life).

TABLE 21A Rate @ 30° C. Estimated Shelf life @ (Total RS %/wk) 30° C.(mo) Formulation Ea min Ea mean Ea max Ea min Ea mean Ea max 5 0.45 0.410.38 2.78 3.04 3.33 6 0.28 0.26 0.23 4.47 4.90 5.37 8 — — — — — —

TABLE 21B Rate @30° C. (Tropic Estimated Shelflife acid %/wk) @30° C.(mo) Formulation Ea min Ea mean Ea max Ea min Ea mean Ea max 5 0.42 0.390.35 2.95 3.24 3.54 6 0.24 0.22 0.20 5.28 5.78 6.33 8 0.06 0.06 0.0519.75 21.64 23.70

At pD 6.2, the deuterated formulation (Formulation 8) has a predictedshelf life of close to 2 years at 30° C.

Table 22 illustrate the predicted shelf life at temperatures of 40° C.,30° C., 25° C., and 2-8° C. for Formulations 4-8 for total RS and tropicacid, respectively.

TABLE 22 Stability Prediction Temperature RS Temperature Tropic AcidFormulation ° C. weeks months ° C. weeks months 4 40 16.5 4.1 40 7.7 1.930 40.2 10.1 30 20.0 5.0 25 64.2 16.0 25 33.0 8.3 2-8 493.4 123.4 2-8296.8 74.2 5 40 2.8 0.7 40 0.9 0.2 30 7.9 2.0 30 2.7 0.7 25 13.7 3.4 254.6 1.2 2-8 151.1 37.8 2-8 50.5 12.6 6 40 5.8 1.4 40 1.7 0.4 30 15.9 4.030 4.8 1.2 25 27.3 6.8 25 8.4 2.1 2-8 281.6 70.4 2-8 95.9 24.0 7 40 11.52.9 40 16.9 4.2 30 23.2 5.8 30 38.4 9.6 25 33.4 8.4 25 59.1 14.8 2-8165.7 41.4 2-8 388.2 97.1 8 40 — — 40 6.2 1.6 30 — — 30 17.0 4.3 25 — —25 28.9 7.2 2-8 — — 2-8 287.1 71.8

Example 11—Additional Formulation Stability Comparison

Atropine sulfate monohydrate (MP Bio; Lot Number 7825K) and tropic acid(Sigma Aldrich; Lot Number STBD6457V) were used for this experiment.Thirteen formulations illustrated in Table 23A were analyzed.Formulations 1-8 had been analyzed at t=0, 2 weeks, 4 weeks, and 8weeks. Formulations 9-13 had been analyzed at t=0, 2 weeks, and 4 weeks.The pH values reported herein are the measured pH values obtained usingthe Thermo Scientific, Orion Dual Star pH/ISE benchtop pH meter and theOrion Double Junction Micro pH probe S/N S01-18520 calibrated with H₂Obased standards.

TABLE 23A Atropine sulfate Formulations Atropine Benzalkonium SulfateChloride Sodium Acetic Citric Formulation Monohydrate (BAK) ChlorideAcid Acid pH/pD Aqueous 1 0.010 0.01 0.90 0.01 — 4.2 SWFI 2 0.025 0.010.90 0.01 — 4.2 SWFI 3 0.010 0.01 0.90 0.01 — 4.8 SWFI 4 0.025 0.01 0.900.01 — 4.8 SWFI 5 0.010 0.01 0.90 — 0.04 5.8 SWFI 6 0.025 0.01 0.90 —0.04 5.8 SWFI 7 0.010 0.01 0.90 0.01 — 5.2 D₂O (pD) 8 0.010 0.01 0.90 —0.04 6.2 D₂O (pD) 9 0.010 — 0.90 — 0.04 6.8 D₂O (pD) 10 0.010 — 0.90 —0.04 6.4 H₂O (control) 11 0.010 — 0.90 — 0.08 6.4 H₂O (control) 12 0.010— 0.90 — 0.04 7.2 D₂O (pD) 13 0.010 — 0.90 — 0.04 6.8 H₂O (control)

The values are % w/v. The formulations were prepared at 100 mL scale involumetric glassware and filled into LDPE eye droppers. In someinstances, the pD is calculated as pD=0.4+pH*, in which pH* is themeasured or observed pH of the solution formulated in a solutioncontaining deuterated water.

Table 23B illustrates analysis time points for the formulations listedin Table 23A.

TABLE 23B Schedule for atropine sulfate formulation testing Storage TimePoint Condition Initial (Horizontal) (t = 0) 2 Week 4 Week 25° C./60% RHX X X 40° C./75% RH X X 60° C. X X

Table 24A and Table 24B illustrate atropine sulfate purity dataassociated with the atropine sulfate formulations. Purity is indicatedas percentage of area under the curve. The ↑ & ↓ indicate the high orlow concentration of atropine sulfate monohydrate (0.01% and 0.025%).The A & C indicate the buffer species used, acetic acid and citric acidrespectively.

TABLE 24A Atropine Sulfate Purity as Area-% for H₂O Formulations SolventCondition t = 0 t = 2 weeks t = 4 weeks Formulation 3  25/60 98.16 98.1698.45 ↓A H₂O pH 4.8 40/75 97.98 97.35 60° C. 95.94 94.65 Formulation 5 25/60 98.16 97.92 97.54 ↓C H₂O pH 5.8 40/75 95.88 93.51 60° C. 80.9466.83 Formulation 10 25/60 98.66 96 67 95.81 ↓C H₂O pH 6.4 40/75 91.0785.27 60° C. 59.77 42.87 Formulation 11 25/60 99.47 97.87 96.69 ↓C(2x)H₂O pH 6.4 40/75 90.97 84.26 60° C. 54.96 34.40 Formulation 13 25/6097.21 95.42 93.24 ↓C H₂O pH 6.8 40/75 83.05 73.00 60° C. 43.99 27.50

TABLE 24B Atropine Sulfate Purity as Area-% for D₂O Formulations SolventCondition t = 0 t = 2 weeks t = 4 weeks Formulation 7  25/60 98.93 99.0798 39 ↓A D₂O pD 5.2 40/75 98.51 97.55 60° C. 96.70 94.01 Formulation 8 25/60 98.93 98.95 98.51 ↓C D₂O pD 6.2 40/75 98 53 97 44 60° C. 95.9792.72 Formulation 9  25/60 99.29 98.42 98.07 ↓C D₂O pD 6.8 40/75 95.2093.22 60° C. 75.17 65.97 F ormulation 12 25/60 98.53 97.17 95.99 ↓C D₂OpD 7.2 40/75 90.75 84.64 60° C. 56.78 46.05

Table 25A and Table 25B illustrate tropic acid formation associated withthe atropine sulfate formulations. Tropic acid is a degradant ofatropine sulfate, and is indicated as percentage of area under thecurve. LOQ was found to be 0.05% for the RP-HPLC method. The ↑ & ↓indicate the high or low concentration of atropine sulfate monohydrate(0.01% and 0.025%). The A & C indicate the buffer species used, aceticacid and citric acid, respectively.

TABLE 25A Tropic Acid as Area-% for H₂O Formulations Solvent Condition t= 0 t = 2 weeks t = 4 weeks Formulation 3  25/60 <LOQ  0.12  0.05 ↓A H₂OpH 4.8 40/75  0.19  0.27 60° C.  0.90  1.58 Formulation 5  25/60 <LOQ 0.40  0.71 ↓C H₂O pH 5.8 40/75  2.22  4.35 60° C. 16.62 29.13Formulation 10 25/60 0.74  1.90  3.21 ↓C H₂O pH 6.4 40/75  7.61 13.4960° C. 37.44 54.06 Formulation 11 25/60 0.09  1.31  2.64 ↓C(2x) H₂O pH6.4 40/75  7.61 14.68 60° C. 42.43 62.23 Formulation 13 25/60 2.21  3.66 6.11 ↓C H₂O pH 6.8 40/75 15.47 25.80 60° C. 53.24 69.34

TABLE 25B Tropic Acid as Area-% for D₂O Formulations Solvent Condition t= 0 t = 2 weeks t = 4 weeks Formulation 7  25/60 <LOQ  0.07  0.08 ↓A D₂OpD 5.2 40/75  0.14  0.24 60° C.  0.71  1.07 Formulation 8  25/60 <LOQ 0.11  0.14 ↓C D₂O pD 6.2 40/75  0.33  0.65 60° C.  2.32  4.03Formulation 9  25/60 0.06  0.55  1.06 ↓C D₂O pD 6.8 40/75  3.16  6.2960° C. 21.09 29.25 Formulation 12 25/60 0.42  1.35  2.62 ↓C D₂O pD 7.240/75  7.27 13.53 60° C. 38.58 48.15

Table 26A and Table 26B illustrate the percentage of potency of atropinein the formulations. The ↑ & ↓ indicate the high or low concentration ofatropine sulfate monohydrate (0.01% and 0.025%). The A & C indicate thebuffer species used, acetic acid and citric acid respectively.

TABLE 26A Percentage of potency for H₂O Formulations Solvent Condition t= 0 t = 2 weeks t = 4 weeks Formulation 3  25/60 106.3 108.0 109.6  ↓AH₂O pH 4.8 40/75 108.1 110.0  60° C. 108.0 109.9  Formulation 5  25/60105.0 105.9 107.1  ↓C H₂O pH 5.8 40/75 103.8 103.5  60° C.  90.2  77.7 Formulation 10 25/60 101.7 100.0  98.0  ↓C H₂O pH 6.4 40 75  89.4  87.0 60° C.  63.7  45.7  Formulation 11 25/60  97.5  96.1  94.3  ↓C(2x) H₂OpH 6.4 40/75  89.4  82.0  60° C.  55.7  35.20 Formulation 13 25/60  99.4 96.9  94.1  ↓C H₂O pH 6.8 40/75  85.0  74.0  60° C.  46.4  29.8 

TABLE 26B Percentage of potency for D₂O Formulations Solvent Condition t= 0 t = 2 weeks t = 4 weeks Formulation 7  25/60 107.3 111.3 112.9 ↓AD₂O pD 5.2 40/75 111.6 113.5 60° C. 111.8 113.5 Formulation 8  25/60 99.0 103.0 105.0 ↓C D₂O pD 6.2 40/75 104.9 104.7 60° C. 101.6 103.0Formulation 9  25/60 101.4  99.9 100.1 ↓C D₂O pD 6.8 40/75  97.4  93.260° C.  78.7  68.9 Formulation 12 25/60 104.9 103.5 101.6 ↓C D₂O pD 7.240/75  96.9  89.1 60° C.  62.5  50.9

Table 27A and Table 27B illustrate the stability of pH or pD for theatropine sulfate formulations. The ↑ & ↓ indicate the high or lowconcentration of atropine sulfate monohydrate (0.01% and 0.025%). The A& C indicate the buffer species used, acetic acid and citric acidrespectively.

TABLE 27A Stability of pH for H₂O Formulations Solvent Condition t = 0 t= 2 weeks t = 4 weeks Formulation 3  25/60 4.85 4.44 4.61 ↓A H₂O pH 4.840/75 4.41 4.54 60° C. 4.32 4.40 Formulation 5  25/60 5.87 5.93 6.03 ↓CH₂O pH 5.8 40/75 5.96 5.96 60° C. 5.82 5.78 Formulation 10 25/60 6.436.41 6.46 ↓C H₂O pH 6.4 40/75 6.62 6.67 60° C. 6.01 5.92 Formulation 1125/60 6.44 6.47 6.72 ↓C(2x) H₂O pH 6.4 40/75 6.66 6.61 60° C. 6.27 6.23Formulation 13 25/60 6.77 6.91 6.91 ↓C H₂O pH 6.8 40/75 6.65 6.62 60° C.6.30 6.19

TABLE 27B Stability of pD for D₂O Formulations Solvent Condition t = 0 t= 2 weeks t = 4 weeks Formulation 7  25/60 5.31 5.10 5.24 ↓A D₂O pD 5.240/75 5.08 5.15 60° C. 5.00 4.93 Formulation 8  25/60 6.25 5.72 5.88 ↓CD₂O pD 6.2 40/75 5.74 5.78 60° C. 5.58 5.50 Formulation 9  25/60 6.766.80 6.81 ↓C D₂O pD 6.8 40/75 6.78 6.86 60° C. 6.45 6.24 Formulation 1225/60 7.25 7.18 7.26 ↓C D₂O pD 7.2 40/75 7.14 7.15 60° C. 6.52 6.36

Example 12. Determination of Shelf Life and Activation Energy forAtropine Sulfate Formulations of Example 11

Activation energy was calculated for the atropine sulfate formulationsdisclosed in Example 11. Specifically, activation energies werecalculated from the total % of related substances (RS) at 40° C. and 60°C. (2 point calculations) and from tropic acid formation at 40° C. and60° C. (2 point calculations). These values were then averaged. Table 28illustrates the activation energy calculation. Table 29 illustratesestimated shelf-lives from the 40° C. rate of formation of % RS andtropic acid, respectively. FIG. 10 illustrates estimated shelf lives forD₂O and H₂O formulations.

TABLE 28 Activation Energy Atropine Formulations Total RS Tropic Acid 5714    19     3 16    17     8 20    21     5 14    Poor Corr  6 15   16    Mean 16.3  18.7  Stdev  2.68  1.90 RSD 16% 10% Poor Corr: One ormore curve had R² < 0.95

TABLE 29 Estimated Shelf Life Estimated Shelf life/mo Total relatedsubstances % Tropic acid % (limit = 8%) (limit = 5%) Formulation 8° C.25° C. 8° C. 25° C. 0.01% w/v Atr 189   26   1427   147   0.01% w/vAcetate 0.9% w/v NaCl 0.01% w/v BAK pD 5.2 D₂O (Formulation 7) 0.01% w/vAtr 211   29   1095   113   0.01% w/v Acetate 0.9% w/vNaCl 0.01% w/v BAKpH 4.8 H₂O (Formulation 3) 0.01% w/v Atr 158   22    369.8  38   0.04%w/v Citrate 0.9% w/v NaCl 0.01% w/v BAK pD 6.2 D₂O (Formulation 8) 0.01%w/v Atr  37    5.2   54     5.5 0.04% w/v Citrate 0.9% w/v NaCl 0.01%w/v BAK pH 5.8 H₂O (Formulation 5) 0.01% Atr  13.6  2.6 0.9% w/v NaCl pH5.9 H₂O extemporaneous preparation

Tables 30 illustrate the predicted shelf life at temperatures of 40° C.,30° C., 25° C., and 2-8° C. for Formulations 2-8 for total RS and tropicacid, respectively.

TABLE 30 Stability Prediction Temper- Formu- Temperature RS ature TropicAcid lation ° C. weeks months ° C. weeks months 2 40 64.5 16.1 40 — — 30153.2 38.3 30 — — 25 241.2 60.3 25 — — 2-8 1747.9 437.0 2-8 — — 3 4031.1 7.8 40 99.5 24.9 30 73.9 18.5 30 268.3 67.1 25 116.3 29.1 25 451.8113.0 2-8 842.9 210.7 2-8 4382.0 1095.5 4 40 30.7 7.7 40 42.1 10.5 3073.0 18.2 30 113.7 28.4 25 114.9 28.7 25 191.5 47.9 2-8 832.6 208.1 2-81857.0 464.2 5 40 5.5 1.4 40 4.9 1.2 30 13.1 3.3 30 13.2 3.3 25 20.6 5.225 22.2 5.5 2-8 149.3 37.3 2-8 215.0 53.8 6 40 10.7 2.7 40 8.8 2.2 3025.5 6.4 30 23.7 5.9 25 40.1 10.0 25 39.8 10.0 2-8 290.5 72.6 2-8 386.596.6 7 40 27.9 7.0 40 129.6 32.4 30 66.4 16.6 30 349.6 87.4 25 104.526.1 25 588.7 147.2 2-8 757.3 189.3 2-8 5709.4 1427.4 8 40 23.3 5.8 4033.6 8.4 30 55.3 13.8 30 90.6 22.6 25 87.2 21.8 25 152.5 38.1 2-8 631.6157.9 2-8 1479.2 369.8

Example 13—Forced Degradation Study of Atropine Formulation 8 in D₂O andH₂O Conditions

Atropine sulfate monohydrate (MP Bio; Lot Number 7825K) was used forthis experiment. A correction factor of 83.3% is used to quantitateamount of free Atropine. Table 31 shows the D₂O and H₂O formulationcompositions.

TABLE 31 Formulation 8 Compositions [Free Atropine] Formulation (μg/mL)Composition 8-D₂O 83.3 0.01% (w/v) Benzalkonium Chloride, 0.9% (w/v)NaCl, 0.208 mM Citric Acid in D₂O, pD 6.2 8-H₂O 83.3 0.01% (w/v)Benzalkonium Chloride, 0.9% (w/v) NaCl, 0.208 mM Citric Acid in H₂O, pH5.8

D₂O-based Formulation 8 and H₂O-based Formulation 8 were subjected toacid, base, light, heat and oxidative stress. Approximately 5-20%degradation was targeted for all stress conditions to produce sufficientdegradation while avoiding secondary degradation. At each condition,Formulation 8 samples were incubated alongside a vehicle controlcontaining BAK. For the light condition, foil wrapped Formulation 8control and foil wrapped vehicle control were prepared to understand ifextraneous degradation, such as heat in the light box, were to occur. ARP-HPLC method was used to carry out the analysis. Mass balance (thecorrelation of potency and purity by area-%) was also evaluated usingEquation 1.

${{Mass}{Balance}} = \frac{( {{Potency}_{initial} + ( {100 - {Purity}_{initial}} )} )}{( {{Potency}_{final} + ( {100 - {Purity}_{final}} )} )}$

The forced degradation results were processed at 210 nm, and arepresented in Tables 32A and 32B for H₂O and D₂O formulations,respectively.

TABLE 32A Forced Degradation Results for Formulation 8-H₂O % % MainRecovery Purity Peak Peak Peak (vs. (vs. Purity Purity Spectrally MassStress Condition Duration Control) Control) Angle Threshold Pure?Balance Control 2-8° C., 3 day 100.9 100.0 0.412 0.657 Y foil wrappedAcid Ambient, 23 day −7.9 −5.9 0.301 0.513 Y 101.8% (1.0N foil HCl)wrapped Base Ambient, 4 hr −5.2 −6.6 0.417 0.725 Y 98.7% (0.001N foilNaOH) wrapped 6 hr −7.3 −7.9 0.462 0.741 Y 99.5% Heat 60° C., 7 day−12.1 −11.9 0.428 0.478 Y 100.3% foil wrapped 10 day −18.4 −18.4 0.4760.752 Y 100.0% Light Ambient, 1.1 −10.1 −7.6 0.478 0.831 Y 102.5% clearmillion glass vial lux hours (10 day) 1.5 −19.1 −12.2 0.597 0.911 Y107.1% million lux hours (14 day) Light Ambient, 1.1 −0.4 −0.5 0.4110.665 Y 99.9% Control foil million wrapped lux hours (10 day) 1.5 −3.0−0.3 0.388 0.592 Y 102.8% million lux hours (14 day) Oxidation Ambient,3 day −16.0 −7.9 0.532 0.791 Y 108.8% (3% foil 4 day −28.0 −13.9 0.4730.777 Y 115.7% H₂O₂) wrapped 7 day −29.4 −13.5 0.705 0.967 Y 118.9%

TABLE 32B Forced Degradation Results for Formulation 8-D₂O % MainRecovery % Purity Peak Peak Peak (vs. (vs. Purity Purity Spectralty MassStress Condition Duration Control) Control) Angle Threshold Pure?Balance Control 2-8° C., 4 day 106.7 98.3 0.361 0.659 Y foil wrappedAcid Ambient, 17 day −6.9 −5.5 0.250 0.469 Y 97.9% (1.0N foil HCl)wrapped Base Ambient, 5 day −2.3 −2.2 0.495 0.849 Y 100.0% (0.001N foilNaOH) wrapped Base Ambient, 30 min −9.7 −9.6 0.601 0.894 Y 100.2%(0.005N foil NaOH) wrapped Heat 60° C., 17 day −18.1 −16.9 0.281 0.550 Y101.1% foil wrapped Light Ambient, 0.44 −14.1 −4.5 0.463 0.733 Y 109.6%clear million glass vial lux hours (4 day) 0.87 −24.2 −11.3 0.528 0.846Y 113.8% million lux hours (8 day) Light Ambient, 0.44 −0.2 1.7 0.3540.640 Y 101.8% Control foil million (foil wrapped lux hours covered) (4day) 0.87 0.0 1.4 0.330 0.599 Y 101.3% million lux hours (8 day)Oxidation Ambient 4 day −10.6 −3.0 0.439 0.720 Y 107.5% (3% foil 8 day−17.9 −8.3 0.385 0.672 Y 109.9% H₂O₂) wrapped

Example 14—Formulation 8 Stability Comparison

The long-term stability of atropine sulfate formulation 8 in D₂O (seeTable 31 for formulation composition) was analyzed at three differentstorage conditions. Table 33 illustrates the stability criteria:appearance, potency, tropic acid level, total purity, and pD at storageconditions of 25° C. with 60% humidity, 40° C. with 75% humidity, and60° C. As discussed above, pD=pH_(reading)+0.4 (Glasoe, et al. “Use ofglass electrodes to measure acidities in deuterium oxide” J. PhysicalChem. 64(1): 188-190 (1960)).

TABLE 33 Formulation 8 Stability Parameter Initial 2 weeks 4 weeks 8weeks 6 months 9 months² 12 months³ Storage Condition: 25° C./60% RHAppearance Clear Colorless Solution Free of Particulates Potency (Assay)99.2% 103.0% 105.0% 96.0% 99.7% 97.7% 101.7% Tropic Acid 0.05% 0.11%0.14% 0.23% 0.55% 0.91% 1.24% Level Total Purity¹ 98.9% 98.9% 98.5%98.1% 99.2% 98.4% 97.8% pD 6.3 5.7 5.9 5.7 5.8 5.7 5.8 (pH 5.9) (pH 5.3)(pH 5.5) (pH 5.3) (pH 5.4) (pH 5.3) (pH 5.4) Storage Condition: 40°C./75% RH Appearance Clear Colorless Solution Free of ParticulatesPotency (Assay) 99.2% 104.8% 104.7% 94.9% 96.6% 94.2% 95.6% Tropic Acid0.05% 0.34% 0.65% 1.24% 3.32% 5.05% 6.71% Level Total Purity¹ 98.9%98.5% 97.5% 96.6% 96.3% 92.5% 90.5% pD 6.3 5.7 5.8 5.6 5.7 5.5 5.7 (pH5.9) (pH 5.3) (pH 5.4) (pH 5.2) (pH 5.3) (pH 5.1) (pH 5.3) StorageCondition: 60° C. Appearance Clear Colorless Solution Free ofParticulates Potency (Assay)⁴ 99.2% 101.6% 103.0% 92.9% 100.6% 104.0%115.9% Tropic Acid 0.05% 2.33% 4.02% 6.01% 10.33% 10.87% 12.97% LevelTotal Purity¹ 98.9% 96.0% 92.8% 88.8% 85.5% 78.0% 72.4% pD 6.3 5.6 5.55.2 5.1 4.9 5.0 (pH 5.9) (pH 5.2) (pH 5.1) (pH 4.8) (pH 4.7) (pH 4.5)(pH 4.6) ¹Slight variability is observed in the total purity results dueto sensitivity differences from one HPLC system to the next. ²Resultsreported are from a second aliquot taken from the original assayeyedropper. ³Results reported are from an aliquot taken from theoriginal assay eyedropper. ⁴A growing unknown related substance peak isobserved to co-elute with the main peak and is included in the AtropineSulfate potency result due to a lack of a clear inflection point betweenthe two species upon integration.

A comparison of Formula 8 in H₂O and D₂O under three storage conditionsis further illustrated in FIG. 11 . FIG. 11A shows the presence oftropic acid degradant at 25° C. with 60% humidity. By week 8, about1.45% of tropic acid was observed in the H₂O formulation while only0.23% of tropic acid was observed in the D₂O formulation. Similarly, at40° C. with 75% humidity storage condition (FIG. 11B), 8.34% of tropicacid was observed in the H₂O formulation while only 1.24% of tropic acidwas observed in the D₂O formulation by week 8. At 60° C. storagecondition (FIG. 11C), 42.8% of tropic acid was observed in the H₂Oformulation while only 6.01% of tropic acid was observed in the D₂Oformulation by week 8.

Example 15—Effect of pH on Ophthalmic Acceptance in Guinea Pigs

A cohort of guinea pigs is administered 50 μL of ophthalmic formulationshaving different pH values described herein. For example, ophthalmicformulations comprising H₂O or deuterated water (e.g., D₂O) areadministered to the animals. Animal behavior is recorded atpredetermined time intervals to evaluate the acceptance of theophthalmic formulations

Example 16—In Vivo Rabbit Eye Irritation Test

The exemplary compositions disclosed herein are subjected to rabbit eyeirritation test to evaluate their safety profile. The test compositionare tested for eye irritation test in New Zealand Rabbits (see forexample Abraham M H, et al., Draize rabbit eye test compatibility witheye irritation thresholds in humans: a quantitative structure-activityrelationship analysis. Toxicol Sci. 2003 December; 76(2):384-91. Epub2003 Sep. 26; see also Gettings S D et al., A comparison of low volhune,Draize and in vitro eye irritation test data. III. Surtactant-basedformulations. Food Chem Toxicol. 1998 March; 36(3):209-31). The studyinvolves single ocular administration into the right eye and the samevolume of its placebo in the left eye of each of the three rabbits.Rabbits are examined immediately and after instillation of thecompositions for 4, 24, 48 and 72 hours post instillation to note thesigns/symptoms of eye irritation, if any. The test compositions show nosign of irritancy in cornea, iris and conjunctivae of the rabbit eyes.

Example 17—In Vivo Testing of Ophthalmic Aqueous Formulation in GuineaPigs

Focus deprivation myopia (FDM) is achieved using a latex shield to coverone eye. For defocus-induced myopia, a latex-made facemask was held inplace by a rubber-band around the head of animals, leaving both eyes,the nose, mouth and ears freely exposed. A −4.00 D lens is glued onto aplastic lens frame. The lens frame is then attached to the facemaskaround one eye by a fabric hook-and-loop fastener after the opticalcenter of the lens was aligned with the pupil center. The lens isdetached and cleaned on both sides with a water-wetted gauze at leastonce daily followed by re-attachment to the facemask. All the animalsare maintained on a cycle of 12-h illumination (500 Lux) and 12-hdarkness during the experimental period

A cohort of guinea pigs at age of 3 weeks are randomly assigned to FDM(a facemask worn monocularly) or defocus-induced myopia (a −4.00 D lensworn monocularly) and control groups. The FDM groups were treated withthe ophthalmic aqueous formulation, the ophthalmic carrier (without theophthalmic agent), or FDM-only. The defocus-induced myopia groups weretreated with the ophthalmic aqueous formulation, the ophthalmic carrier(without the ophthalmic agent), or defocus-only. The control groups weretreated with the ophthalmic aqueous formulation, the ophthalmic carrier(without the ophthalmic agent), or no treatment. Ocular biometricparameters are measured in both eyes of individual animals before and at11 days of treatment

Biometric parameters (e.g. refraction, corneal curvature, and axialcomponents of the eye) are measured by an optometrist, orthoptist, orophthalmologist with help from an animal care assistant during the lightcycle (daytime) after removal of the facemask or lens. The optometrist,orthoptist, or ophthalmologist is masked in regard to the treatmentconditions for each animal.

Refraction is measured by retinoscopy after the pupil is completelydilated by topical administration of 1% cyclopentolate hydrochloride.The results of retinoscopy are recorded as the mean value of thehorizontal and vertical meridians.

Corneal curvature is measured with a keratometer modified by attachmentof an +8 D lens onto the anterior surface of the keratometer. A group ofstainless steel balls with diameters from 5.5 to 11.0 mm are measured bythe modified keratometer. Three readings are recorded for eachmeasurement to provide a mean result. The radius of corneal curvature isthen deduced from the readings on the balls with known radii.

A-scan ultrasonagraph is used to measure axial components of the eye(lens thickness and vitreous length and axial length). The conductingvelocity was 1,723.3 m/s for measurement of the lens thickness and 1,540m/s for measurement of the vitreous length as described previously. Eachof the axial components is calculated as the mean of 10 repeatedmeasurements.

Example 18—Safety and Efficacy Studies of Ophthalmic Aqueous Formulation

A clinical trial is performed to investigate the efficacy and safety ofophthalmic aqueous formulations described herein in patents with myopia.In some instances, the study is open-label, single blind, or doubleblind study. Patient selection criteria include myopic refraction of atleast 1.0D in both eyes, and additional factors such as astigmatism, adocumented myopic progression, age, sex, and/or health conditions.

The patients are randomized to receive 0.05%, 0.01%, or 0.001 atropineaqueous formulation formulated in either H₂O or deuterated water (e.g.,D₂O) once nightly in both eyes. Allocation ratio in some instances isdefined based the patient population.

The patients are evaluated on day 0 (baseline), day 14, day 30, and thenat 2, 3, 4, 5, 6, 8, 10, 12, 18, 20, 24, and 36 months. At each visit,best-corrected distance log Mar visual acuity (BCVA) is assessed by anoptometrist, orthoptist, or ophthalmologist using the Early TreatmentDiabetic Retinopathy study chart. Near visual acuity is assessed usingbest-corrected distance spectable correction with a reduced log Marreading chart placed at 40 cm under well-lit conditions. The near pointof accommodation (NPA) is measured using a RAF rule using best-correcteddistance spectable correction. Patients are instructed to move thetarget inwards till the N5 print becomes slightly blurred and thenoutwards till it just becomes clear. Accommodation amplitude iscalculated as the inverse of NPA. Mesopic pupil size is measured withProcyon 3000 pupilometer. Photopic pupil size is measured using theNeuroptics pupilometer.

Cycloplegic autorefraction is determined 30 minutes after 3 drops ofcyclopentolate 1% are administered at 5 minutes apart using a CanonRK-F1 autorefractor. A Zeiss IOL Master, a non-contact partial coherenceinterferometry, is used to measure the ocular axial length.

The primary outcome is myopia progression over the time period of thestudy. Safety is assessed by adverse events including allergicreactions, irritation, or development of blurring of vision in one orboth eyes.

Example 19—Preparation of an Ointment Formulation Containing AtropineSulfate

Atropine sulfate is mixed with the dispersing agent (e.g.polyethyleneglycol) wider heating and sonication and this mixture isfurther thoroughly mixed with a molten ointment base (e.g. a mixture ofwool wax, white petrolatum, and liquid paraffin). The mixture is placedin a pressure vessel, and sterilized at 125° C. for 30-45 minutes andcooled to room temperature. In another embodiment, autoclaving isconducted under nitrogen. The resulting ophthalmic ointment isaseptically filled into pre-sterilized containers (e.g. tubes).

Example 20—Atropine-Mucus Penetrating Particle Composition

A 0.01% atropine-mucus penetrating particle composition was preparedutilizing a milling procedure. An aqueous dispersion containing atropineparticles and an MPP-enabling mucus penetrating agent was milled withgrinding medium until particle size was reduced to approximately 200 nmwith a polydispersity index less than 0.15 as measured by dynamic lightscattering. Additional agents such as preservatives are also addedduring the milling procedure. Subsequently, the atropine-MPP compositionare be stored at temperatures of between about 15° C. and about 25° C.

Example 21—Atropine Sulfate-Mucus Penetrating Particle Composition

A 0.01% atropine sulfate-mucus penetrating particle composition wasprepared utilizing a milling procedure. An aqueous dispersion containingatropine particles and an MPP-enabling mucus penetrating agent wasmilled with grinding medium until particle size was reduced toapproximately 200 nm with a polydispersity index less than 0.15 asmeasured by dynamic light scattering. Additional agents such aspreservatives are also be added during the milling procedure.Subsequently, the atropine-MPP composition are be stored at temperaturesof between about 15° C. and about 25° C.

According to another aspect of the disclosure, described herein is anophthalmic composition that comprises from about 0.001 wt % to about0.05 wt % of a muscarinic antagonist and water, at a pH of from about3.8 to about 7.5.

In some instances, the muscarinic antagonist comprises atropine,atropine sulfate, noratropine, atropine-N-oxide, tropine, tropic acid,hyoscine, scopolomine, tropicamide, cyclopentolate, pirenzapine,homatropine, or a combination thereof. In some cases, the muscarinicantagonist is atropine. In some cases, the muscarinic antagonist isatropine sulfate.

In some instances, the ophthalmic composition comprises one of: at leastabout 80%, at least about 85%, at least about 90%, at least about 93%,at least about 95%, at least about 97%, at least about 98%, or at leastabout 99% of the muscarinic antagonist based on initial concentrationafter extended period of time under storage condition.

In some instances, the ophthalmic composition has a pH of one of: lessthan about 7.3, less than about 7.2, less than about 7.1, less thanabout 7, less than about 6.8, less than about 6.5, less than about 6.4,less than about 6.3, less than about 6.2, less than about 6.1, less thanabout 6, less than about 5.9, less than about 5.8, less than about 5.2,less than about 4.8, or less than about 4.2 after extended period oftime under storage condition.

In some instances, the ophthalmic composition further has a potency ofone of: at least 80%, at least 85%, at least 90%, at least 93%, at least95%, at least 97%, at least 98%, or at least 99% after extended periodof time under storage condition.

In some instances, the extended period of time is one of: about 1 week,about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3months, about 4 months, about 5 months, about 6 months, about 8 months,about 10 months, about 12 months, about 18 months, about 24 months,about 36 months, about 4 years, or about 5 years.

In some instances, the storage condition has a storage temperature ofone of: about 25° C., about 40° C., or about 60° C. In some cases, thestorage condition has a storage temperature of from about 2° C. to about10° C. or from about 16° C. to about 26° C. In some cases, the storagecondition has a relative humidity of about 60% or about 75%.

In some instances, the ophthalmic composition is in the form of anaqueous solution. In some cases, the muscarinic antagonist is present inthe composition at a concentration of one of; from about 0.001 wt % toabout 0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about0.001 wt % to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt%, from about 0.001 wt % to about 0.01 wt %, from about 0.001 wt % toabout 0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.

In some instances, the ophthalmic composition further comprises anosmolarity adjusting agent. In some cases, the osmolarity adjustingagent is sodium chloride.

In some instances, the ophthalmic composition further comprises apreservative. In some cases, the preservative is selected frombenzalkonium chloride, cetrimonium, sodium perborate, stabilizedoxychloro complex, SofZia, polyquaternium-1, chlorobutanol, edetatedisodium, polyhexamethylene biguanide, or combinations thereof.

In some instances, the ophthalmic composition further comprises a bufferagent. In some cases, the buffer agent is selected from borates,borate-polyol complexes, phosphate buffering agents, citrate bufferingagents, acetate buffering agents, carbonate buffering agents, organicbuffering agents, amino acid buffering agents, or combinations thereof.

In some instances, the ophthalmic composition further comprises atonicity adjusting agent. In some cases, the tonicity adjusting agent isselected from sodium chloride, sodium nitrate, sodium sulfate, sodiumbisulfate, potassium chloride, calcium chloride, magnesium chloride,zinc chloride, potassium acetate, sodium acetate, sodium bicarbonate,sodium carbonate, sodium thiosulfate, magnesium sulfate, disodiumhydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogenphosphate, dextrose, mannitol, sorbitol, dextrose, sucrose, urea,propylene glycol, glycerin, or a combination thereof.

In some instances, the ophthalmic composition is stored in a plasticcontainer. In some cases, the material of the plastic containercomprises low-density polyethylene (LDPE).

In some instances, the ophthalmic composition has a dose-to-dosemuscarinic antagonist concentration variation of one of: less than 50%,less than 40%, less than 30%, less than 20%, less than 10%, or less than5%. In some cases, the dose-to-dose muscarinic antagonist concentrationvariation is based on one of: 10 consecutive doses, 8 consecutive doses,5 consecutive doses, 3 consecutive doses, or 2 consecutive doses.

In some instances, the ophthalmic composition has a pH of one of: fromabout 3.8 to about 7.5, from about 4.2 to about 7.5, from about 4.8 toabout 7.3, from about 5.2 to about 7.2, from about 5.8 to about 7.1,from about 6.0 to about 7.0, or from about 6.2 to about 6.8.

In some instances, the ophthalmic composition further comprises a pHadjusting agent. In some cases, the pH adjusting agent comprises HCl,NaOH, CH₃COOH, or C₆H₈O₇.

In some instances, the ophthalmic composition comprises one of: lessthan 5% of D₂O, less than 4% of D₂O, less than 3% of D₂O, less than 2%of D₂O, less than 1% of D₂O, less than 0.5% of D₂O, less than 0.1% ofD₂O, or 0% D₂O. In some cases, the ophthalmic composition is essentiallyfree of D₂O.

In some instances, the ophthalmic composition further comprises apharmaceutically acceptable carrier.

In some instances, the ophthalmic composition is formulated as anophthalmic solution for the treatment of an ophthalmic disorder. In somecases, the ophthalmic disorder or condition is pre-myopia, myopia, orprogression of myopia.

In some instances, the ophthalmic composition is not formulated as aninjectable formulation.

While preferred embodiments of the present disclosure have been shownand described herein, such embodiments are provided by way of exampleonly. Various alternatives to the embodiments described herein areoptionally employed in practicing the disclosure. It is intended thatthe following claims define the scope of the disclosure and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

What is claimed:
 1. A stabilized ophthalmic composition for treatingpre-myopia, myopia, or progression of myopia, comprising from about0.001 wt % to about 0.05 wt % of atropine or atropine sulfate and water,wherein the stabilized ophthalmic composition further comprises abuffering agent at a pH from about 4.4 to about 6.4, wherein thestabilized ophthalmic composition is a liquid, wherein the buffer agenthas a buffer capacity sufficient to maintain the pH of the solutionbetween about 4.4 to about 6.4 for an extended period of time of atleast 1 month.
 2. The stabilized ophthalmic composition of claim 1,further comprising noratropine, atropine-N-oxide, tropine, tropic acid,hyoscine, scopolamine, tropicamide, cyclopentolate, pirenzepine,homatropine, or a combination thereof.
 3. The stabilized ophthalmiccomposition of claim 1, wherein the atropine or atropine sulfate ispresent in the composition at a concentration of from about 0.001 wt %to about 0.03 wt %.
 4. The stabilized ophthalmic composition of claim 1,wherein the atropine or atropine sulfate is present in the compositionat a concentration of from about 0.001 wt % to about 0.02 wt %.
 5. Thestabilized ophthalmic composition of claim 1, wherein the atropine oratropine sulfate is present in the composition at a concentration offrom about 0.001 wt % to about 0.01 wt %.
 6. The stabilized ophthalmiccomposition of claim 1, wherein the buffering agent comprises an acetatebuffering agent, a citrate buffering agent, a carbonate buffering agent,an organic buffering agent, and amino acid buffering agent, or acombination thereof.
 7. The stabilized ophthalmic composition of claim1, wherein the buffering agent comprises an acetate buffering agent or acitrate buffering agent, or a combination thereof.
 8. The stabilizedophthalmic composition of claim 1, wherein the stabilized ophthalmiccomposition further comprises a tonicity adjusting agent.
 9. Thestabilized ophthalmic composition of claim 8, wherein the tonicityadjusting agent comprises a halide salt of a monovalent cation.
 10. Thestabilized ophthalmic composition of claim 1, further comprising anophthalmically acceptable viscosity agent.
 11. The stabilized ophthalmiccomposition of claim 10, wherein the ophthalmically acceptable viscosityagent comprises hydroxyethyl cellulose, hydroxypropyl cellulose, orhydroxypropylmethyl-cellulose (HPMC).
 12. The stabilized ophthalmiccomposition of claim 1, further comprising a preservative.
 13. Thestabilized ophthalmic composition of claim 12, wherein a concentrationof the preservative is from about 0.0001% to about 1%.
 14. Thestabilized ophthalmic composition of claim 12, wherein the preservativeis selected from benzalkonium chloride, cetrimonium, sodium perborate,stabilized oxychloro complex, polyquaternium-1, chlorobutanol, edetatedisodium, polydexamethylene biguanide, or combinations thereof.
 15. Thestabilized ophthalmic composition of claim 1, wherein the stabilizedophthalmic composition is essentially free of procaine and benactyzine,or pharmaceutically acceptable salts thereof.
 16. A method of treatingthe pre-myopia, myopia or progression of myopia in an individual in needthereof, comprising administering to an eye of the individual aneffective amount of the stabilized ophthalmic composition of claim 1.17. The method of claim 16, wherein the stabilized ophthalmiccomposition is administered topically.
 18. The method of claim 16,wherein the stabilized ophthalmic composition is administered byinstillation.
 19. The method of claim 16, wherein the stabilizedophthalmic composition is administered through an eye drop bottlecontaining the stabilized ophthalmic composition.